Engineered Anti-PD-l1 scfv conjugates

The engineered anti-PD-L1 scFv conjugate with a site-specific non-natural amino acid and albumin-binding motif improves half-life and target specificity, overcoming the limitations of full-length antibodies and scFvs in antibody conjugates.

WO2026235527A1PCT designated stage Publication Date: 2026-11-12PROABTECH CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2026/096754
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing antibody conjugates face challenges in controlling the drug-to-antibody ratio (DAR) and maintaining antigen-binding affinity, particularly with full-length antibodies, which have low tissue permeability, high production costs, and induce immune responses. Additionally, scFvs suffer from short half-life and renal excretion, necessitating improved pharmacokinetic properties.

Method used

An engineered anti-PD-L1 scFv conjugate is developed with a site-specifically inserted non-natural amino acid, incorporating an albumin-binding motif and ASGPR-targeting glycan, to enhance half-life and target specificity while allowing controlled payload conjugation.

Benefits of technology

The engineered scFv maintains target binding function, extends half-life through albumin binding, and enables site-specific glycan conjugation, addressing the limitations of conventional antibody conjugates.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2026096754_12112026_PF_FP_ABST
    Figure KR2026096754_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present specification relates to an engineered anti-PD-L1 scFv comprising an albumin-binding moiety and one or more unnatural amino acids. In addition, the present specification relates to an engineered anti-PD-L1 scFv conjugate in which an ASGPR-targeting glycan is linked to the engineered anti-PD-L1 scFv.
Need to check novelty before this filing date? Find Prior Art

Description

Engineered anti-PD-L1 scFv conjugate

[0001] This application relates to a novel engineered anti-PD-L1 scFv.

[0002] The present application relates to a novel engineered anti-PD-L1 scFv conjugate and its use.

[0003]

[0004] Relevant Prior Art: PCT Patent Application (Publication No.: WO 2024 / 039238 A1)

[0005] antibody conjugate

[0006] Antibody conjugates are a technology field attracting attention alongside the continuous growth of the antibody therapeutics market. In particular, active research is being conducted on antibody conjugates designed to simultaneously utilize the target specificity of antibodies and the therapeutic efficacy of payloads by binding a payload to an antibody.

[0007] Various methods are used to attach a payload to an antibody. For example, a widely used method involves chemically binding the payload using a conjugating linker capable of reacting with specific amino acid residues contained in the antibody.

[0008] Among antibody-conjugates, most currently FDA-approved antibody-drug conjugates (ADCs) are produced using conjugating linkers capable of reacting with lysine or cysteine ​​residues. However, using conjugating linkers capable of reacting with lysine or cysteine ​​residues presents the problem that it is difficult to uniformly control the drug-to-antibody ratio (DAR). Additionally, there is the issue that antibody sequence manipulation is required to avoid compromising the antibody's antigen-binding affinity.

[0009] One method used to resolve the aforementioned problem is conjugation via site-specific non-natural amino acid insertion. This method involves inserting a non-natural amino acid possessing a site-specific click chemical functional group into an antibody and conjugating a payload using that click chemical functional group. This method has the advantage of allowing the payload-antibody ratio to be consistently controlled and minimizing the impact of payload conjugation on antibody function.

[0010] However, according to recent research trends, non-natural amino acids are frequently inserted into the Fc region of full-length antibodies. In contrast, studies on the insertion of non-natural amino acids into single-chain variable fragments (scFvs) have been reported relatively limitedly compared to full-length antibodies.

[0011]

[0012] Disadvantages of full-length antibody-based antibody conjugates

[0013] Antibody conjugates that have been widely used in the past are based on full-length antibodies (intact antibodies). However, full-length antibody-based conjugates have several limitations compared to antibody fragment-based conjugates (e.g., single-stranded variable fragment [scFv]). First, full-length antibodies have low tissue permeability due to their relatively large size. Consequently, full-length antibody-based conjugates have difficulty penetrating deep into tissues. Second, full-length antibodies contain numerous disulfide bonds and complex structures, making them difficult to produce using microorganism-based expression systems. Therefore, full-length antibody-based conjugates have the limitation of being relatively expensive to produce. Third, the Fc region contained in full-length antibodies can induce an Fc-mediated immune response, which may lead to unintended immune reactions.

[0014] Therefore, there is a technical need to effectively deliver a target substance to a target site while solving the aforementioned problems associated with conventional full-length antibody-based antibody conjugates.

[0015] scFv's short half-life

[0016] The inventor of the present application aims to increase efficiency by utilizing an antibody fragment having target selectivity while enabling it to have a long half-life in the body.

[0017] scFv (single-chain variable fragment), which corresponds to an antibody fragment, has the disadvantage of having a short half-life because it is a peptide with a relatively small molecular weight. In addition, scFv has the disadvantage of being easily excreted through renal elimination. Consequently, the pharmacokinetic properties of scFv-based conjugates are significantly reduced. Therefore, in the case of technologies utilizing scFv, it is necessary to increase the in vivo half-life while maintaining the target selectivity of scFv.

[0018] Development of an optimal bonding method

[0019] To be applied to LYTAC technology, this specification aims to provide a novel engineered anti-PD-L1 scFv capable of site-specifically conjugating a glycan targeting asialoglycoprotein receptors (ASGPR).

[0020] Meanwhile, the ability to conjugate a glycan capable of targeting ASGPR to the engineered anti-PD-L1 scFv must be selected by considering various factors. For example, the engineered anti-PD-L1 scFv must be designed to maintain the characteristic of being able to attach to the target (PD-L1) even after the glycan is conjugated. In particular, although the scFv serving as the basis for the engineered anti-PD-L1 scFv includes a complementary determining region (CDR) capable of target-specific binding, it typically consists of only about 200 to 250 amino acids; therefore, the locations where the glycan can be properly conjugated are more limited. As another example, the engineered anti-PD-L1 scFv must be designed to maintain the characteristic of being able to bind to albumin even after the glycan is conjugated. This is because the engineered anti-PD-L1 scFv of the present application is characterized by including an albumin-binding motif (ABM) capable of binding to albumin to increase the half-life.

[0021] Considering all the points mentioned above, it is difficult for a person skilled in the art to arbitrarily select and proceed with properly joining the glycans. Therefore, there is a technical need to find an optimal joining method.

[0022]

[0023] To solve the above problem, the inventors of the present application provide a new type of engineered anti-PD-L1 scFv and an engineered anti-PD-L1 scFv conjugate based on scFv.

[0024] Providing scFv-based conjugates with increased half-life

[0025] The inventors of the present application have developed a construct designed to i) solve the problems of full-length antibody-based conjugates by using a single-chain variable fragment (scFv), ii) solve the problem of the short half-life of scFv by including an ABM at a specific location, and iii) enable the site-specific binding of an ASGPR-targeting glycan.

[0026] Specifically, the "engineered anti-PD-L1 scFv" of the present application utilizes a scFv that maintains binding ability to anti-PD-L1, and is characterized by including a region to which albumin can be bound to increase the half-life. Additionally, one or more of the amino acids constituting the engineered anti-PD-L1 scFv are non-natural amino acids having a click chemical functional group capable of binding to other functional substances.

[0027] That is, the present specification discloses a multifunctional engineered anti-PD-L1 scFv that i) can specifically bind to a target (PD-L1) by means of the function of the scFv's CDR, ii) can extend its duration in the body by increasing its half-life through binding to albumin via an albumin binding moiety, and iii) can conjugate to a glycan (and a suitable linker) through a click chemical functional group of a non-natural amino acid inserted in a site-specific manner.

[0028] Provides a structure in which non-natural amino acids are inserted at optimal locations

[0029] Since the engineered anti-PD-L1 scFv of this application is a relatively low-molecular-weight recombinant protein, even a single amino acid change can cause structural or functional changes. Therefore, it is very important to appropriately select the site where the non-natural amino acid is introduced. While utilizing a system for site-specific control of the introduction site of the non-natural amino acid, the inventors selected the insertion site by considering the following points.

[0030] For example, the degree of production (expression) of engineered anti-PD-L1 scFv may vary depending on the position of non-natural amino acids. As another example, when engineered anti-PD-L1 scFv is produced in a microorganism-based expression system, structural changes may affect the folding of the protein or expression into a soluble form. Accordingly, the degree of expression of engineered anti-PD-L1 scFv in a soluble form may vary depending on the position of non-natural amino acids. As yet another example, scFv has a small molecular size, so the space available for introducing hydrophobic substances is limited, and it is more sensitive to chemical modifications. Therefore, the efficiency of substance conjugation may vary depending on the position of non-natural amino acids. As yet another example, depending on the position of non-natural amino acids, the effects on i) the in vivo albumin binding capacity of the albumin-binding moiety, ii) the specific antigen-targeting function of the scFv CDR, and iii) the structural stability of the recombinant protein may vary.

[0031] With the above points in mind, this specification discloses an engineered anti-PD-L1 scFv structure comprising a non-natural amino acid at a selected position using the method disclosed in this application, and the use thereof.

[0032]

[0033] This specification provides a new type of engineered anti-PD-L1 scFv comprising an albumin-binding moiety and a non-natural amino acid, and a method for producing the same.

[0034] This specification provides an engineered anti-PD-L1 scFv comprising a non-natural amino acid at a specific position and a method for producing the same.

[0035] The present specification provides an engineered anti-PD-L1 scFv conjugate in which an ASGPR-targeting glycan is conjugated to the engineered anti-PD-L1 scFv, and a method for manufacturing the same.

[0036] According to the present invention, by providing an engineered anti-PD-L1 scFv comprising an albumin binding motif and a site-specifically inserted non-natural amino acid, the problem of the short in vivo half-life of scFv can be effectively improved. In addition, by selectively binding ASGPR-targeting glycans through site-specific conjugation using non-natural amino acids, an antibody fragment-based conjugate suitable for LYTAC technology can be provided while maintaining the target binding function.

[0037]

[0038] Figure 1 shows the results of confirming the expression of each type of engineered anti-PD-L1 scFv produced according to Experimental Example 1. The top electrophoresis image shows the results for engineered anti-PD-L1 scFv derived from avelumab, the middle electrophoresis image shows the results for engineered anti-PD-L1 scFv derived from atezolizumab, and the bottom electrophoresis image shows the results for engineered anti-PD-L1 scFv derived from durvalumab. The type of engineered anti-PD-L1 scFv is indicated at the top of each electrophoresis image. Additionally, S indicates the degree of expression in the soluble state, and IS indicates the degree of expression in the insoluble state.

[0039] Figure 2 shows the experimental results confirming the binding ability of avelumab, atezolizumab, or durvalumab-derived albubody to PD-L1.

[0040] Figure 3 shows the experimental results confirming the binding ability to PD-L1 of each type of engineered anti-PD-L1 scFv derived from atezolizumab or durvalumab. The table below shows the K for each type. D Represents the value.

[0041] Figure 4 shows the structure of the conjugating linker-ASGPR targeting glycan compound used in the experiment.

[0042] Figure 5 shows the electrophoresis results for two types of engineered anti-PD-L1 scFv and engineered anti-PD-L1 scFv conjugates. The graph on the left shows the results after labeling with DBCO-FITC, while the graph on the right shows the results after only simple protein staining. Descriptions for each lane are as listed in the table. Albubody (unconjugated) refers to S201X among the engineered anti-PD-L1 scFv.

[0043] Figure 6 shows the SEC-HPLC and RP-HPLC results for engineered anti-PD-L1 scFv (S201X) and two engineered anti-PD-L1 scFv conjugates (LYTAC(tri-GalNAc) and LYTAC(A3G3[3])). Albubody refers to S201X among the engineered anti-PD-L1 scFvs.

[0044] Figure 7 shows the total ion chromatogram (TIC) results for atezolizumab-derived albubody, engineered anti-PD-L1 scFv (S201X), and engineered anti-PD-L1 scFv conjugate (LYTAC(A3G3[3])). Albubody-WT represents atezolizumab-derived albubody, Albubody-S201X represents engineered anti-PD-L1 scFv (S201X), and LYTAC-A3G3[3] represents engineered anti-PD-L1 scFv conjugate (LYTAC(A3G3[3])).

[0045] Figure 8 shows the deconvolution mass spectra results for atezolizumab-derived albubody, engineered anti-PD-L1 scFv (S201X), and engineered anti-PD-L1 scFv conjugate (LYTAC(A3G3[3])). Albubody-WT represents atezolizumab-derived albubody, Albubody-S201X represents engineered anti-PD-L1 scFv (S201X), and LYTAC-A3G3[3] represents engineered anti-PD-L1 scFv conjugate (LYTAC(A3G3[3])).

[0046] FIG. 9 shows the experimental results confirming the binding ability to PD-L1 of engineered anti-PD-L1 scFv (S201X) and two engineered anti-PD-L1 scFv conjugates (LYTAC(tri-GalNAc) and LYTAC(A3G3[3])). The table below shows K for each. D Represents the value.

[0047] Figure 10 shows the experimental results confirming the binding ability of engineered anti-PD-L1 scFv (S201X) and two engineered anti-PD-L1 scFv conjugates (LYTAC(tri-GalNAc) and LYTAC(A3G3[3])) to human serum albumin. The table below shows K for each. D Represents the value.

[0048] Figure 11 shows the experimental results of a ligand binding assay (LBA) for ASGR1 to confirm the binding ability of the engineered anti-PD-L1 scFv conjugate (LYTAC(A3G3[3])) to ASGPR. K is on the right side of the graph. D The value is also displayed.

[0049] Figure 12 shows the experimental results of bio-layer interferometry (BLI) performed on ASGR1 to confirm the binding ability of the engineered anti-PD-L1 scFv conjugate (LYTAC(tri-GalNAc)) to ASGPR. In the graph, the top two rows and the bottom two rows represent the results of repeated experiments for each concentration. K at the bottom D The value is displayed.

[0050] Figure 13 shows the experimental results confirming lysosome-associated localization according to Experimental Example 4. The fluorescence imaging results are displayed on the left. In the fluorescence imaging data, the vertical axis indicates the substances used; 'control' represents the group without substance treatment, 'Albubody' represents the group treated with engineered anti-PD-L1 scFv (S201X), 'LYTAC(tri-GalNAc)' represents the group treated with LYTAC(tri-GalNAc), and 'LYTAC-A3G3[3]' represents the group treated with LYTAC(A3G3[3]). Additionally, the horizontal axis in the fluorescence imaging data indicates which fluorescence experiment data was used; 'overlay' is a photograph showing albumin647 and LAMP-1 fluorescence images simultaneously, and 'enlarge' is a photograph magnified from the square box indicated by the dotted line in the overlay. Furthermore, the graph on the right shows the results confirming how similar the positions of the Albumin647 signal and the LAMP1 signal overlap. As shown in the graph on the right, it was confirmed that the Albumin647 signal and the LAMP1 signal were detected at similar locations (distances) as a result of processing the engineered anti-PD-L1 scFv conjugate.

[0051] Figure 14 shows the experimental results confirming the removal ability of PD-L1 for each substance treatment. Groups 3 to 7 represent groups treated with IFN-γ as well. The designations for each treatment group are as shown in the table on the right. In the table, Control refers to the group not treated with buffer, and No treat refers to the group treated only with buffer without LYTAC substances, etc.

[0052] Figure 15 quantitatively shows the results of confirming the PD-L1 removal ability for each substance treatment. IFN-γ(-) represents the group not treated with IFN-γ, and IFN-γ(+) represents the group treated with IFN-γ, and no separate engineered anti-PD-L1 scFv or engineered anti-PD-L1 scFv conjugate was treated. Additionally, albubody represents an albubody derived from atezolizumab, and the others represent the results of treatment with each respective substance. Albubody, LYTAC(tri-GalNAc), LYTAC(A3G3[3]), and LYTAC(A3G3[3]·PEG12)) all represent results using cells treated with IFN-γ.

[0053] Figure 16 shows the results of Western blot analysis confirming whether PD-L1 is eliminated depending on treatment with a lysosomal inhibitor (chloroquine, CQ) or a proteosome inhibitor (MG132). The albubody represents an atezolizumab-derived albubody.

[0054] Figure 17 shows photographs of PD-L1 fluorescently labeled for each substance treatment to confirm the inhibitory activity of PD-L1.

[0055] Figure 18 shows the results confirming the activation of Jurkat cells depending on whether PHA was administered.

[0056] Figure 19 shows the results of confirming cell death when Jurkat cells and liver cancer cells are co-cultured. The left side shows the results of microscopic observation regarding whether cell death occurred, and the graph on the right shows the results of quantitatively representing cell viability based on the control group. Control refers to the group not treated with S201X or LYTAC. **** indicates a statistically significant difference.

[0057] Figure 20 shows the experimental results for determining the optimal molar ratio of engineered anti-PD-L1 scFv and conjugating linker-ASGPR targeting glycan compounds. The description for each group is as shown in the table, where LYTAC, 1:2 in the table represents the molar ratio of engineered anti-PD-L1 scFv and conjugating linker-ASGPR targeting glycan compounds.

[0058] Figure 21 shows the respective RP-HPLC results for the products in an experiment to determine the optimal molar ratio of engineered anti-PD-L1 scFv and conjugating linker-ASGPR targeting glycan compounds.

[0059] Figure 22 is a graph showing the stability over time for each buffer containing a conjugating linker-ASGPR targeting glycan compound. D0 represents day 0, D1 represents day 1, and D3 represents day 3. Also, M represents ladder, 1 represents control, 2 represents buffer 1, 3 represents buffer 2, 4 represents buffer 3, 5 represents buffer 4, and 6 represents buffer 5. Additionally, the graph on the left shows the results of protein labeling, and the graph on the right shows the results of DBCO-FITC fluorescence.

[0060] Figure 23 shows the results of confirming the binding ability to PD-L1 over time for each buffer containing a conjugating linker-ASGPR targeting glycan compound. D0 represents day 0, D1 represents day 1, and D3 represents day 3.

[0061] Figure 24 shows the results of confirming the binding ability of the substance contained in buffer 4 to PD-L1 over time. LYTAC refers to LYTAC(tri-GalNAc). D0, D1, D5, and D7 represent day 0, day 1, day 5, and day 7, respectively.

[0062] FIG. 25 shows the results of producing engineered anti-PD-L1 scFv through scale-up manufacturing according to Experimental Example 8.

[0063] FIG. 26 shows the results of producing an engineered anti-PD-L1 scFv conjugate using an engineered anti-PD-L1 scFv through scale-up manufacturing according to Experimental Example 8.

[0064] FIG. 27 shows the results of RP-HPLC and SEC-HPLC performed on the anti-PD-L1 scFv engineered by scale-up manufacturing according to Experimental Example 8 and the anti-PD-L1 scFv conjugate (LYTAC(A3G3[3]) and LYTAC(A3G3[3]·PEG12)) engineered by scale-up manufacturing according to Experimental Example 8 produced using the same.

[0065] FIG. 28 shows the results of confirming the binding ability to PD-L1 for the anti-PD-L1 scFv engineered through scale-up manufacturing according to Experimental Example 8 and the anti-PD-L1 scFv conjugates (LYTAC(A3G3[3]) and LYTAC(A3G3[3]·PEG12)) engineered through scale-up manufacturing according to Experimental Example 8 produced using the same.

[0066] Figure 29 shows the results of confirming the expression of ASGPR and PD-L1 in 7 types of HCC cell lines.

[0067] Figure 30 shows the results of confirming ASGPR and PD-L1 expression after treatment with 0.1% DMSO, 20 ng / ml IFN-γ, 50 ng / ml EGF, or PLC / 20 nM Alpelisib on HepG2, SNU449, and Hep3B cell lines.

[0068] Figure 31 shows the results of confirming PD-L1 expression in HepG2 after treatment with IFN-γ using flow cytometry.

[0069] FIG. 32 shows additional information regarding A3G3[3] and A3G3[3]·PEG12 used in the present experimental example.

[0070]

[0071] This specification discloses an engineered anti-PD-L1 scFv conjugate represented by the following structural formula:

[0072] [constitutional formula]

[0073] [engineered anti PD-L1 scFv (S)]-[junction (J)]-[linking group (L)]-[Glycan (G)] g ,

[0074] g is a natural number selected from 1 to 3, and

[0075] The above-mentioned engineered anti-PD-L1 scFv is represented by a single amino acid sequence selected from SEQ ID NOs. 4 to 35 and 158 to 189, and

[0076] X of the above sequence numbers 4 to 35 and 158 to 189 is an amino acid residue represented by the following [Chemical Formula 5], and

[0077] [Chemical Formula 5]

[0078] ,

[0079] AA1 and AA2 are adjacent amino acid residue(s), and

[0080] The above joint includes a structure formed by click chemistry.

[0081] The above connector includes a structure that is absent or connects a joint and a glycan, and

[0082] The above glycan is an ASGPR-targeting glycan.

[0083]

[0084] Definition of Terms

[0085] In this specification, the term “about” means a value that may vary within a range of about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, or 30% relative to the referenced amount, level, value, number, frequency, percentage, dimension, size, weight, or length.

[0086] In this specification, "click chemistry" refers collectively to chemical reactions or chemical bonding methods in which chemical functional groups that are paired with each other react selectively through a click reaction. In this case, the click reaction can be carried out relatively simply with high selectivity and efficiency using chemical functional groups that satisfy certain conditions, without applying heat or the aid of complex catalysts.

[0087] In this specification, a chemical functional group capable of performing a click reaction is referred to as a "click chemistry functional group." The click chemistry functional group may be any one selected from terminal alkyne, azide, strained alkyne, diene, dineophile, alkene, thiol, norbornene, dibenzocyclooxin-amine, trans-cyclooctene, and tetrazine, but is not limited thereto.

[0088] In order to perform a reaction, the click chemical functional group reacts in combination with another click chemical functional group. In this case, the click chemical functional group capable of reacting with a specific click chemical functional group may be referred to as the first click chemical functional group and the second click chemical functional group, respectively, and the first click chemical functional group and the second click chemical functional group are in a relationship capable of performing a click reaction with each other.

[0089] In this specification, the click response may include various types of responses.

[0090] For example, the above click reaction may be a copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC).

[0091] The above CuAAC may mean the following reactions.

[0092]

[0093] For example, the above click reaction may be strain-promoted azide-alkyne cycloaddition (SPAAC).

[0094] The above SPAAC may mean the following reactions.

[0095]

[0096] For example, the above click reaction may be an inverse electron-demand Diels-Alder (IEDDA) reaction.

[0097] The above IEDDA reaction may refer to the following reactions.

[0098]

[0099] In this specification, "non-natural amino acid" means an amino acid other than the 20 standard amino acids naturally used in vivo (alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine). Unless otherwise stated, in the context of describing engineered anti-PD-L1 scFv in this application, "non-natural amino acid" is a non-natural amino acid containing a click chemical functional group. For example, in this application, non-natural amino acid may mean, but is not limited to, 4-Azido-L-phenylalanine (pAzF) or 4-(1,2,4,5-tetrazin-3-yl)phenylalanine (frTet).

[0100] In this specification, "amino acid side chain" refers to an R residue other than an amino group, a carboxyl group, and hydrogen bonded to the alpha carbon (central carbon) of an amino acid. The amino acid side chain may also be referred to as "side chain" or "R residue" for convenience. Additionally, in this specification, the side chain of a non-natural amino acid may have a click chemical functional group.

[0101] In this specification, "amino acid residue" refers to the structure remaining in each amino acid after the water component has been removed when two or more amino acids combine to form a peptide. That is, each constituent unit of the peptide may be referred to as an amino acid residue. Additionally, amino acid residues may be referred to by numbering them starting from the N-terminus of the peptide. For example, if the 44th amino acid residue from the N-terminus of a specific peptide is glycine, it may be referred to as G44. Furthermore, in this specification, "amino acid" may refer to an amino acid residue, and this should be interpreted appropriately according to the context.

[0102] In this specification, "single-chain variable fragment (scFv)" refers to an antibody fragment comprising a configuration in which a heavy chain variable region (VH) and a light chain variable region (VL) are linked via a linker on a single protein chain. The arrangement order of said VH and VL may not be limited. Additionally, scFv may refer to a form of a single protein chain that is generally small in size (about 25 kDa) and contains two or fewer disulfide bonds. In this specification, scFv is interpreted to include scFv as appropriately understood by a person skilled in the art.

[0103] In this specification, the "Complementarity-determining region (CDR)" refers to a region that directly binds to the antigen when an antibody, antibody fragment, or single-stranded variable fragment binds to the antigen, and is a portion that is complementary to the epitope structure. The said complementarity-determining region exists in the variable region of the antibody, antibody fragment, or single-stranded variable fragment.

[0104] In this specification, "variant" means a protein modified by one or more amino acid substitutions, deletions, or insertions based on a base protein. The term "variant" in this application may be used to collectively refer to variants such as the engineered anti-PD-L1 scFv in this application. Alternatively, the term "variant" in this application may be used to refer to a protein in which some amino acid sequences are altered or added while maintaining the function of the base protein.

[0105] In this specification, "conjugating linker" refers to a linker comprising a second click chemical functional group capable of binding to a first click chemical functional group. The conjugating linker can bind to a non-natural amino acid having a first click chemical functional group. In this specification, the conjugating linker is used to conjugate an ASGPR-targeting glycan to a scFv. In addition to the second click chemical functional group, the conjugating linker may additionally include various functional compositions, and in particular, may include a functional group for linking to the ASGPR-targeting glycan.

[0106] In this specification, "scFv linker" is a collective term for a region that connects the heavy chain variable region and the light chain variable region of scFv. In this specification, i) the entire sequence of the region connecting the heavy chain variable region and the light chain variable region constituting scFv may be referred to as 'scFv linker', ii) a peptide sequence including an ABM that connects the heavy chain variable region and the light chain variable region may also be referred to as 'scFv linker', and iii) a part of the sequences of i) and ii) (for example, a sequence excluding the ABM of the peptide sequence including the ABM that connects the heavy chain variable region and the light chain variable region) may also be referred to as 'scFv linker'. The above meaning may be appropriately interpreted according to the context.

[0107] In this specification, "free" is used to describe a state in which a substance having a click chemical functional group is not covalently bonded to a molecule or group having another click chemical functional group. That is, a 'free scFv' having a click chemical functional group means a scFv having only click chemical functional groups that are not covalently bonded to other click chemical functional groups (e.g., conjugating linkers). The term "free" is used to emphasize that, despite the substance containing click chemical functional groups, the click chemical functional groups possessed by the substance have not reacted with other click chemical functional groups. For example, in this application, "free engineered anti-PD-L1 scFv" means an engineered anti-PD-L1 scFv that has not reacted with a conjugating linker. Additionally, "free engineered anti-PD-L1 scFv" means an engineered anti-PD-L1 scFv in which all possessed click chemical functional groups have not reacted with other click chemical functional groups.

[0108] In this specification, "free" may be omitted for convenience where it is evident from the context. For example, a freely engineered claim PD-L1 scFv may be referred to as "freely engineered claim PD-L1 scFv" or "engineered claim PD-L1 scFv". This may be interpreted appropriately according to the context.

[0109] Additionally, in this specification, "freedom" may be used to distinguish the state of matter from the following "units." Further details are described below.

[0110] In this specification, "unit" means "a substance in a state combined with another substance" or "a substance that functions as a specific component within a compound." In particular, it is used to distinguish it from the substance in the "free" state. The terms "free" and "unit" will be explained below using free antibodies and antibody units as examples.

[0111] A free antibody having a first click chemical functional group can form an antibody conjugate by undergoing a click reaction with a conjugating linker having a second click chemical functional group. At this time, the portion of the antibody conjugate derived from the free antibody may be referred to as an "antibody unit."

[0112] However, if necessary, a portion of the part derived from the free antibody may be referred to as an antibody unit. Alternatively, a portion derived from the free antibody and a portion of the conjugating linker may be integrated and referred to as an antibody unit. This is because it is impossible to accurately distinguish whether each individual component in the structure of the antibody conjugate is derived from the free antibody, or it may make the subject more ambiguous.

[0113] Below, antibody units are described under the assumption that a payload consisting of a free antibody having an azide group and a conjugating linker having DBCO undergoes a click reaction to form an antibody conjugate. The following example can be similarly applied even if the click chemical reactor is modified.

[0114] When a payload in which a free antibody having an azide group (in particular, a free antibody containing a non-natural amino acid having a specific amino acid side chain containing an azide group) (the side chain excluding the azide group is indicated as A1 in the drawing below) and a conjugating linker having DBCO are connected to form an antibody conjugate through a click reaction, the portion derived from the free antibody is as shown in the dotted box below. At this time, it is impossible to accurately distinguish and designate the portion derived from the free antibody in the antibody conjugate.

[0115]

[0116] At this time, since it is impossible to accurately distinguish and designate the portion derived from the free antibody in the antibody conjugate by the part within the box indicated by the dotted line in the drawing below, the area including or not including the part within the dotted box below may be arbitrarily distinguished and designated as the antibody unit.

[0117]

[0118] In one specific example, the antibody unit of this specification may refer to the portion indicated by the dotted box below. However, unless otherwise specifically described, a portion different from the following may be referred to as the antibody unit, and this should be appropriately applied and interpreted according to the context in which the antibody-conjugate is referred to. Furthermore, the above description applies appropriately to the engineered anti-PD-L1 scFv and engineered anti-PD-L1 scFv conjugate of this specification.

[0119]

[0120] As used herein, the term “pharmaceuticalally acceptable” is used to refer to materials, compositions, and / or dosage forms suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic reactions, or other problems or complications, within the scope of reasonable medical judgment and corresponding to a reasonable benefit / risk ratio.

[0121] In this specification, "halogen" or "halo" refers to a substance belonging to the group of halogen elements in the periodic table.

[0122] In this specification, "hetero" refers to a compound or group comprising at least one atom that is not carbon or hydrogen.

[0123] In this specification, "alkyl" or "alkane" means a chain-like or branched, fully saturated hydrocarbon.

[0124] In this specification, "C x-y" means, for example, when used with an alkyl group, that it contains a residue comprising x to y carbons in the chain or ring. Also, "C x-y " is used to include all substituted or unsubstituted, chain-shaped alkyl groups, branched-shaped alkyl groups, or cyclic structures. In this case, CO alkyl means hydrogen.

[0125] In this specification, "alkylene" means a divalent linker derived from an alkyl group. For example, an alkylene may be -CH2-, -CH2CH2-, -CH2CH2CH2-, or -CH2CH2CH2CH2-, but is not limited thereto. Additionally, "alkylene" is used to include all of the following: substituted or unsubstituted chain-like alkyl groups, branched-like alkyl groups, or cyclic structures. In this specification, "heteroalkylene" means a divalent linker in which one or more chain-forming atoms (carbon atoms) within the alkylene chain are replaced by heteroatoms such as O, N, S, etc.

[0126] In this specification, "cycloalkanes" or "cycloalkyl" groups refer to fully saturated cyclic hydrocarbons.

[0127] In this specification, the “aryl” group refers to an aromatic ring or a group derived from an aromatic hydrocarbon such as phenyl or naphthyl. Herein, “aryl” includes monocyclic and polycyclic rings.

[0128] In this specification, "glycan" refers to a structure formed by the linkage of one or more sugar molecules. In particular, this specification discloses a technique utilizing a glycan capable of inducing lysosome-mediated degradation through interaction with ASGPR, and said glycan capable of causing lysosome-mediated degradation through interaction with ASGPR is referred to in this specification as an "ASGPR-targeting glycan."

[0129] In this specification, "N-linked glycan" means a glycan covalently bonded to a nitrogen atom. In particular, N-linked glycan may mean a glycan covalently bonded to a nitrogen atom of a side-chain amide of asparagine. The N-linked glycan may have a core structure including GlcNAc (N-acetylglucosamine) and may have two or more branched (antenna) structures branched from the core.

[0130] In this specification, "bitennary" means a two-branched structure. Bitennary glycan means a glycan having two branched structures.

[0131] In this specification, "triantennary" means a three-branched structure. A triantennary glycan means a glycan having a three-branched structure.

[0132] In this specification, "terminal sugar" refers to a sugar located at the outermost end of a glycan. That is, a sugar that has no further outwardly connected sugars is referred to as a terminal sugar. The terminal sugar may also be referred to as a terminal residue or the terminus of the glycan.

[0133] In this specification, "non-reducing terminus" refers to a terminal region of a glycan that does not have an anomeric carbon free in the structure. Since the anomeric carbon of the terminal sugar residue participates in a glycosidic bond, the non-reducing terminus forms an open-chain structure and does not exhibit reducing properties. A sugar at such a non-reducing terminus is referred to as a non-reducing terminal sugar or a non-reducing terminal sugar residue.

[0134] In this specification, "positional isomer" refers to a compound or structure having the same molecular formula or the same basic skeletal structure, but differing in the positions of bonding or branching structures. The positional isomers may be distinguished from one another by differences in the positions where they are bonded or arranged, even though the types and number of constituent components are the same. For example, in this application, A3G3 refers to a glycan having three galactose as terminal sugars, and unless otherwise specifically stated, A3G3 means including all positional isomers of a glycan having three galactose as terminal sugars.

[0135] In this specification, "ASGPR targeting glycan" may be characterized by having at least one galactose or GalNAc (N-acetylgalactosamine) as a non-reducing terminal sugar, but is not limited thereto. As an example, an ASGPR targeting glycan may include NeuAc (N-acetylneuraminic acid) in a portion of the terminal for appropriate ASGPR targeting. That is, an ASGPR targeting glycan may be interpreted as having a structure appropriately recognized by a person skilled in the art. Furthermore, in this specification, "Gal-terminated glycan" refers to a glycan having at least one galactose at a non-reducing terminal position. Also, in this specification, "Gal-terminated glycan" refers to a glycan having at least one GalNAc at a non-reducing terminal position.

[0136] In this specification, "conjugation" is a general term for the covalent connection of a specific substance to an antibody or antibody fragment, and "conjugate" is a general term for a substance formed by conjugating a specific substance to an antibody or antibody fragment.

[0137] In this specification, "binding ability" refers to the ability of a molecule, protein, compound, or biomaterial to recognize a specific target substance and interact with it to bind. The binding ability does not merely mean the presence or absence of binding, but encompasses the degree of strength with which it binds to the target substance and whether it binds selectively, distinguishing it from other substances. Accordingly, the binding ability may be used to include affinity, specificity, or selectivity.

[0138] In this specification, " " is used to indicate the chemical formula corresponding to the area to be explained.

[0139]

[0140] Features of the disclosure in this specification

[0141] The present application discloses a novel variant structure based on an albubody structure previously studied by the inventors. The novel variant structure comprises a non-natural amino acid containing a click chemical functional group capable of being conjugated with other substances. The non-natural amino acid is introduced at an appropriate location that does not substantially impair the function of the albubody, thereby enabling the variant to be conjugated with other substances. A PCT patent application (publication number: WO2024 / 039238) regarding the albubody is incorporated herein by reference. In the present application, an albubody refers to a structure that is a variant of scFv and includes an albumin binding moiety having albumin binding ability in the middle of the scFv linker of the scFv.

[0142] That is, the "engineered anti-PD-L1 scFv" of the present application is a scFv variant fabricated based on scFv, comprising a heavy chain variable region and a light chain variable region, and comprising an albumin binding moiety between them.

[0143] Accordingly, when the engineered anti-PD-L1 scFv of the present application is administered into the blood, it can bind to serum albumin through an albumin binding moiety. As a result, the half-life of the engineered anti-PD-L1 scFv in the body may be increased. Additionally, the circulation time of the engineered anti-PD-L1 scFv in the blood may be increased. Furthermore, the efficiency of action of the engineered anti-PD-L1 scFv on the target protein may be improved.

[0144] Additionally, the engineered anti-PD-L1 scFv of this application comprises a non-natural amino acid containing a click chemical functional group. Accordingly, the engineered anti-PD-L1 scFv of this application can be selectively conjugated to a substance containing other chemical functional groups (e.g., a conjugating linker-ASGPR targeting glycan compound). The introduction site of the non-natural amino acid is appropriately selected to maintain binding ability to the antigen and / or albumin. Accordingly, the engineered anti-PD-L1 scFv of this application can maintain binding ability to the antigen and / or albumin while containing a non-natural amino acid.

[0145] Additionally, the engineered anti-PD-L1 scFv of the present application may include non-natural amino acids at selected positions considering the production (expression) of the engineered anti-PD-L1 scFv. Accordingly, the engineered anti-PD-L1 scFv of the present application may have a structure with improved productivity. Furthermore, the method for producing the engineered anti-PD-L1 scFv of the present application can achieve a higher expression yield.

[0146] Furthermore, the "engineered anti-PD-L1 scFv" of the present application can be used to manufacture the "engineered anti-PD-L1 scFv conjugate" described below.

[0147] Hereinafter, the engineered anti-PD-L1 scFv of the present application will be described first, and the engineered anti-PD-L1 scFv conjugate of the present application will be described.

[0148]

[0149] Chapter 1 Engineered Anti-PD-L1 scFv

[0150] generalization

[0151] This specification discloses an engineered anti-PD-L1 scFv. The engineered anti-PD-L1 scFv refers to a variant in which one or more amino acids are changed (substituted) to non-natural amino acids containing click chemical functional groups, in an anti-PD-L1 scFv in which an albumin binding moiety is inserted between a scFv linker between a heavy chain variable region (VH) and a light chain variable region (VL). Hereinafter, non-natural amino acids containing click chemical functional groups are referred to as "non-natural amino acids". Such abbreviation should not be interpreted as meaning that the engineered anti-PD-L1 scFv of this application does not contain non-natural amino acids that do not contain click chemical functional groups.

[0152] As previously mentioned, in this specification, scFvs inserted with an albumin-binding moiety are also referred to as "Albubody." The engineered anti-PD-L1 scFv of this application refers to an albubody comprising one or more non-natural amino acids. The position of the non-natural amino acid may be an albumin-binding moiety, a scFv linker, VH, and / or VL.

[0153] Consequently, in this specification, "an anti-PD-L1 scFv variant comprising an albumin-binding moiety and one or more non-natural amino acids" is referred to as "engineered anti-PD-L1 scFv," but may also be referred to as "an anti-PD-L1 albubody variant" or "engineered anti-PD-L1 albubody."

[0154] Unless otherwise noted, the engineered anti-PD-L1 scFv described in Chapter 1 refers to the "free-engineering anti-PD-L1 scFv" in a state where no payload, etc., is coupled.

[0155] Below, the structure and characteristics of the engineered anti-PD-L1 scFv are described in detail.

[0156] Structure of engineered anti-PD-L1 scFv

[0157] The engineered claim PD-L1 scFv of the present application can be represented by the following structural formula. The orientation of the N-terminus and C-terminus of the following structural formula is not limited, but preferably, the following structural formula is described in the order from the N-terminus to the C-terminus:

[0158] [Heavy chain variable region (VH)]-[scFv linker containing albumin binding moiety (ABM)]-[Light chain variable region (VL)].

[0159] Meanwhile, the above [scFv linker including an albumin binding moiety (ABM)] can also be expressed as [first scFv linker]-[albumin binding moiety (ABM)]-[second scFv linker].

[0160] Accordingly, in a different manner of expression, the engineered claim PD-L1 scFv of the present application can be represented by the following structural formula. The orientation of the N-terminus and C-terminus of the following structural formula is not limited, but preferably, the following structural formula is described in order from the N-terminus to the C-terminus:

[0161] [Heavy chain variable region (VH)]-[1st scFv linker]-[Albumin binding moiety (ABM)]-[2nd scFv linker]-[Light chain variable region (VL)]

[0162] The above [heavy chain variable region (VH)] and [light chain variable region (VL)] are characterized by being able to bind to PD-L1 together. This is explained in more detail below in [Composition (1) Heavy chain variable region and light chain variable region]. The above [Albumin binding moiety (ABM)] is characterized by having the ability to bind to albumin. This is explained in more detail in [Composition (2) scFv linker containing ABM].

[0163] Meanwhile, [first scFv linker], [second scFv linker], [albumin binding moiety (ABM)], [heavy chain variable region] or / and [light chain variable region] may each include one or more non-natural amino acids. The non-natural amino acid refers to a non-natural amino acid containing a click chemical functional group. This is explained in more detail in the [unnatural amino acid (UAA)] section.

[0164] The above-mentioned engineered anti-PD-L1 scFv has a structure that 1) maintains binding ability to PD-L1, 2) possesses binding ability to albumin, and 3) can be conjugated to a conjugated linker-ASGPR-targeting glycan compound. Furthermore, the above-mentioned engineered anti-PD-L1 scFv 4) can still retain binding ability to PD-L1 and albumin even when conjugated to a conjugated linker-ASGPR-targeting glycan compound. This is explained in more detail in [Characteristics of Engineered Anti-PD-L1 scFv].

[0165] Additionally, the engineered anti-PD-L1 scFv may further include additional sequences for expression at the terminals. For example, it may further include an initiation amino acid (e.g., methionine) required for expression at the N-terminus. Furthermore, the engineered anti-PD-L1 scFv may further include additional sequences required when using restriction enzymes to produce a vector expressing the engineered anti-PD-L1 scFv.

[0166] For example, an engineered anti-PD-L1 scFv may include an additional sequence consecutive to the initiation amino acid (methionine). For another example, an engineered anti-PD-L1 scFv may include an additional sequence at the C-terminus. Additionally, the engineered anti-PD-L1 scFv may further include a portion for purification at the terminal. For example, it may further include a His-tag portion at the C-terminus. For another example, an engineered anti-PD-L1 scFv may further include an additional sequence and a His-tag portion in the direction from the N-terminus to the C-terminus. It will be obvious to a person skilled in the art that such additional sequences or His-tag sequences do not significantly alter the properties of the protein depending on their presence or type.

[0167] The following describes in detail each component constituting the structure of the engineered anti-PD-L1 scFv.

[0168] Composition (1) Heavy chain variable portion and light chain variable portion

[0169] The engineered anti-PD-L1 scFv of the present application comprises variable regions of heavy chain (VH) and variable regions of light chain (VL).

[0170] The above heavy chain variable region may be derived from a single-strand variable domain of the heavy chain of an antibody having the ability to bind to PD-L1, and the above light chain variable region may be derived from a single-strand variable domain of the light chain of an antibody having the ability to bind to PD-L1. In addition, the above heavy chain variable region and the light chain variable region each include a complementary determining region (CDR), which is an antigen-binding site capable of directly binding to PD-L1. Therefore, the above heavy chain variable region and the light chain variable region can specifically bind by recognizing a specific part of PD-L1 as an epitope. Examples of antibodies having the ability to bind to PD-L1 are atezolizumab, durvalumab, or avelumab.

[0171] The above-mentioned heavy chain variable region and light chain variable region have amino acid lengths of 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, respectively. 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248,It may be selected from 249 or 250 aa. For example, the amino acid lengths of the heavy chain variable region and the light chain variable region may each be 50 to 250 aa. In one embodiment, the amino acid lengths of the heavy chain variable region and the light chain variable region may each be 100 to 130 aa.

[0172] Whether the heavy chain variable region and light chain variable region of the engineered anti-PD-L1 scFv of the present application contain non-natural amino acids may vary depending on the location where the non-natural amino acid is included in the engineered anti-PD-L1 scFv.

[0173] For example, in the case where the engineered anti-PD-L1 scFv of the present application contains non-natural amino acids only in the scFv linker containing ABM, the engineered anti-PD-L1 scFv may include a heavy chain variable region and a light chain variable region that do not contain non-natural amino acids.

[0174] As another example, the anti-PD-L1 scFv engineered in this application may include a heavy chain variable region containing a non-natural amino acid and a light chain variable region not containing a non-natural amino acid. As another example, the anti-PD-L1 scFv engineered in this application may include a heavy chain variable region not containing a non-natural amino acid and a light chain variable region containing a non-natural amino acid. As another example, the anti-PD-L1 scFv engineered in this application may include a heavy chain variable region and a light chain variable region, each containing a non-natural amino acid.

[0175] The heavy chain variable region and the light chain variable region each include one or more complementarity determining regions (CDRs) and form antigen binding regions involved in binding with antigens. Preferably, the heavy chain variable region and the light chain variable region each include three complementarity determining regions. Additionally, the heavy chain variable region and the light chain variable region each include one or more framework regions (FRs). Preferably, the heavy chain variable region and the light chain variable region each include four framework regions.

[0176] Accordingly, the above-mentioned heavy chain variable region and light chain variable region can each be represented in the following arrangement:

[0177] V H :[FR1]-[CDR1]-[FR2]-[CDR2]-[FR3]-[CDR3]-[FR4];

[0178] V L :[FR1]-[CDR1]-[FR2]-[CDR2]-[FR3]-[CDR3]-[FR4].

[0179] The above order refers to the direction from the N-terminal to the N-terminal.

[0180] In the following description, the meaning that the variable portion may include three CDRs means that, unless otherwise noted, they are included in the order of CDR1, CDR2, and CDR3. Also, in the following description, the meaning that the variable portion may include four FRs means that, unless otherwise noted, they are included in the order of FR1, FR2, FR3, and FR4.

[0181] If the above heavy chain variable region and light chain variable region include non-natural amino acids, the non-natural amino acids may preferably be included in the framework region.

[0182] The engineered anti-PD-L1 scFv of the present application may include non-natural amino acids in the heavy chain variable site and / or light chain variable site. Whether and where said non-natural amino acids are introduced may vary depending on the design.

[0183] For example, the heavy chain variable region and the light chain variable region may each independently include one or more non-natural amino acids. For another example, the heavy chain variable region may include one or more non-natural amino acids and the light chain variable region may not include any. For yet another example, the light chain variable region may include one non-natural amino acid and the heavy chain variable region may not include any.

[0184] As described in [Characteristics of Engineered Anti-PD-L1 scFv] below, the heavy chain variable site and light chain variable site included in the engineered anti-PD-L1 scFv of the present application are characterized by maintaining binding ability to PD-L1 even when non-natural amino acids are included, and furthermore, even when an ASGPR-targeting glycan is conjugated through the click chemical functional group of said non-natural amino acid.

[0185] Hereinafter, specific examples of heavy chain variable regions and light chain variable regions included in the engineered anti-PD-L1 scFv of the present application are described.

[0186] Composition (1) Specific examples of heavy chain variable portions and light chain variable portions

[0187] The sequences of the heavy chain variable region and the light chain variable region included in the engineered anti-PD-L1 scFv of the present application may vary. Hereinafter, the sequences of the heavy chain variable region and the light chain variable region are described as preferred examples.

[0188] For example, if the heavy chain variable region and light chain variable region included in the engineered anti-PD-L1 scFv of the present application do not contain non-natural amino acids, the heavy chain variable region and light chain variable region may each have the same sequence as the heavy chain variable region and light chain variable region of the antibody from which they originate.

[0189] In one specific example, if the heavy chain variable region included in the engineered anti-PD-L1 scFv of the present application is derived from atezolizumab and does not contain non-natural amino acids, the sequence of the heavy chain variable region may be the amino acid sequence represented by SEQ ID NO. 36. Additionally, if the light chain variable region included in the engineered anti-PD-L1 scFv of the present application is derived from atezolizumab and does not contain non-natural amino acids, the sequence of the light chain variable region may be the amino acid sequence represented by SEQ ID NO. 43.

[0190] In another specific example, if the heavy chain variable region included in the engineered anti-PD-L1 scFv of the present application is derived from durvalumab and does not contain non-natural amino acids, the sequence of the heavy chain variable region may be the amino acid sequence represented by SEQ ID NO. 48. Additionally, if the light chain variable region included in the engineered anti-PD-L1 scFv of the present application is derived from durvalumab and does not contain non-natural amino acids, the sequence of the light chain variable region may be the amino acid sequence represented by SEQ ID NO. 54.

[0191] In another specific example, if the heavy chain variable region included in the engineered anti-PD-L1 scFv of the present application is derived from avelumab and does not contain non-natural amino acids, the sequence of the heavy chain variable region may be the amino acid sequence represented by SEQ ID NO. 60. Additionally, if the light chain variable region included in the engineered anti-PD-L1 scFv of the present application is derived from avelumab and does not contain non-natural amino acids, the sequence of the light chain variable region may be the amino acid sequence represented by SEQ ID NO. 66.

[0192] As another example, if the heavy chain variable region included in the engineered anti-PD-L1 scFv of the present application contains a non-natural amino acid, said heavy chain variable region may be a modified version of one amino acid residue in the heavy chain variable region of the source antibody. Similarly, if the light chain variable region included in the engineered anti-PD-L1 scFv of the present application contains a non-natural amino acid, said light chain variable region may be a modified version of one amino acid residue in the light chain variable region of the source antibody. X in the sequence corresponding to each sequence number described in the following specific examples represents a non-natural amino acid.

[0193] In one embodiment, when the heavy chain variable region included in the engineered anti-PD-L1 scFv of the present application is derived from atezolizumab and contains non-natural amino acids, the sequence of the heavy chain variable region may be one amino acid sequence selected from SEQ ID NOs 37 to 42. Additionally, when the light chain variable region included in the engineered anti-PD-L1 scFv of the present application is derived from atezolizumab and contains non-natural amino acids, the sequence of the light chain variable region may be one amino acid sequence selected from SEQ ID NOs 44 to 47.

[0194] In another specific example, when the heavy chain variable region included in the engineered anti-PD-L1 scFv of the present application is derived from durvalumab and contains non-natural amino acids, the sequence of the heavy chain variable region may be one amino acid sequence selected from SEQ ID NOs 49 to 53. Additionally, when the light chain variable region included in the engineered anti-PD-L1 scFv of the present application is derived from durvalumab and contains non-natural amino acids, the sequence of the light chain variable region may be one amino acid sequence selected from SEQ ID NOs 55 to 59.

[0195] In another specific example, when the heavy chain variable region included in the engineered anti-PD-L1 scFv of the present application is derived from avelumab and contains non-natural amino acids, the sequence of the heavy chain variable region may be one amino acid sequence selected from SEQ ID NOs 61 to 65. Additionally, when the light chain variable region included in the engineered anti-PD-L1 scFv of the present application is derived from avelumab and contains non-natural amino acids, the sequence of the light chain variable region may be one amino acid sequence selected from SEQ ID NOs 67 to 72.

[0196] The sequences of the heavy chain variable region and the light chain variable region may be expressed as sequences having a certain degree of homology. For example, the heavy chain variable region sequence may include an amino acid sequence having about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% homology with any one of the amino acid sequences selected from SEQ ID NOs 36 to 42, 48 to 53 and 60 to 65. Additionally, the light chain variable region sequence may include an amino acid sequence having about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% homology with any one of the amino acid sequences selected from SEQ ID NOs 43 to 47, 54 to 59 and 66 to 72.

[0197] The heavy chain variable region and light chain variable region of the engineered anti-PD-L1 scFv of the present application may be represented as comprising a specific CDR and FR. Additionally, each FR described below may also be represented as a sequence having homology of a certain degree or greater. For example, a specific FR comprising the heavy chain variable region or light chain variable region of the engineered anti-PD-L1 scFv of the present application may include an amino acid sequence having about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% homology with any one of the amino acid sequences described below.

[0198] In one specific embodiment, when the heavy chain variable region of the anti-PD-L1 scFv engineered in this application is derived from atezolizumab and does not contain non-natural amino acids, the heavy chain variable region may include amino acid sequences represented by SEQ ID NOs 73 to 75 as CDRs and amino acid sequences represented by SEQ ID NOs 91 to 94 as FRs. Additionally, when the light chain variable region of the anti-PD-L1 scFv engineered in this application is derived from atezolizumab and does not contain non-natural amino acids, the light chain variable region may include amino acid sequences represented by SEQ ID NOs 76 to 78 as CDRs and amino acid sequences represented by SEQ ID NOs 101 to 104 as FRs.

[0199] In another specific example, where the heavy chain variable region of the anti-PD-L1 scFv engineered in this application is derived from durvalumab and does not contain non-natural amino acids, said heavy chain variable region may include amino acid sequences represented by SEQ ID NOs 79 to 81 as CDRs and amino acid sequences represented by SEQ ID NOs 109 to 112 as FRs. Additionally, where the light chain variable region of the anti-PD-L1 scFv engineered in this application is derived from durvalumab and does not contain non-natural amino acids, said light chain variable region may include amino acid sequences represented by SEQ ID NOs 82 to 84 as CDRs and amino acid sequences represented by SEQ ID NOs 118 to 121 as FRs.

[0200] In another specific example, when the heavy chain variable region of the anti-PD-L1 scFv engineered in this application is derived from avelumab and does not contain non-natural amino acids, said heavy chain variable region may include amino acid sequences represented by SEQ ID NOs 85 to 87 as CDRs and amino acid sequences represented by SEQ ID NOs 127 to 130 as FRs. Additionally, when the light chain variable region of the anti-PD-L1 scFv engineered in this application is derived from avelumab and does not contain non-natural amino acids, said light chain variable region may include amino acid sequences represented by SEQ ID NOs 88 to 90 as CDRs and amino acid sequences represented by SEQ ID NOs 136 to 139 as FRs.

[0201] In addition, even when the engineered anti-PD-L1 scFv of the present application comprises a heavy chain variable region and a light chain variable region comprising non-natural amino acids, said heavy chain variable region and light chain variable region may be represented as a structure comprising a specific CDR and FR. At least one of said FR may comprise a non-natural amino acid.

[0202] Hereinafter, examples are described regarding cases where one of FR1, FR2, FR3, and FR4 contains a non-natural amino acid. Additionally, each FR described below may also be expressed as a sequence having homology of a certain degree or higher. For example, a specific FR included in the heavy chain variable region or light chain variable region of the engineered anti-PD-L1 scFv of the present application may include an amino acid sequence having about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% homology with any one of the amino acid sequences described below. Preferably, among the specific FRs included in the heavy chain variable region or light chain variable region of the engineered anti-PD-L1 scFv of the present application, the FR that does not include non-natural amino acids may be expressed as a sequence having homology of a certain degree or higher.

[0203] In one embodiment, when the heavy chain variable region of the engineered anti-PD-L1 scFv of the present application contains non-natural amino acids and is derived from atezolizumab, said heavy chain variable region may include amino acid sequences represented by SEQ ID NOs 73 to 75 as CDRs. Additionally, it may include a framework region as shown in Table 1 below. In the following, "entire sequence" refers to the entire sequence of the heavy chain variable region including the complementarity determining region and the framework region.

[0204] Total Sequence FR1 FR2 FR3 FR4 Sequence Number 37 Sequence Number 91 Sequence Number 95 Sequence Number 93 Sequence Number 94 Sequence Number 38 Sequence Number 91 Sequence Number 92 Sequence Number 96 Sequence Number 94 Sequence Number 39 Sequence Number 91 Sequence Number 92 Sequence Number 97 Sequence Number 94 Sequence Number 40 Sequence Number 91 Sequence Number 92 Sequence Number 98 Sequence Number 94 Sequence Number 41 Sequence Number 91 Sequence Number 92 Sequence Number 99 Sequence Number 94 Sequence Number 42 Sequence Number 91 Sequence Number 92 Sequence Number 100 Sequence Number 94

[0205] Additionally, if the light chain variable region of the engineered anti-PD-L1 scFv of the present application contains non-natural amino acids and is derived from atezolizumab, said light chain variable region may include amino acid sequences represented by SEQ ID NOs 76 to 78 as CDRs. In addition, said light chain variable region may include a framework region as shown in Table 2 below. In the following, "entire sequence" refers to the entire sequence of the light chain variable region including the complementarity determining region and the framework region.

[0206] Total Sequence FR1 FR2 FR3 FR4 Sequence No. 44 Sequence No. 105 Sequence No. 102 Sequence No. 103 Sequence No. 104 Sequence No. 45 Sequence No. 106 Sequence No. 102 Sequence No. 103 Sequence No. 104 Sequence No. 46 Sequence No. 101 Sequence No. 107 Sequence No. 103 Sequence No. 104 Sequence No. 47 Sequence No. 101 Sequence No. 108 Sequence No. 103 Sequence No. 104

[0207] In one embodiment, when the heavy chain variable region of the engineered anti-PD-L1 scFv of the present application contains non-natural amino acids and is derived from durvalumab, said heavy chain variable region may include amino acid sequences represented by SEQ ID NOs 79 to 81 as CDRs. In addition, said heavy chain variable region may include a framework region as shown in Table 3 below. In the following, "entire sequence" refers to the entire sequence of the heavy chain variable region including the complementarity determining region and the framework region.

[0208] Total Sequence FR1 FR2 FR3 FR4 Sequence No. 49 Sequence No. 109 Sequence No. 113 Sequence No. 111 Sequence No. 112 Sequence No. 50 Sequence No. 109 Sequence No. 110 Sequence No. 114 Sequence No. 112 Sequence No. 51 Sequence No. 109 Sequence No. 110 Sequence No. 115 Sequence No. 112 Sequence No. 52 Sequence No. 109 Sequence No. 110 Sequence No. 116 Sequence No. 112 Sequence No. 53 Sequence No. 109 Sequence No. 110 Sequence No. 117 Sequence No. 112

[0209] In one embodiment, when the light chain variable region of the engineered anti-PD-L1 scFv of the present application contains non-natural amino acids and is derived from durvalumab, said light chain variable region may include amino acid sequences represented by SEQ ID NOs 82 to 84 as CDRs. In addition, said light chain variable region may include a framework region as shown in Table 4 below. In the following, "entire sequence" refers to the entire sequence of the light chain variable region including the complementarity determining region and the framework region.

[0210] Total Sequence FR1 FR2 FR3 FR4 Sequence No. 55 Sequence No. 122 Sequence No. 119 Sequence No. 120 Sequence No. 121 Sequence No. 56 Sequence No. 123 Sequence No. 119 Sequence No. 120 Sequence No. 121 Sequence No. 57 Sequence No. 124 Sequence No. 119 Sequence No. 120 Sequence No. 121 Sequence No. 58 Sequence No. 118 Sequence No. 119 Sequence No. 125 Sequence No. 121 Sequence No. 59 Sequence No. 118 Sequence No. 119 Sequence No. 126 Sequence No. 121

[0211] In one embodiment, when the heavy chain variable region of the engineered anti-PD-L1 scFv of the present application contains non-natural amino acids and is derived from avelumab, said heavy chain variable region may include amino acid sequences represented by SEQ ID NOs 85 to 87 as CDRs. In addition, said heavy chain variable region may include a framework region as shown in Table 5 below. In the following, "entire sequence" refers to the entire sequence of the heavy chain variable region including the complementarity determining region and the framework region.

[0212] Total Sequence FR1 FR2 FR3 FR4 Sequence No. 61 Sequence No. 127 Sequence No. 128 Sequence No. 131 Sequence No. 130 Sequence No. 62 Sequence No. 127 Sequence No. 128 Sequence No. 132 Sequence No. 130 Sequence No. 63 Sequence No. 127 Sequence No. 128 Sequence No. 133 Sequence No. 130 Sequence No. 64 Sequence No. 127 Sequence No. 128 Sequence No. 134 Sequence No. 130 Sequence No. 65 Sequence No. 127 Sequence No. 128 Sequence No. 129 Sequence No. 135

[0213] In one embodiment, when the light chain variable region of the engineered anti-PD-L1 scFv of the present application contains non-natural amino acids and is derived from avelumab, said light chain variable region may include amino acid sequences represented by SEQ ID NOs 88 to 90 as CDRs. Additionally, said light chain variable region may include a framework region as shown in Table 6 below. In the following, "entire sequence" refers to the entire sequence of the light chain variable region including the complementarity determining region and the framework region.

[0214] Total Sequence FR1 FR2 FR3 FR4 Sequence No. 67 Sequence No. 140 Sequence No. 137 Sequence No. 138 Sequence No. 139 Sequence No. 68 Sequence No. 141 Sequence No. 137 Sequence No. 138 Sequence No. 139 Sequence No. 69 Sequence No. 142 Sequence No. 137 Sequence No. 138 Sequence No. 139 Sequence No. 70 Sequence No. 143 Sequence No. 137 Sequence No. 138 Sequence No. 139 Sequence No. 71 Sequence No. 136 Sequence No. 137 Sequence No. 144 Sequence No. 139 Sequence No. 72 Sequence No. 136 Sequence No. 137 Sequence No. 145 Sequence No. 139

[0215] The heavy chain variable region or light chain variable region of the engineered anti-PD-L1 scFv of the present application may be represented as a whole sequence having a certain homology of the aforementioned range, while including a specific CDR and a FR containing non-natural amino acids.

[0216] For example, the anti-PD-L1 scFv engineered in this application may include a sequence having a certain homology to SEQ ID NO. 37 as a heavy chain variable region. Additionally, the heavy chain variable region may include amino acid sequences represented by SEQ ID NOs 76 to 78 as a CDR and SEQ ID NO. 95 as an FR2. For another example, the anti-PD-L1 scFv engineered in this application may include a sequence having a certain homology to SEQ ID NO. 44 as a light chain variable region. In this case, the light chain variable region may include amino acid sequences represented by SEQ ID NOs 76 to 78 as a CDR and SEQ ID NO. 105 as an FR1. For another example, other variable regions in Tables 1 to 6 may also include a non-natural amino acid in at least one of the FRs while maintaining the CDR configuration in the same manner as described above, and the entire sequence may be represented as a variable region having a certain range of homology.

[0217] Configuration (2) scFv linker including ABM

[0218] The engineered anti-PD-L1 scFv of the present application comprises a “scFv linker including an ABM” that connects the aforementioned heavy chain variable region and light chain variable region.

[0219] The scFv linker including the above ABM refers to a peptide linker including an albumin binding moiety (ABM), a first scFv linker, and a second scFv linker.

[0220] For example, an scFv linker containing the above ABM has a structure described below. In the structure below, the orientation of the N-terminus and the C-terminus is not limited, but preferably, the structure below is described in the order from the N-terminus to the C-terminus:

[0221] -[1st scFv linker]-[Albumin binding moiety (ABM)]-[2nd scFv linker]-.

[0222] In a preferred example, in a scFv linker comprising the ABM, the ABM is located between a first scFv linker and a second scFv linker. The first scFv linker refers to a polypeptide connecting a heavy chain variable region and an albumin binding moiety. Additionally, the second scFv linker refers to a polypeptide connecting a light chain variable region and an albumin binding moiety.

[0223] The first scFv linker and the second scFv linker have the function of controlling the relative distance and spatial orientation between the heavy chain variable region, the light chain variable region, and the albumin binding moiety. Through this, the first scFv linker and the second scFv linker maintain the flexibility, structural stability, and appropriate binding affinity to antigens and albumin of the engineered anti-PD-L1 scFv.

[0224] In order to maintain the flexibility, structural stability, and proper binding affinity to antigens and albumin of the engineered anti-PD-L1 scFv, the lengths of the first scFv linker and the second scFv linker can be appropriately selected. For example, the lengths of the first scFv linker and the second scFv linker may be selected from 1aa, 2aa, 3aa, 4aa, 5aa, 6aa, 7aa, 8aa, 9aa, 10aa, 11aa, 12aa, 13aa, 14aa, 15aa, 16aa, 17aa, 18aa, 19aa, 20aa, 21aa, 22aa, 23aa, 24aa, 25aa, 26aa, 27aa, 28aa, 29aa, and 30aa, respectively, or between two selected values. When the lengths of the first scFv linker and the second scFv linker are each 3aa or more, the engineered anti-PD-L1 scFv may possess flexibility, structural stability, binding affinity to antigens, and binding affinity to albumin. In one embodiment, the lengths of the first scFv linker and the second scFv linker may be 13aa.

[0225] For example, the sequences of the first scFv linker and the second scFv linker may each include (GS)n, (GGS)n, (GTSGS)n, (GGGGS)n, or a combination thereof. The n is any natural number and may be 1 to 10, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. The order of these combinations and the number of repetitions are not limited.

[0226] In one sun, one or more non-natural amino acids may be included in a linker site selected from the first scFv linker and the second scFv linker.

[0227] For example, the first scFv linker may contain one non-natural amino acid, and the second scFv linker may not contain one. For another example, the second scFv linker may contain one non-natural amino acid, and the first scFv linker may not contain one.

[0228] The scFv linker containing the above ABM includes an albumin binding moiety (ABM) as described above. The albumin binding moiety is a general term for a moiety composed of a peptide having the ability to bind to albumin. For example, the albumin binding moiety is a general term for a moiety composed of a peptide having the ability to bind to human serum albumin (HSA). In one embodiment, the albumin binding moiety may be a peptide known to have albumin binding ability derived from bacteria, etc.

[0229] When the engineered anti-PD-L1 scFv of the present application is administered into the body through the inclusion of an albumin-binding moiety, the albumin-binding moiety binds to albumin in the body, thereby increasing the half-life of the engineered anti-PD-L1 scFv. Additionally, the albumin-binding moiety binds to albumin in the body, thereby increasing the retention time of the engineered anti-PD-L1 scFv in the body. Furthermore, the albumin-binding moiety binds to albumin in the body, thereby enhancing the targeting of the engineered anti-PD-L1 scFv against tumors. The length of the albumin-binding moiety is not limited. For example, the amino acid lengths of the albumin-binding moiety are 5aa, 6aa, 7aa, 8aa, 9aa, 10aa, 11aa, 12aa, 13aa, 14aa, 15aa, 16aa, 17aa, 18aa, 19aa, 20aa, 21aa, 22aa, 23aa, 24aa, 25aa, 26aa, 27aa, 28aa, 29aa, 30aa, 31aa, 32aa, 33aa, 34aa, 35aa, 36aa, 37aa, 38aa, 39aa, 40aa, 41aa, 42aa, 43aa, 44aa, 45aa, 46aa, 47aa, 48aa, 49aa, 50aa, 51aa, 52aa, 53aa, 54aa, 55aa, 56aa, 57aa, 58aa, 59aa, 60aa, 61aa, 62aa, 63aa, 64aa, 65aa, 66aa, 67aa, 68aa, 69aa, 70aa, 71aa, 72aa, 73aa, 74aa, 75aa, 76aa, 77aa, 78aa, 79aa, 80aa, 81aa, 82aa, 83aa, 84aa, 85aa, 86aa, 87aa, 88aa, 89aa, 90aa, 91aa, 92aa, 93aa, 94aa, 95aa, 96aa, 97aa, 98aa, 99aa, 100aa, 101aa, 102aa, 103aa, 104aa, 105aa, 106aa, 107aa, 108aa, 109aa, 110aa, 111aa,112aa, 113aa, 114aa, 115aa, 116aa, 117aa, 118aa, 119aa, 120aa, 121aa, 122aa, 123aa, 124aa, 125aa, 126aa, 127aa, 128aa, 129aa, 130aa, 131aa, 132aa, 133aa, 134aa, 135aa, 136aa, 137aa, 138aa, 139aa, 140aa, 141aa, 142aa, 143aa, 144aa, 145aa, 146aa, 147aa, 148aa, 149aa, 150aa, 151aa, 152aa, 153aa, 154aa, 155aa, 156aa, 157aa, 158aa, 159aa, 160aa, 161aa, 162aa, 163aa, 164aa, 165aa, 166aa, 167aa, 168aa, 169aa, 170aa, 171aa, 172aa, 173aa, 174aa, 175aa, 176aa, 177aa, 178aa, 179aa, 180aa, 181aa, It may be a value selected from 182aa, 183aa, 184aa, 185aa, 186aa, 187aa, 188aa, 189aa, 190aa, 191aa, 192aa, 193aa, 194aa, 195aa, 196aa, 197aa, 198aa, 199aa, and 200aa. In one embodiment, the amino acid length of the albumin-bound moiety may be 30 to 150 aa. In another embodiment, the amino acid length of the albumin-bound moiety may be 30 to 50 aa.

[0230] The above albumin binding moiety is not limited to the type of albumin to which it can bind.

[0231] Hereinafter, specific examples of scFv linkers comprising an ABM included in the engineered claim PD-L1 scFv of the present application are described.

[0232] Composition (2) Specific example of a scFv linker including ABM

[0233] The scFv linker comprising ABM in this application is not limited to its sequence as long as it is a scFv linker capable of connecting VH and VL while comprising ABM. Hereinafter, a specific example of a scFv linker comprising ABM is described as a preferred example.

[0234] The sequence of the scFv linker containing the ABM of the present application may differ depending on the position in which the engineered anti-PD-L1 scFv of the present application contains a non-natural amino acid.

[0235] For example, in the case where the engineered anti-PD-L1 scFv of the present application does not contain non-natural amino acids in the scFv linker containing ABM, the sequences of the first scFv and the second scFv linker may be represented as SEQ ID NO. 146. Additionally, the albumin-binding moiety may be represented by the sequence of the albumin-binding domain derived from Streptococcal protein G (SEQ ID NO. 148). In another example, the albumin-binding moiety may be represented by the sequence derived from the protein PAB of Finegoldia magna (SEQ ID NO. 150). In yet another example, the albumin-binding moiety may be represented by the VNAR (V domain of cartilage oligomeric matrix protein, chondrocyte-derived) sequence derived from the cartilage oligomeric matrix protein of a sea shark (SEQ ID NO. 151). Preferably, the albumin-binding moiety may be an albumin-binding domain derived from Streptococcal protein G (SEQ ID NO. 148). As another example, a person skilled in the art may appropriately select and use known ABM sequences. For example, 10.1074 / jbc.M109943200, 10.1093 / protein / gzn028, 10.26355 / eurrev_202012_24038, or 10.1038 / s41589-021-00770-1 may be referenced.

[0236] In another example, when the engineered anti-PD-L1 scFv of the present application includes a non-natural amino acid in a scFv linker containing an ABM (preferably, when the engineered anti-PD-L1 scFv includes VH and VL derived from avelumab), the sequences of the first scFv and the second scFv linker may be represented by SEQ ID NO. 146, and the ABM may be represented by SEQ ID NO. 149. The ABM represented by SEQ ID NO. 149 refers to an albumin-binding domain derived from Streptococcal protein G in which one amino acid residue is modified to a non-natural amino acid.

[0237] unnatural amino acid (UAA)

[0238] As described above, the engineered anti-PD-L1 scFv of the present application comprises one or more non-natural amino acids. In one embodiment, one or more selected sites among the scFv linker comprising a heavy chain variable site, a light chain variable site, and an ABM comprise a non-natural amino acid.

[0239] The number of non-natural amino acids included in the engineered anti-PD-L1 scFv is not limited. For example, the engineered anti-PD-L1 scFv may include 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 non-natural amino acids. In one embodiment, it may include 1 or 2 non-natural amino acids.

[0240] Hereinafter, the types and positions of non-natural amino acids included in the engineered anti-PD-L1 scFv of the present application are described.

[0241] Types of non-natural amino acids

[0242] The non-natural amino acid included in the engineered anti-PD-L1 scFv of the present application is used to conjugate an ASGPR-targeting glycan through a click reaction. Accordingly, the non-natural amino acid is characterized by including a click chemical functional group capable of performing a click reaction.

[0243] The types of click chemical functional groups included in the above non-natural amino acid are not limited. For example, the above non-natural amino acid may include azide or tetrazine.

[0244] The click chemical functional group included in the above non-natural amino acid may be a functional group having special bioorthogonal reactivity [bioorthogonal functional group] that is not present in natural amino acids within the cell. For example, the above non-natural amino acid may include a click chemical functional group such as azide or tetrazine and a bioorthogonal reactive group.

[0245] The structure of the above-mentioned non-natural amino acid is not limited to any specific type as long as it contains a click chemical functional group.

[0246] For example, the above-mentioned non-natural amino acid may include the following click chemical functional groups:

[0247] [Chemical Formula 1-1]

[0248] (including 1,2,4,5-tetrazine), or

[0249] [Chemical Formula 1-2]

[0250] (including triazine),

[0251] R1 is any one selected from H, halogen, C1-3 alkyl, C3-6 cycloalkyl, C3-6 heterocycloalkyl, aryl and heteroaryl, and

[0252] The above heterocycloalkyl, or heteroaryl, comprises one or more heteroatom groups selected from the group consisting of -NH-, -O-, -S-, -ON=, -S(=O)-, and -S(=O)2-, or one or more heteroatoms selected from the group consisting of O, N, and S.

[0253] As another example, the above-mentioned non-natural amino acid may include the following click chemical functional groups:

[0254] [Chemical Formula 2]

[0255] (Azide).

[0256] Below, as examples of the above-mentioned non-natural amino acids, types of non-natural amino acids including azide or tetrazine are described in more detail. Furthermore, the non-natural amino acids mentioned below are described in the form of amino acid residues. Also, in the following figures, AA1 is an amino acid(s) or H connected to an amino acid with an alpha carbon connected to a junction, and AA2 is an amino acid(s) or OH connected to an amino acid with an alpha carbon connected to a junction. The fact that AA1 is H means that a non-natural amino acid represented by a specific chemical formula exists at the N-terminus, and represents a neutral state. Therefore, the fact that AA1 is H indicates that the N-terminus of the anti-PD-L1 scFv engineered according to the aqueous solution environment is in a quantized state (e.g., NH3 + It should not be interpreted as excluding the possibility that ) may be. Furthermore, the statement that the above AA2 is OH means that a non-natural amino acid represented by a specific chemical formula is present at the C-terminus. Also, in the same context as the above explanation regarding the N-terminus, the fact that the above AA2 is OH implies that the C-terminus of the engineered anti-PD-L1 scFv, depending on the aqueous environment, is in a quantized state (e.g., COO -It should not be interpreted as excluding the possibility that ) may be. Also, the presence of AA1 and AA2 should not be interpreted as restricting the position of non-natural amino acid residues. Additionally, AA1 and AA2 may be omitted.

[0257] In one embodiment, the non-natural amino acid may be represented by the following chemical formula:

[0258] [Chemical Formula 3-1]

[0259]

[0260] In this case, A1 is non-existent (i.e., combined) or -A 11 -A 12 - and,

[0261] At this time, A 11 is absent, or -C1-5alkylene-, and

[0262] At this time, A 12 is non-existent, or -[Arilene] p -, -[Arilen] p -C 1-5 Alkylene-, -[arylene] p -C 1-5 Heteroalkylene-, -arylene-C 1-5 Alkylene-arylene-, -arylene-C 1-5 Heteroalkylene-arylene-, -arylene-heteroarylene-, -[heteroarylene] p -, -[Heteroarylene] p -C 1-5 Alkylene-, -[heteroarylene] p -C 1-5 Heteroalkylene-, -heteroarylene-C 1-5 Alkylene-arylene-, -heteroarylene-C 1-5 Alkylene-heteroarylene-, -heteroarylene-C 1-5 Heteroalkylene-arylene-, and -heteroarylene-C 1-5 It is any one selected from heteroalkylene-heteroarylene-, where p is an integer between 1 and 3 inclusive, and

[0263] In this case, R1 is H, halogen, -C 1-3Alkyl, -C 3-6 Cycloalkyl, -C 3-6 It is any one selected from heterocycloalkyl, aryl, and heteroaryl, and

[0264] At this time, the heterocycloalkyl or heteroaryl comprises one or more heteroatom groups selected from the group consisting of -NH-, -O-, -S-, -ON=, -S(=O)-, and -S(=O)2-, or one or more heteroatoms selected from the group consisting of O, N, and S.

[0265] In one specific example, the non-natural amino acid may be 4-(1,2,4,5-tetrazin-3-yl)phenylalanine (4-(1,2,4,5-tetrazin-3-yl)phenylalanine)[frTet] represented by the following chemical formula 3-2, or 4-(6-methyl-1,2,4,5-tetrazin-3-yl)phenylalanine (4-(6-methyl-1,2,4,5-tetrazin-3-yl)phenylalanine)[Tet_v2.0] represented by the following chemical formula 3-3.

[0266] [Chemical Formula 3-2]

[0267] ,

[0268] [Chemical Formula 3-3]

[0269] .

[0270] In another embodiment, the non-natural amino acid may be represented by the following chemical formula:

[0271] [Chemical Formula 4-1]

[0272]

[0273] In this case, A1 is non-existent (i.e., combined) or -A 11 -A 12 - and,

[0274] At this time, A 11 is absent, or -C1-5alkylene-, and

[0275] At this time, A 12is non-existent, or -[Arilene] p -, -[Arilen] p -C 1-5 Alkylene-, -[arylene] p -C 1-5 Heteroalkylene-, -arylene-C 1-5 Alkylene-arylene-, -arylene-C 1-5 Heteroalkylene-arylene-, -arylene-heteroarylene-, -[heteroarylene] p -, -[Heteroarylene] p -C 1-5 Alkylene-, -[heteroarylene] p -C 1-5 Heteroalkylene-, -heteroarylene-C 1-5 Alkylene-arylene-, -heteroarylene-C 1-5 Alkylene-heteroarylene-, -heteroarylene-C 1-5 Heteroalkylene-arylene-, and -heteroarylene-C 1-5 It is any one selected from heteroalkylene-heteroarylene-, where p is an integer between 1 and 3 inclusive, and

[0276] At this time, the heterocycloalkyl or heteroaryl comprises one or more heteroatom groups selected from the group consisting of -NH-, -O-, -S-, -ON=, -S(=O)-, and -S(=O)2-, or one or more heteroatoms selected from the group consisting of O, N, and S.

[0277] In one specific embodiment, the non-natural amino acid may be p-azido-L-phenylalanine (pAzF) represented by the following chemical formula 4-2:

[0278] [Chemical Formula 4-2]

[0279]

[0280] Location of non-natural amino acids

[0281] The location in which the engineered anti-PD-L1 scFv of this application contains non-natural amino acids is not limited. Meanwhile, since the properties of the engineered anti-PD-L1 scFv of this application may change depending on the location in which the non-natural amino acids are included, it is important that the non-natural amino acids be included at an appropriate location. Below, the location in which the engineered anti-PD-L1 scFv of this application contains non-natural amino acids is described.

[0282] Prior to this, the non-natural amino acid positions contained in the engineered anti-PD-L1 scFv can be expressed in various ways. For example, the sequence of the engineered anti-PD-L1 scFv can be expressed by representing it as a sequence containing non-natural amino acids. In one specific embodiment, the non-natural amino acid positions contained in the engineered anti-PD-L1 scFv can be expressed by representing the sequence of the engineered anti-PD-L1 scFv as a specific amino acid sequence in which X is included at a specific position, and indicating that X is a specific non-natural amino acid. As another example, it can be expressed by specifying the amino acid positions that change to non-natural amino acids in the scFv (albubody) into which the albumin-binding moiety is inserted. In one specific example, the non-natural amino acid position of the engineered anti-PD-L1 scFv can be expressed by the fact that the specific engineered anti-PD-L1 scFv is a scFv in which a nth amino acid of an scFv (albubody) into which an albumin binding moiety of a specific sequence is inserted is changed to a specific non-natural amino acid.

[0283] In the above-described engineered anti-PD-L1 scFv, non-natural amino acids may be included at the location of one or more regions selected from a scFv linker including a heavy chain variable region, a light chain variable region, and an ABM. A detailed description thereof is as described in "Configuration (1) Heavy chain variable region and light chain variable region" and "Configuration (2) scFv linker including ABM".

[0284] The position of non-natural amino acids can be influenced by various factors. Meanwhile, the engineered anti-PD-L1 scFv of this application may be designed such that an amino acid at a specific position in the scFv (albubody) from which the albumin-binding moiety is inserted is changed to a non-natural amino acid. In this context, the position of the amino acid to be changed may be selected by considering the effect resulting from changing the amino acid at a specific position in the scFv (albubody) from which the albumin-binding moiety is inserted to a non-natural amino acid. First, the position of the non-natural amino acid may be selected by considering the effect that the insertion of the non-natural amino acid has on the structural stability of the engineered anti-PD-L1 scFv. Accordingly, the position of the non-natural amino acid may be selected by considering the degree of change in free energy resulting from changing the amino acid at a specific position in the scFv (albubody) from which the albumin-binding moiety is inserted to a non-natural amino acid. Second, the position of the non-natural amino acid can be selected considering its influence on the binding ability of the engineered anti-PD-L1 scFv to the antigen. For example, the position of the non-natural amino acid can be selected excluding the complementation determining site of the engineered anti-PD-L1 scFv. Third, the position of the non-natural amino acid can be selected considering the reaction between the conjugating linker and the ASGPR-targeting glycan compound when intending to link the ASGPR-targeting glycan. For example, the position of the non-natural amino acid can be selected considering solvent accessibility. Fourth, the position of the non-natural amino acid can be selected considering the expression yield of the engineered anti-PD-L1 scFv. For example, based on an albumin-binding scFv (albubody), the position of the non-natural amino acid can be selected by comparing whether another specific engineered anti-PD-L1 scFv in which a different amino acid is changed to a non-natural amino acid has a higher expression yield than a specific engineered anti-PD-L1 scFv in which a certain amino acid is changed to a non-natural amino acid.Detailed criteria for this are explained in more detail in [Site Selection Criteria for Non-Natural Amino Acids].

[0285] Below, for each example of an scFv with an inserted albumin-binding moiety, examples of the positions of non-natural amino acids in an engineered anti-PD-L1 scFv, which is a preferred example in which the positions of the non-natural amino acids are selected considering the above factors, are described.

[0286] For example, the scFv inserted with an albumin-binding moiety targeting antigen PDL1 may be a peptide consisting of the amino acid sequence of SEQ ID NO. 1 or SEQ ID NO. 155 (with a his-tag added to SEQ ID NO. 1), and the engineered anti-PD-L1 scFv of the present application may be a variant in which one or more amino acids selected from K45, S77, K78, S87, A90, E91, Q195, S201, K234, and K237 in the amino acid sequence of SEQ ID NO. 1 or SEQ ID NO. 155 are each changed to pAzF or frTet. In another expression, the engineered anti-PD-L1 scFv may be a fusion protein (polypeptide) comprising one amino acid sequence selected from SEQ ID NOs. 4 to 13 and 158 to 167. In SEQ ID NOs. 4 to 13 and 158 to 167, X is a non-natural amino acid. For example, X can be pAzF or frTet.

[0287] As another example, the scFv inserted with an albumin-binding moiety targeting antigen PDL1 may be a peptide consisting of the amino acid sequence of SEQ ID NO. 2 or SEQ ID NO. 156 (with a his-tag added to SEQ ID NO. 2), and the engineered anti-PD-L1 scFv of the present application may be a variant in which one or more amino acids selected from K45, A77, K78, S87, A90, V198, P203, G204, D256, and P276 in the amino acid sequence of SEQ ID NO. 2 are each changed to pAzF or frTet. In another expression, the engineered anti-PD-L1 scFv may be a fusion protein (polypeptide) comprising one amino acid sequence selected from SEQ ID NOs. 14 to 23 and 168 to 177. In SEQ ID NOs. 14 to 23 and 168 to 177, X is a non-natural amino acid. For example, X can be pAzF or frTet.

[0288] As another example, the scFv having an albumin-binding moiety targeting antigen PDL1 inserted may be a peptide consisting of the amino acid sequence of SEQ ID NO. 3 or SEQ ID NO. 157 (with a his-tag added to SEQ ID NO. 3), and the engineered anti-PD-L1 scFv of the present application may be a variant in which one or more amino acids selected from S77, S87, A90, E91, Q114, P181, S196, T199, A202, S203, S252, and S263 in the amino acid sequence of SEQ ID NO. 2 are changed to pAzF or frTet. In another expression, the engineered anti-PD-L1 scFv may be a fusion protein (polypeptide) comprising one amino acid sequence selected from SEQ ID NOs 24 to 35 and 178 to 189. In this case, in sequence numbers 24 to 35 and 178 to 189, X is a non-natural amino acid. For example, X may be pAzF or frTet.

[0289] Location selection criteria for non-natural amino acids

[0290] Depending on the position of the non-natural amino acid in the engineered anti-PD-L1 scFv of the present application, the function and effect of the engineered anti-PD-L1 scFv may vary.

[0291] For example, the binding affinity of the engineered anti-PD-L1 scFv may vary depending on the position of the non-natural amino acid included. In particular, the engineered anti-PD-L1 scFv is formed by changing one or more amino acids of the derived albubody to non-natural amino acids. Accordingly, changing one or more amino acids to non-natural amino acids can alter the binding affinity of the derived albubody to the antigen. That is, the binding affinity of the engineered anti-PD-L1 scFv may vary depending on the position of the non-natural amino acid. For example, changing the amino acid of the complementarity determining region of the albubody to a non-natural amino acid can alter the binding affinity of the albubody to the antigen. As another example, changing the amino acid of a part of the framework region of the albubody or a part of the scFv linker to a non-natural amino acid can alter the binding affinity of the albubody to the antigen.

[0292] Accordingly, the non-natural amino acid position of the engineered anti-PD-L1 scFv may be selected as a position that does not significantly alter the binding affinity to the antigen of the albubody. For example, the position of the non-natural amino acid may be selected as a position capable of possessing about 90% or more, about 80% or more, about 70% or more, about 60% or more, about 50% or more, about 40% or more, or about 30% or more of the binding affinity to the antigen of the albubody.

[0293] The above-mentioned engineered anti-PD-L1 scFv may have different binding affinities to albumin depending on the position of the non-natural amino acid it contains. In particular, the above-mentioned engineered anti-PD-L1 scFv is a modified version in which one or more amino acids of the derived albumin are changed to non-natural amino acids. Accordingly, changing one or more amino acids to non-natural amino acids can alter the binding affinity of the derived albumin to albumin. That is, the above-mentioned engineered anti-PD-L1 scFv may have different binding affinities to albumin depending on the position of the non-natural amino acid. For example, changing the amino acids of some framework regions of the albumin or some scFv linkers to non-natural amino acids can alter the binding affinity of the albumin to albumin.

[0294] For example, the non-natural amino acid position of the engineered anti-PD-L1 scFv may be selected to a position that does not significantly alter the binding affinity to the albumin of the albumin of the albumin. For example, the position of the non-natural amino acid may be selected to a position that retains about 90% or more, about 80% or more, about 70% or more, about 60% or more, about 50% or more, about 40% or more, or about 30% or more of the binding affinity to the albumin of the albumin of the albumin.

[0295] The degree of binding affinity of the above-mentioned engineered anti-PD-L1 scFv and albumin to antigens and albumin can be measured in various ways. For example, the binding affinity can be measured through an evaluation of binding affinity to antigens and albumin.

[0296] The above-mentioned engineered anti-PD-L1 scFv is a modified version in which one or more amino acids of the source albumin are changed to non-natural amino acids. Due to the modified non-natural amino acids, the engineered anti-PD-L1 scFv may have structural differences from the source albumin. Accordingly, changing one or more amino acids to non-natural amino acids can alter the function and structure of the albumin. For example, it may affect the binding affinity to the antigen and the binding affinity to albumin. In this case, structural changes based on the position of the non-natural amino acids are not predicted solely by the region (position) containing the non-natural amino acids. That is, the position of the non-natural amino acids must be individually selected by considering the structure of the albumin that forms the basis of the engineered anti-PD-L1 scFv, the composition of the albumin, the length of the albumin, etc.

[0297] To select the position of the above-mentioned non-natural amino acid, a natural amino acid (similar amino acid) having a structure similar to the non-natural amino acid to be modified may be used. That is, if the amino acid at a specific position of the albubody forming the basis of the engineered anti-PD-L1 scFv is changed to a natural amino acid having a structure similar to the non-natural amino acid to be modified, the non-natural amino acid modification site can be selected at a position with a small change in free energy.

[0298] For example, to select the position of pAzF, tyrosine or phenylalanine having a structure similar to pAzF can be used. That is, if the amino acid at a specific position of the albubody that forms the basis of the engineered anti-PD-L1 scFv is changed to tyrosine or phenylalanine, the position of pAzF can be selected at a position with a small change in free energy. This can be applied as is when the natural amino acid most similar to the non-natural amino acid to be inserted is tyrosine or phenylalanine. In other words, the position of pAzF selected by the above method can also be used as a position for inserting the other non-natural amino acid. For example, it can also be used as a position for inserting ftTet.

[0299] The non-natural amino acid position of the above-mentioned engineered anti-PD-L1 scFv can be selected considering accessibility to the solvent.

[0300] The above-mentioned engineered anti-PD-L1 scFv is produced using a cell line capable of producing proteins with inserted non-natural amino acids and a vector containing a specific codon (e.g., an amber codon) encoding the engineered anti-PD-L1 scFv.

[0301] At this time, even among engineered anti-PD-L1 scFvs produced based on the same albubody, the degree of expression of the engineered anti-PD-L1 scFv varies depending on where the position is changed to a non-natural amino acid. In particular, the degree of expression in the receptor state differs. The higher the degree of expression in the receptor state, the higher the proportion of engineered anti-PD-L1 scFv that can be used without additional processing. That is, an engineered anti-PD-L1 scFv containing a non-natural amino acid at a specific position may be an engineered anti-PD-L1 scFv that is better expressed in the receptor state compared to an engineered anti-PD-L1 scFv containing a non-natural amino acid at a different position, even if the composition other than the non-natural amino acid position is identical. In this specification, the meaning of being better expressed in the receptor state may also be expressed as having a high expression yield. Furthermore, the above comparison may be made in various ways according to known technology.

[0302] Additionally, the position of the above non-natural amino acid can be selected considering solvent accessibility.

[0303] Characteristics of engineered anti-PD-L1 scFv (1)_maintaining the characteristics of scFv

[0304] The engineered anti-PD-L1 scFv of the present application can be fabricated based on a conventional scFv. Accordingly, the engineered anti-PD-L1 scFv can possess various characteristics of the scFv.

[0305] First, engineered anti-PD-L1 scFv possesses high diffusivity, vascular permeability, and tissue permeability. Consequently, engineered anti-PD-L1 scFv penetrates deep into tumor tissue more easily than full-length antibodies. Second, engineered anti-PD-L1 scFv can be produced in a microorganism-based expression system. As a result, engineered anti-PD-L1 scFv can be produced at a relatively low production cost. Third, since engineered anti-PD-L1 scFv does not contain Fc, an Fc-mediated immune response does not occur. Therefore, the engineered anti-PD-L1 scFv does not have side effects caused by Fc-mediated immune responses.

[0306] Furthermore, the engineered anti-PD-L1 scFv of the present application possesses binding ability to an antigen. In particular, the engineered anti-PD-L1 scFv of the present application is characterized by possessing binding ability to an antigen despite containing non-natural amino acids. Additionally, it is a feature of the engineered anti-PD-L1 scFv of the present application that binding ability to the antigen can be maintained even when an ASGPR-targeting glycan is conjugated to the engineered anti-PD-L1 scFv of the present application.

[0307] Characteristics of engineered anti-PD-L1 scFv (2)_Half-life can be increased through albumin attachment

[0308] The engineered anti-PD-L1 scFv of the present application possesses several characteristics, including an albumin-binding moiety. First, the half-life of the engineered anti-PD-L1 scFv can be enhanced by the binding of albumin to the albumin-binding moiety. Second, the engineered anti-PD-L1 scFv enables FcRn-mediated recycling by the binding of albumin to the albumin-binding moiety. Furthermore, the engineered anti-PD-L1 scFv is not renally excreted through the albumin bound to the albumin-binding moiety. Third, the engineered anti-PD-L1 scFv can achieve stronger tumor targeting by binding to serum albumin. This is because albumin accumulates more preferentially in malignant and inflammatory tissues that have highly permeable blood vessels and lack efficient lymphatic drainage. Additionally, receptor-mediated endocytosis further promotes the accumulation of albumin within the tumor. Accordingly, this can serve as a means to more easily target the tumor site.

[0309] The engineered anti-PD-L1 scFv of the present application has an increased half-life by binding to albumin. For example, when albumin is bound to the engineered anti-PD-L1 scFv of the present application, compared to the engineered anti-PD-L1 scFv or scFv without albumin binding, the half-life is about 10 times, about 20 times, about 30 times, about 40 times, about 50 times, about 60 times, about 70 times, about 80 times, about 90 times, about 100 times, about 110 times, about 120 times, about 130 times, about 140 times, about 150 times, about 160 times, about 170 times, about 180 times, about 190 times, about 200 times, about 210 times, about 220 times, about 230 times, about 240 times, about 250 times, about 260 times, about 270 times, about 280 times, about 290 times, about It can be increased by 300 times, approximately 310 times, approximately 320 times, approximately 330 times, approximately 340 times, approximately 350 times, approximately 360 times, approximately 370 times, approximately 380 times, approximately 390 times, approximately 400 times, approximately 410 times, approximately 420 times, approximately 430 times, approximately 440 times, approximately 450 times, approximately 460 times, approximately 470 times, approximately 480 times, approximately 490 times, and approximately 500 times. In one specific example, it can be increased by more than about 200 times.

[0310] Characteristics of engineered anti-PD-L1 scFv (3)_ASGPR targeting glycan conjugable

[0311] The engineered anti-PD-L1 scFv of the present application is characterized by comprising a non-natural amino acid containing a click chemical functional group. Additionally, the engineered anti-PD-L1 scFv of the present application may be designed with the position of the non-natural amino acid in consideration of solvent accessibility. Accordingly, the engineered anti-PD-L1 scFv of the present application may be characterized by being able to conjugate to an ASGPR-targeting glycan. More specifically, the engineered anti-PD-L1 scFv of the present application may be characterized by being able to conjugate to a conjugating linker-ASGPR-targeting glycan compound. A detailed explanation thereof is provided below in [Chapter 6: Method for Producing Engineered Anti-PD-L1 scFv Conjugate].

[0312] Characteristics of engineered anti-PD-L1 scFv (4)_Retains characteristics (1) and (2) even when conjugated with ASGPR targeting glycans.

[0313] The engineered anti-PD-L1 scFv of the present application may be characterized by maintaining the characteristics of the aforementioned scFv and the characteristics of the ABM-containing protein even when conjugated with a conjugating linker-ASGPR targeting glycan compound.

[0314] Uses of engineered anti-PD-L1 scFv

[0315] The anti-PD-L1 scFv engineered in this application can be used to produce the anti-PD-L1 scFv conjugate engineered in this application. That is, the anti-PD-L1 scFv engineered in this application can be used for conjugation with an ASGPR-targeting glycan. Meanwhile, the anti-PD-L1 scFv engineered in this application can be used as described above only if a click chemical functional group (a second click chemical functional group) capable of reacting with a click chemical functional group (a first click chemical functional group) included in the anti-PD-L1 scFv engineered in this application is connected to the ASGPR-targeting glycan. Therefore, it can also be expressed that the anti-PD-L1 scFv engineered in this application is used for conjugation with a conjugating linker-ASGPR-targeting glycan compound containing the second click chemical functional group.

[0316] Specific example of engineered anti-PD-L1 scFv

[0317] Hereinafter, specific embodiments of the engineered claim PD-L1 scFv of the present application are described. The following embodiments are merely examples and are not limited thereto.

[0318] For example, the engineered anti-PD-L1 scFv may be a variant designed based on a scFv derived from a specific antibody. In one embodiment, the engineered anti-PD-L1 scFv may be a variant made based on an atezolizumab, durvalumab, or avelumab-derived scFv (e.g., a scFv with VH and VL linked to the scFv represented by SEQ ID NO. 147) (other examples, SEQ ID NOs. 152 to 154, respectively; SEQ ID NOs. 190 to 192, respectively, where a Hig-tag is included).

[0319] For example, the engineered anti-PD-L1 scFv may be an engineered anti-PD-L1 scFv based on a scFv (albubody) with an inserted albumin-binding moiety designed using a scFv derived from a specific antibody and an ABD derived from Streptococcal protein G. In one embodiment, it may be an engineered anti-PD-L1 scFv based on a scFv (albubody) with an inserted albumin-binding moiety comprising one of the amino acid sequences represented by SEQ ID NOs 1 to 3.

[0320] In one specific example, the engineered anti-PD-L1 scFv may be a variant protein comprising an amino acid sequence selected from SEQ ID NOs 4 to 35. In this case, X included in SEQ ID NOs 4 to 35 refers to a non-natural amino acid. In this case, X included in SEQ ID NOs 4 to 35 may refer to pAzF or frTet.

[0321] In one specific example, the engineered anti-PD-L1 scFv may be a variant in which one or more amino acid residues selected from K45, K78, S77, S87, A90, E91, Q195, S201, K234, and K237 in a scFv (albubody) having an albumin-binding moiety inserted as SEQ ID NO. 1 are changed to non-natural amino acids. In this case, the non-natural amino acid may be pAzF or frTet.

[0322] In one specific example, the engineered anti-PD-L1 scFv may be a variant in which one or more amino acid residues selected from K45, A77, K78, S87, A90, V198, P203, G204, D256, and P276 in a scFv (albubody) having an albumin-binding moiety inserted as SEQ ID NO. 2 are changed to non-natural amino acids. In this case, the non-natural amino acid may be pAzF or frTet.

[0323] In one specific example, the engineered anti-PD-L1 scFv may be a variant in which one or more amino acid residues selected from S77, S87, A90, E91, Q114, P181, S196, T199, A202, S203, S252, and S263 in a scFv (albubody) having an albumin-binding moiety inserted as SEQ ID NO. 3 are changed to non-natural amino acids. In this case, the non-natural amino acid may be pAzF or frTet.

[0324] Table 8 describes specific examples of the engineered anti-PD-L1 scFv of the present application, including locations and regions containing each non-natural amino acid. In the table below, "origin" refers to the antibody from which the heavy chain variable region or light chain variable region of the engineered anti-PD-L1 scFv originated. Additionally, "classification" refers to numbering to distinguish the engineered anti-PD-L1 scFv from one another. Furthermore, "albubody sequence" refers to the entire sequence of the scFv (albubody) containing the albumin moiety that formed the basis of the engineered anti-PD-L1 scFv. "Full-length sequence" refers to the full-length sequence of the engineered anti-PD-L1 scFv. "Regions and sequences containing non-natural amino acids" indicates the regions of the engineered anti-PD-L1 scFv containing non-natural amino acids and the sequences of the corresponding regions. For example, if the engineered anti-PD-L1 scFv contains a non-natural amino acid in the FR3 of the light chain variable region, it is indicated as "VH_FR3, SEQ ID NO OO". Except for the indicated region, it includes a region with the same sequence as the underlying albumin. "Position" indicates the insertion location of the non-natural amino acid relative to the underlying albumin sequence. Additionally, the following specific sequence includes a sequence (MG) in which the aforementioned initiating amino acid and an addition sequence are consecutive at the N-terminus, and an addition sequence (LE) at the C-terminus. Furthermore, for the engineered anti-PD-L1 scFv represented by one of the amino acids in SEQ ID NOs 4 to 35, the sequence additionally including His-Tag (HHHHHH) at the C-terminus is represented by one of the amino acid sequences 158 to 189.

[0325] Derivative Classification Albubody Sequence Full Length Sequence Non-natural Amino Acid Containing Region and Sequence Location Atezolizumab 1 Sequence No. 1 Sequence No. 4 VH_FR2, Sequence No. 95 K45 Atezolizumab 2 Sequence No. 1 Sequence No. 5 VH_FR3, Sequence No. 96 K78 Atezolizumab 3 Sequence No. 1 Sequence No. 6 VL_FR1, Sequence No. 105 S201 Atezolizumab 4 Sequence No. 1 Sequence No. 7 VL_FR2, Sequence No. 107 K234 Atezolizumab 5 Sequence No. 1 Sequence No. 8 VL_FR2, Sequence No. 108 K237 Atezolizumab 6 Sequence No. 1 Sequence No. 9 VH_FR3, Sequence No. 97 S77 Atezolizumab 7 Sequence No. 1 Sequence No. 10 VH_FR3, Sequence No. 98S87 Atezolizumab 8 Sequence No. 1 Sequence No. 11 VH_FR3, Sequence No. 99A90 Atezolizumab 9 Sequence No. 1 Sequence No. 12 VH_FR3, Sequence No. 100E91 Atezolizumab 10 Sequence No. 1 Sequence No. 13 VL_FR1, Sequence No. 106Q195 Durvalumab 1 Sequence No. 2 Sequence No. 14 VH_FR3, Sequence No. 114K78 Durvalumab 2 Sequence No. 2 Sequence No. 15 VH_FR3, Sequence No. 115S87 Durvalumab 3 Sequence No. 2 Sequence No. 16 VH_FR3, Sequence No. 116A90 Durvalumab 4 Sequence No. 2 Sequence No. 17 VL_FR3, Sequence No. 125D256 Durvalumab 5 Sequence No. 2 Sequence No. 18VL_FR3, Sequence No. 126P276 durvalumab 6 Sequence No. 2 Sequence No. 19VH_FR2, Sequence No. 113K45 durvalumab 7 Sequence No. 2 Sequence No. 20VH_FR3, Sequence No. 117A77 durvalumab 8 Sequence No. 2 Sequence No. 21VL_FR1, Sequence No. 122V198 durvalumab 9 Sequence No. 2 Sequence No. 22VL_FR1, Sequence No. 123P203 durvalumab 10 Sequence No. 2 Sequence No. 23VL_FR1, Sequence No. 124G204 avelumab 1 Sequence No. 3 Sequence No. 24VH_FR3, Sequence No. 131S77 avelumab 2 Sequence No. 3 Sequence No. 25VH_FR3, Sequence No. 132S87 avelumab 3 Sequence No. 3 Sequence No. 26VH_FR3, Sequence No. 133A90 Avelumab 4 Sequence No. 3 Sequence No. 27VH_FR3, Sequence No. 134E91 Avelumab 5 Sequence No. 3 Sequence No. 28VH_FR4, Sequence No. 135Q114 Avelumab 6 Sequence No. 3 Sequence No. 29ABM,Sequence No. 149P181 Avelumab 7 Sequence No. 3 Sequence No. 30 VL_FR1, Sequence No. 140S196 Avelumab 8 Sequence No. 3 Sequence No. 31 VL_FR1, Sequence No. 141T199 Avelumab 9 Sequence No. 3 Sequence No. 32 VL_FR1, Sequence No. 142A202 Avelumab 10 Sequence No. 3 Sequence No. 33 VL_FR1, Sequence No. 143S203 Avelumab 11 Sequence No. 3 Sequence No. 34 VL_FR3, Sequence No. 144S252 Avelumab 12 Sequence No. 3 Sequence No. 35 VL_FR3, Sequence No. 145S263,

[0326] The engineered anti-PD-L1 scFv of the present application may be represented as a sequence having a certain homology to the entire sequence while including specific CDRs and FRs. For each full-length sequence, the CDRs and FRs are as described above in "Specific examples of configuration (1) heavy chain variable regions and light chain variable regions." As an example, the engineered anti-PD-L1 scFv of the present application may include a sequence having a certain homology to SEQ ID NO. 4. In this case, the engineered anti-PD-L1 scFv includes amino acid sequences represented by SEQ ID NOs. 76 to 78 as CDRs and includes SEQ ID NO. 95 as anti-PD-L1 VH_FR2. As another example, the above representation is also possible for other engineered anti-PD-L1 scFvs in Table 7.

[0327]

[0328] Chapter 2 Engineered Anti-PD-L1 scFv Conjugate

[0329] generalization

[0330] This specification discloses an engineered anti-PD-L1 scFv conjugate.

[0331] The above-mentioned engineered anti-PD-L1 scFv conjugate refers to a conjugate in which an ASGPR-targeting glycan is conjugated to the aforementioned engineered anti-PD-L1 scFv. Accordingly, in this specification, the above-mentioned engineered anti-PD-L1 scFv conjugate may also be referred to as an 'engineered anti-PD-L1 scFv-glycan conjugate'.

[0332] The engineered anti-PD-L1 scFv conjugate of the present application is not limited to any specific structure, provided that an ASGPR-targeting glycan is conjugated using the click chemical functional group of a non-natural amino acid of the aforementioned engineered anti-PD-L1 scFv. However, for the convenience of description, this specification describes the engineered anti-PD-L1 scFv conjugate of the present application by exemplifying a specific structure. To explain the said structure, an example of the process by which the engineered anti-PD-L1 scFv conjugate is formed is provided.

[0333] Engineered anti-PD-L1 scFv conjugates can be produced by conjugating engineered anti-PD-L1 scFv with a conjugating linker-ASGPR targeting glycan compound. That is, engineered anti-PD-L1 scFv conjugates can be produced by the reaction of the click chemical functional groups on the side chains of non-natural amino acids contained in the engineered anti-PD-L1 scFv with the click chemical functional groups contained on the conjugating linker side to form covalent bonds. When each click chemical functional group reacts as described above, a specific chemical structure will be generated as a reaction product.

[0334] In this specification, in order to appropriately divide and explain the results produced by the above result:

[0335] 1) A structure formed by the reaction of a side chain of a non-natural amino acid contained in an engineered anti-PD-L1 scFv with a click chemical functional group contained on the conjugating linker side is referred to as a [junction];

[0336] 2) Among the parts derived from the engineered anti-PD-L1 scFv, the part connected to the junction is referred to as [engineered anti-PD-L1 scFv];

[0337] 3) Among the parts derived from the conjugating linker, the part that connects the junction and the ASGPR targeting glycan is referred to as the [connector];

[0338] 4) ASGPR-targeting glycans are referred to as [glycans].

[0339] Consequently, as an example of the present application, the anti-PD-L1 scFv conjugate engineered in the present application can be represented by the following structural formula:

[0340] <Structural Formula>

[0341] [engineered anti PD-L1 scFv (S)]-[junction (J)]-[linking group (L)]-[Glycan (G)] k .

[0342] The above [engineered anti-PD-L1 scFv] refers to a unit having almost the same configuration as the aforementioned engineered anti-PD-L1 scFv but connected to a junction. Meanwhile, as described above regarding the engineered anti-PD-L1 scFv, the [engineered anti-PD-L1 scFv] as a configuration of the junction may be referred to in various ways in this specification as needed, such as an engineered anti-PD-L1 scFv unit, an albubody variant unit, etc.

[0343] The above [conjugate] refers to a structure in which the side chain of a non-natural amino acid of engineered anti-PD-L1 scFv used in the production of engineered anti-PD-L1 scFv conjugates and the click chemical functional group of a conjugating linker react.

[0344] The [linker] above refers to the portion of the conjugating linker-ASGPR-targeting glycan compound used in the production of the engineered anti-PD-L1 scFv conjugate, excluding the click chemical functional group and the ASGPR-targeting glycan. In other words, the [linker] above refers to the portion that connects the junction and the glycan in the engineered anti-PD-L1 scFv conjugate.

[0345] The above [glycan] refers to an ASGPR-targeting glycan coupled to an anti-PD-L1 scFv engineered through a junction and a connector. Additionally, k is a natural number selected from 1 to 30. In a preferred example, k may be from 1 to 6.

[0346] The engineered anti-PD-L1 scFv conjugate of the present application is not limited in type or production method, provided that it is expressed by the structure of the aforementioned engineered anti-PD-L1 scFv. For example, the engineered anti-PD-L1 scFv conjugate may be a conjugate produced by conjugating the engineered anti-PD-L1 scFv with a conjugating linker-ASGPR targeting glycan compound through a click chemical reaction. For another example, the engineered anti-PD-L1 scFv conjugate may be a conjugate produced by conjugating the engineered anti-PD-L1 scFv with a conjugating linker through a click chemical reaction, and conjugating the ASGPR targeting glycan by reacting with another part of the conjugated conjugating linker.

[0347] Hereinafter, each component of the engineered anti-PD-L1 scFv conjugate of the present application is described in detail.

[0348] Configuration (1) S (Engineered Anti-PD-L1 scFv)

[0349] The engineered anti-PD-L1 scFv conjugate of the present application comprises engineered anti-PD-L1 scFv.

[0350] In this case, the engineered anti-PD-L1 scFv included in the above-mentioned engineered anti-PD-L1 scFv conjugate refers to an engineered anti-PD-L1 scFv unit. Accordingly, as necessary, S within the conjugate in this specification may be referred to as "engineered anti-PD-L1 scFv" or "engineered anti-PD-L1 scFv unit" depending on the context. The specific configuration of the above-mentioned engineered anti-PD-L1 scFv is included by reference to the contents of "Chapter 1 Engineered Anti-PD-L1 scFv" mentioned above.

[0351] As mentioned above, the engineered anti-PD-L1 scFv unit included in the conjugate refers to the remaining portion of the derived engineered anti-PD-L1 scFv, excluding the conjugate formed by the reaction of the side chain of a non-natural amino acid with the click chemical functional group of the conjugating linker.

[0352] Accordingly, the above-mentioned engineered anti-PD-L1 scFv unit may have a form in which one or more amino acid residues are connected to the junction. In this case, the junction is formed through the side chain of the non-natural amino acid residue, and as a result, the alpha carbon (α-carbon) of the corresponding amino acid residue is connected to the junction as part of the protein backbone. Below, the engineered anti-PD-L1 scFv unit of this form is described in more detail.

[0353] The engineered anti-PD-L1 scFv unit included in the engineered anti-PD-L1 scFv conjugate of the present application may be represented as containing one or more amino acid residues represented by the following chemical formula 5 to express the connection relationship with the conjugate. The position of the amino acid residue represented by the following chemical formula 5 is the position of the non-natural amino acid of the free-engineered anti-PD-L1 scFv used in the production of the conjugate. Meanwhile, for convenience of designation, the amino acid residue represented by the following chemical formula 5 may also be referred to as the type of non-natural amino acid of the free-engineered anti-PD-L1 scFv from which it originated.

[0354] [Chemical Formula 5]

[0355]

[0356] AA1 means an amino acid residue connected to the conjugate as a result of conjugation and an amino acid(s) or hydrogen (H) connected at the N-terminal side, and AA2 means an amino acid(s) or hydroxyl group (OH) connected to the amino acid residue and an amino acid connected at the C-terminal side.

[0357] The fact that AA1 is H above means that the amino acid represented by [Chemical Formula 5] is present at the N-terminus, and it represents a neutral state. Therefore, the fact that AA1 is H above indicates that the N-terminus of the anti-PD-L1 scFv unit engineered according to the aqueous environment is in a quantized state (e.g., NH3 + It should not be interpreted as excluding the possibility that it may be.

[0358] Furthermore, the statement that the above AA2 is OH means that the amino acid represented by [Chemical Formula 5] is present at the C-terminus. Also, in the same context as the above explanation regarding the N-terminus, the fact that the above AA2 is OH implies that the C-terminus of the anti-PD-L1 scFv unit engineered according to the aqueous environment is in a quantized state (e.g., COO - It should not be interpreted as excluding the possibility that it may be.

[0359] In addition, the presence of AA1 and AA2 in the above [Formula 5] should not be interpreted as restricting the position of the amino acid residue represented by [Formula 5].

[0360] If necessary, the above [Formula 5] may be replaced with the following [Formula 5-1]. [Formula 5-1] represents the same amino acid residues as [Formula 5], but the expression that it is connected to AA1 and AA2 is omitted from the formula. Unless otherwise specifically noted, [Formula 5-1] should be interpreted as being connected to AA1 and AA2 in the same sense as described above.

[0361] [Chemical Formula 5-1]

[0362]

[0363] In addition, as previously mentioned, J is a junction, L is a linking group, G is a glycan, and g is a natural number selected from 1 to 10. The junction, linking group, and glycan are described in more detail in a separate section below.

[0364] In one embodiment, the engineered anti-PD-L1 scFv unit may be represented as comprising a specific amino acid sequence. In one embodiment, the engineered anti-PD-L1 scFv unit may be represented as being composed of a specific amino acid sequence including X, wherein X may be an amino acid represented by the aforementioned [Formula 5].

[0365] Composition (2) J (joint)

[0366] The engineered anti-PD-L1 scFv junction of the present application comprises a junction (J).

[0367] The above conjugate is a structure formed by the reaction of the non-natural amino acid side chain of the free-engineered anti-PD-L1 scFv and the second click chemical functional group of the conjugating linker during the process of manufacturing the engineered anti-PD-L1 scFv conjugate. That is, the above conjugate contains elements derived from the free-engineered anti-PD-L1 scFv prior to conjugation. Additionally, the above conjugate contains elements derived from the conjugating linker prior to conjugation.

[0368] The above conjugate is not limited to any type provided that the engineered anti-PD-L1 scFv conjugate of the present application is stably maintained under desired physiological conditions (e.g., inside blood) and is not cleaved while circulating through various tissues.

[0369] In addition, the above junction is not limited to any specific type as long as it is a structure formed by the reaction of a non-natural amino acid side chain of a free-engineered anti-PD-L1 scFv and a click chemical functional group of a conjugating linker.

[0370] For example, the junction may include a structure formed by connecting a side chain containing tetrazine of an engineered anti-PD-L1 scFv and a corresponding click chemical functional group.

[0371] In one specific example, the joint may be represented by the following chemical formula. Additionally, the following chemical formulas are intended to represent the structure of the joint, and the meanings of S, L, and [G]g in the following chemical formulas are as described above.

[0372] [Chemical Formula 6-1]

[0373]

[0374] A1 is non-existent (i.e., combined) or -A 11 -A 12 - and,

[0375] A 11 is absent, or -C1-5alkylene-, and

[0376] A12 is non-existent, or -[Arilene] p -, -[Arilen] p -C 1-5 Alkylene-, -[arylene] p -C 1-5 Heteroalkylene-, -arylene-C 1-5 Alkylene-arylene-, -arylene-C 1-5 Heteroalkylene-arylene-, -arylene-heteroarylene-, -[heteroarylene] p -, -[Heteroarylene] p -C 1-5 Alkylene-, -[heteroarylene] p -C 1-5 Heteroalkylene-, -heteroarylene-C 1-5 Alkylene-arylene-, -heteroarylene-C 1-5 Alkylene-heteroarylene-, -heteroarylene-C 1-5 Heteroalkylene-arylene-, and -heteroarylene-C 1-5 It is any one selected from heteroalkylene-heteroarylene-, where p is an integer between 1 and 3 inclusive, and

[0377] R1 is H, halogen, -C 1-3 Alkyl, -C 3-6 Cycloalkyl, -C 3-6 It is any one selected from heterocycloalkyl, aryl, and heteroaryl, and

[0378] The above heterocycloalkyl, or heteroaryl, comprises one or more heteroatom groups selected from the group consisting of -NH-, -O-, -S-, -ON=, -S(=O)-, and -S(=O)2-, or one or more heteroatoms selected from the group consisting of O, N, and S.

[0379] The structure represented by [Chemical Formula 6-1] above may be a structure formed by the following reaction.

[0380]

[0381] In one specific embodiment, the junction may have a structure represented by [Chemical Formula 6-2] as follows. The structure represented by [Chemical Formula 6-2] is a structure formed by combining the side chain of frTet with TCO.

[0382] [Chemical Formula 6-2]

[0383]

[0384] For example, the junction may be a structure formed by connecting a side chain containing an azide group of an engineered anti-PD-L1 scFv and a click chemical functional group.

[0385] In one specific example, the joint may be represented by the following chemical formula.

[0386] [Chemical Formula 7-1]

[0387]

[0388] [Chemical Formula 7-2]

[0389]

[0390] [Chemical Formula 7-3]

[0391]

[0392] [Chemical Formula 7-4]

[0393]

[0394] A1 is non-existent (i.e., combined) or -A 11 -A 12 - and,

[0395] A 11 is absent, or -C1-5alkylene-, and

[0396] A 12 is non-existent, or -[Arilene] p -, -[Arilen] p -C 1-5 Alkylene-, -[arylene] p -C 1-5 Heteroalkylene-, -arylene-C 1-5 Alkylene-arylene-, -arylene-C1-5 Heteroalkylene-arylene-, -arylene-heteroarylene-, -[heteroarylene] p -, -[Heteroarylene] p -C 1-5 Alkylene-, -[heteroarylene] p -C 1-5 Heteroalkylene-, -heteroarylene-C 1-5 Alkylene-arylene-, -heteroarylene-C 1-5 Alkylene-heteroarylene-, -heteroarylene-C 1-5 Heteroalkylene-arylene-, and -heteroarylene-C 1-5 It is one selected from heteroalkylene and heteroarylene, where p is an integer between 1 and 3.

[0397] The structure represented by [Chemical Formula 7-1] above may be a structure produced by the following reaction.

[0398]

[0399] The structure represented by [Chemical Formula 7-2] above may be a structure formed by the following reaction.

[0400]

[0401] The structure represented by [Chemical Formula 7-3] above may be a structure formed by the following reaction.

[0402]

[0403] The structure represented by [Chemical Formula 7-4] above may be a structure produced by the following reaction.

[0404]

[0405] In one specific embodiment, the junction may have a structure represented by the following [Chemical Formula 7-5]. The structure represented by [Chemical Formula 7-5] may be a structure formed by combining the side chain of pAzF with DBCO:

[0406] [Chemical Formula 7-5]

[0407]

[0408] In one specific embodiment, the junction may have a structure represented by the following [Chemical Formula 7-6]. The structure represented by [Chemical Formula 7-6] may be a structure formed by combining a side chain of pAzF with BCN:

[0409] [Chemical Formula 7-6]

[0410]

[0411] Configuration (3) L (connector)

[0412] The engineered anti-PD-L1 scFv conjugate of the present application includes a linking group (L).

[0413] In the conjugate of the present application, the structure formed between the junction and the ASGPR targeting glycan is referred to as a [connector]. In other words, in the engineered claim PD-L1 scFv conjugate of the present application, the connector (L) refers to a structure connecting the junction (J) and the ASGPR targeting glycan (G).

[0414] The above linker is not limited to its chemical structure as long as it is a structure that connects the junction and the ASGPR-targeting glycan. In particular, the above linker may have various structures that can be recognized by a person skilled in the art as structures for connecting specific two moieties used in the field of antibody-drug conjugates.

[0415] The above linker may include a configuration for improving solubility or a configuration for improving conjugation reactivity, etc. As an example, the above linker may include a succinic acid-derived structure or / and a PEG structure, etc. As another example, the above linker may include an amide, ester, thioester, carbamate, carbonate or / and disulfide bond.

[0416] In one specific example, the connector is -C1-150 Alkylene-, -C 1-150 It may include heteroalkylene- or / and combinations thereof. The above C 1-150 Alkylene is unsubstituted C 1-150 Alkylene or substituted C 1-150 It may be an alkylene. In addition, the above C 1-150 Heteroalkylene is unsubstituted C 1-150 Heteroalkylene or substituted C 1-150 It may be a heteroalkylene. The above substitution C 1-150 Alkylene is C 1-150 It refers to an alkylene in which at least one of the chain-forming atoms of the alkylene is substituted with another element or group. As an example, the above substitution C 1-150 Alkylene is C 1-150 C in which at least one of the chain-forming atoms of the alkylene is substituted with one group independently selected from oxo, hydroxy, amino, carboxyl, thiol, sulfonic acid, phosphate, and halogen. 1-150 It may be an alkylene. As another example, the above substitution C 1-150 Heteroalkylene is C 1-150 C in which at least one of the chain-forming atoms of the heteroalkylene is substituted with one group independently selected from oxo, hydroxy, amino, carboxyl, thiol, sulfonic acid, phosphate, and halogen. 1-150 It can be a heteroalkylene.

[0417] In one specific example, the connector is non-existent (i.e., connected) -B1-B2-B3-, and

[0418] B1 is not limited to its structure but may include a structure derived from the process of connecting a second click chemical functional group to a conjugate linker used for conjugate production. As another example, B1 is absent or -C 1-20 Alkylene-, -C 1-20 It may include heteroalkylene- or / and combinations thereof, each described as above. As another example, B1 is absent or (-CH2) n1 -, (-CH2) n1 -SS-,(-CH2) n1 -O-, (-CH2) n1 -(C=O)-O-, (-CH2) n1 -(C=O)-, (-CH2) n1 -(C=0)-NH-, -(C=0)-NH(-CH2) n1 -, -(C=0)(-CH2) n1 -(C=0)-, -(C=0)(-CH2) n1 -NH-(C=0)-, -(C=0)-NH(-CH2) n1 -(C=0)-, -(C=0)-NH(-CH2) n1 -NH-(C=0)-, -(C=0)(-CH2) n1 -(C=0)-NH-,-O-(C=O)-NH-, -O-(C=O)-NH(-CH2) n1 -, -O-(C=O)-NH(-CH2) n1 -(C=O)-NH-, -O-(C=O)-NH(-CH2) n1 -(C=O)-O-, or a combination thereof, may be included but is not limited thereto. In this case, n1 independently represents a natural number between 1 and 10. Meanwhile, the above structural formula may have the front part connected to the junction and the back part connected to B2. As an example, the above (-CH2) n1 -O- is [J](-CH2) n1It may represent a connection relationship such as -O-[B2], and this may also be applied to the other structural formulas mentioned above. Furthermore, unless otherwise stated, if B1 is expressed as a specific structural formula in this specification, it shall be interpreted in the same sense as described above.

[0419] B2 may be a portion containing a structure to enhance solubility, such as PEG, and the structure is not limited. For example, B2 may be absent or -C 1-80 Alkylene-, -C 1-80 It may include heteroalkylene- or / and combinations thereof, each described as above. As another example, B2 is absent or [-CH2-CH2-O] n2 (PEG n2 )-, [-CH2-CH2-O] n2 (PEG n2 )-(C=O)-, [-CH2-CH2-O] n2 (PEG n2 )-CH2-CH2-(C=O)-, -NH-[-CH2-CH2-O] n2 (PEG n2 )-(C=O)-,-NH-[-CH2-CH2-O] n2 (PEG n2 )-CH2-CH2-(C=O)-, [-CH2-CH2-O] n2 (PEG n2 )-NH-(C=O)-, [-CH2-CH2-O] n2 (PEG n2 )-CH2-CH2-NH-(C=O)-, [-CH2-CH2-O] n2 (PEG n2 )-(C=O)-NH-, [-CH2-CH2-O] n2 (PEG n2 )-CH2-CH2-(C=O)-NH-, [-CH2-CH2-O] n2 (PEG n2 )-(C=O)-O-, [-CH2-CH2-O] n2 (PEG n2 )-CH-CH-(C=O)-O-, [-CH2-CH2-O] n2 (PEGn2 It may include )-(C=O)-CH2-CH2-, or a combination thereof, but is not limited thereto. The above n2 independently represents a natural number between 1 and 20 inclusive. Meanwhile, the above structural formula may have the front part connected to B1 and the back part connected to B3. As an example, the above [-CH2-CH2-O] n2 (PEG n2 )- is [B1][-CH2-CH2-O] n2 (PEG n2 It may represent a connection relationship such as )-(C=O)-[B3], and this may also be applied to other structural formulas mentioned above. Furthermore, unless otherwise stated, if B2 is expressed as a specific structural formula in this specification, it shall be interpreted in the same sense as above.

[0420] B3 contains a suitable structure for an ASGPR-targeting glycan to be connected to a linker, but is not limited to such structure. B3 is absent or -C 1-50 Alkylene-, -C 1-50 It may include heteroalkylenes—or / and combinations thereof, and the description for each is as described above. As another example, B3 may be absent, or a linker structure or branched linker structure using an amino acid (or amino acid derivative).

[0421] The structure of the linker using the above amino acid (or amino acid derivative) is not limited. As an example, the linker using the above amino acid (or amino acid derivative) may include a structure represented by the following chemical formula. In this case, the following chemical formula represents the chemical formula of a linker using asparagine.

[0422] [Chemical Formula 8]

[0423]

[0424] The structure of the branched linker is not limited as long as it has a structure for connecting two or more glycans. For example, the branched linker can be represented by the following chemical formula:

[0425] [Chemical Formula 9-1]

[0426] , or

[0427] [Chemical Formula 9-2]

[0428] .

[0429] Each of the above B4s is independently non-existent (i.e., combined), or -C 1-20 Alkylene-, -C 1-20 It may include heteroalkylenes—or and / or combinations thereof, each described as above. In one embodiment, B4 may be -CH2-O-CH2-CH2-(C=O)-NH-CH2-CH2-CH2-NH-(C=O)-CH2-CH2-CH2-CH2-O-[G]. Additionally, in the present specification, where two or more glycans are connected to one -[junction]-[linker]- structure, the engineered claim PD-L1 scFv of this application should be interpreted as comprising said branched linker.

[0430] The engineered anti-PD-L1 scFv conjugate of the present application can be produced by reacting a free-engineered anti-PD-L1 scFv with a conjugating linker and an ASGPR-targeting glycan compound. In this case, the linker is derived from the conjugating linker used to conjugate the ASGPR-targeting glycan to the engineered anti-PD-L1 scFv. Accordingly, the linker refers to the structure of the region existing between the junction and the ASGPR-targeting glycan in the region remaining after one side of the conjugating linker reacts with a non-natural amino acid to form a bonded junction. Accordingly, the linker may also be referred to as a conjugating linker unit. Furthermore, the content described in the relevant chapter may be appropriately incorporated by reference as a description of the conjugating linker, and the following description of the conjugating linker may be appropriately incorporated by reference into this chapter.

[0431] Such a linker (L) contributes to maintaining the flexibility, structural stability, and appropriate binding properties to antigens and albumin of the engineered anti-PD-L1 scFv conjugate by appropriately controlling the relative distance and spatial orientation between the heavy chain variable site, the light chain variable site, and the albumin binding moiety.

[0432] Composition (4) G (Glycan)

[0433] The engineered anti-PD-L1 scFv conjugate of the present application comprises an ASGPR-targeting glycan. The ASGPR-targeting glycan included in the engineered anti-PD-L1 scFv conjugate of the present application refers to an ASGPR-targeting glycan in a state conjugated with the engineered anti-PD-L1 scFv through the conjugate and the linker. Accordingly, if necessary, G on the conjugate may also be referred to as an ASGPR-targeting glycan unit.

[0434] The above ASGPR-targeting glycan refers to a structure comprising one or more linked sugars capable of inducing lysosome-mediated degradation by interacting with ASGPR (Asialoglycoprotein Receptor). The above ASGPR-targeting glycan is not limited to its structure.

[0435] For example, the ASGPR-targeting glycan may have a linear or branched structure. For another example, the ASGPR-targeting glycan may be an N-linked glycan. In one embodiment, the ASGPR-targeting glycan may be an N-linked bibranched glycan. In another embodiment, the ASGPR-targeting glycan may be an N-linked ternary glycan. For another example, the ASGPR-targeting glycan may be a glycan having a non-reducing terminal structure. For another example, the ASGPR-targeting glycan may preferably comprise a sugar (sugar residue) capable of binding to ASGPR (e.g., galactose or GalNAc (N-acetylgalactosamine)), but is not limited thereto. More preferably, the ASGPR-targeting glycan may comprise at least one sugar capable of binding to ASGPR at the glycan terminal. As another example, the ASGPR-targeting glycan may include a sugar capable of binding to at least one ASGPR at a non-reducing terminal position. As another example, the ASGPR-targeting glycan may include at least one galactose or / and GalNAc as a non-reducing terminal sugar. That is, the ASGPR-targeting glycan may be a Gal-terminal glycan or a GalNAc-terminal glycan.

[0436] In one embodiment, the ASGPR targeting glycan may be A3G3. In another embodiment, the ASGPR targeting glycan may be A3G3[3] or A3G3[6]. [3] and [6] may be as understood by a person skilled in the art regarding glycan naming.

[0437] In another specific example, the ASGPR-targeting glycan can be represented by one of the following chemical formulas.

[0438] [Chemical Formula 10-1]

[0439] ;

[0440] [Chemical Formula 10-2]

[0441] ;

[0442] [Chemical Formula 10-3]

[0443] ;

[0444] [Chemical Formula 10-4]

[0445] ; or

[0446] [Chemical Formula 10-5]

[0447] (GalNAc).

[0448] The above L represents a [linker]. In addition, the direction of the glycation bond and the names of each unit are indicated in the chemical formula [GlcNAc: N-acetylglucosamine, NeuAc: N-acetylneuraminic acid].

[0449] Characteristics of engineered anti-PD-L1 scFv conjugate (1)_Possessing characteristics of engineered anti-PD-L1 scFv

[0450] The engineered anti-PD-L1 scFv conjugate of the present application can be produced by reacting the engineered anti-PD-L1 scFv with a conjugating linker-ASGPR targeting glycan compound. Accordingly, it may possess the characteristics of the engineered anti-PD-L1 scFv. Detailed information regarding the characteristics of the engineered anti-PD-L1 scFv is incorporated by reference into [Chapter 1 Engineered Anti-PD-L1 scFv] above.

[0451] Characteristics of engineered anti-PD-L1 scFv conjugates (2)_Lysosome-mediated degradation induction for PD-L1 removal

[0452] The engineered anti-PD-L1 scFv conjugate contains an ASGPR-targeting glycan. Accordingly, the engineered anti-PD-L1 scFv conjugate can bind to PD-L1 via the engineered anti-PD-L1 scFv, while also interacting with ASGPR present on the surface of cells in the liver / liver tissue via the ASGPR-targeting glycan. Through these interactions, the engineered anti-PD-L1 scFv conjugate can induce ASGPR-mediated endocytosis and lysosome-mediated degradation pathways. In other words, the engineered anti-PD-L1 scFv conjugate is characterized by being designed to maintain the function of scFv and the ASGPR-targeting function of the glycan while being based on the anti-PD-L1 scFv.

[0453] Accordingly, the engineered anti-PD-L1 scFv conjugate can remove PD-L1 from the surface of liver cells in the body. The significance of the above PD-L1 removal function is described in more detail below in [Chapter 5 Pharmaceutical Composition].

[0454] Specific example of an engineered anti-PD-L1 scFv conjugate

[0455] Hereinafter, specific examples of the anti-PD-L1 scFv conjugate engineered in this application are described. The following examples are merely illustrative and are not limited thereto.

[0456] For example, the above-mentioned engineered anti-PD-L1 scFv conjugate may be an engineered anti-PD-L1 scFv conjugate made using a specific engineered anti-PD-L1 scFv and a specific conjugating linker-ASGPR targeting glycan compound. That is, it may be an engineered anti-PD-L1 scFv conjugate produced by the method described in the "Specific Example of Method for Producing Engineered Anti-PD-L1 scFv Conjugate of the Present Application" below.

[0457] For example, the above-mentioned engineered anti-PD-L1 scFv conjugate is represented by the following [Structural Formula 1], and

[0458] [Structural Formula 1]

[0459] [Engineered term PD-L1 scFv (S)]-[Junction (J)]-[Coupler (L)]-[Glycan (G)]k, where k is 1 or 3, and

[0460] The above [engineered anti-PD-L1 scFv(S)] is represented by one amino acid sequence of SEQ ID NOs 4 to 35 and 158 to 189, and in the amino acid sequence represented by one of SEQ ID NOs 4 to 35 and 158 to 189, X may be an amino acid residue represented by the following [Formula 5]:

[0461] [Chemical Formula 5]

[0462] (g is 1 or 3)

[0463] In one specific example, the above J can be represented by one selected from the following chemical formulas.

[0464] [Chemical Formula 6-2]

[0465] ;

[0466] [Chemical Formula 7-5]

[0467] ; or

[0468] [Chemical Formula 7-6]

[0469] .

[0470] In one embodiment, the above L can be represented by one selected from the following chemical formulas:

[0471] [Chemical Formula 11-1]

[0472] ;or

[0473] [Chemical Formula 11-2]

[0474] .

[0475] At this time, G is an ASGPR targeting glycan, and J is a junction. Also, n is 12.

[0476] In one specific example, when L is represented by [Chemical Formula 11-1] or [Chemical Formula 11-2], G can be represented by one selected from the following chemical formulas.

[0477] [Chemical Formula 10-1]

[0478] ,

[0479] [Chemical Formula 10-2]

[0480] ,

[0481] [Chemical Formula 10-3]

[0482] , or

[0483] [Chemical Formula 10-4]

[0484] .

[0485] In this case, L represents a [linker]. Additionally, the direction of the glycation bond and the names of each unit are indicated in the chemical formula [GlcNAc: N-acetylglucosamine, NeuAc: N-acetylneuraminic acid].

[0486] In another embodiment, in one embodiment, the above L is represented by the following chemical formula, and

[0487] [Chemical Formula 11-3]

[0488]

[0489] Each of the above B4s can be expressed as -CH2-O-CH2-CH2-(C=O)-NH-CH2-CH2-CH2-NH-(C=O)-CH2-CH2-CH2-CH2-O-[G].

[0490] In addition, if the above L is expressed by [Chemical Formula 11-3], the above G can be expressed by the following chemical formula:

[0491] [Chemical Formula 10-5]

[0492] (GalNAc).

[0493]

[0494] Chapter 3 Pharmaceutical composition comprising an engineered anti-PD-L1 scFv conjugate

[0495] generalization

[0496] This specification discloses a pharmaceutical composition comprising the aforementioned engineered anti-PD-L1 scFv conjugate and a method for using the same. The engineered anti-PD-L1 scFv conjugate included in the pharmaceutical composition is not particularly limited in its structure or mode of manufacture, provided that it is the engineered anti-PD-L1 scFv conjugate disclosed herein. Accordingly, the entire contents of Chapter 2 of this specification are incorporated by reference as a description of the engineered anti-PD-L1 conjugate included in the pharmaceutical composition.

[0497] The pharmaceutical composition of the present application is characterized by being able to induce PD-L1 elimination using the LYTAC mechanism by including an engineered anti-PD-L1 scFv conjugate. In addition, the pharmaceutical composition of the present application is characterized by being able to induce apoptosis of liver cancer cells by preventing immune evasion of liver cancer cells by including an engineered anti-PD-L1 scFv conjugate.

[0498] The pharmaceutical compositions of this chapter may also be referred to as compositions. Accordingly, this application also discloses compositions comprising an engineered anti-PD-L1 scFv conjugate. The following applies appropriately to compositions.

[0499] The characteristics, uses, formulations, etc. of the above pharmaceutical composition are described in more detail below.

[0500] Characteristics of the pharmaceutical composition (1) PD-L1 elimination ability

[0501] The pharmaceutical composition of the present application comprises the engineered anti-PD-L1 scFv conjugate of the present application. Meanwhile, the engineered anti-PD-L1 scFv conjugate of the present application is characterized by comprising VH and VL having binding ability to PD-L1, and comprising a glycan capable of interacting with ASGPR.

[0502] Accordingly, the engineered anti-PD-L1 scFv conjugate of the present application can interact with ASGPR via ASGPR-targeting glycans while bound to PD-L1 on the cell surface. Through this interaction, the conjugate undergoes endocytosis with PD-L1 and can induce the degradation of PD-L1 via a lysosome-mediated degradation pathway. Consequently, the pharmaceutical composition of the present application may be characterized by being able to remove PD-L1. Furthermore, particularly considering that ASGPR is a receptor expressed particularly in liver cancer cells, the pharmaceutical composition of the present application may be characterized by being able to remove PD-L1 on the cell surface of liver cancer cells.

[0503] Whether the above-mentioned PD-L1 clearance ability exists can be evaluated according to known techniques. As an example, the existence of PD-L1 clearance ability can be confirmed by treating liver cancer cells simultaneously expressing ASGPR and PD-L1 with a test substance and verifying whether PD-L1 has decreased compared to an untreated group. As a preferred example, the existence of PD-L1 clearance ability can be evaluated by treating Hep3B or HepG2 cells in which PD-L1 expression was induced by IFN-γ with a test substance and verifying via Western blot whether PD-L1 has decreased compared to an untreated group.

[0504] Characteristics of the pharmaceutical composition (2) Ability to eliminate liver cancer cells

[0505] The pharmaceutical composition of the present application may be characterized by being capable of removing PD-L1 present in liver cancer cells as described above. Furthermore, PD-L1 is a protein known to be able to evade immune responses by interacting with PD-1 on T cells while present on the surface of cancer cells. Therefore, by removing PD-L1 on the surface of liver cancer cells, the pharmaceutical composition of the present application induces liver cancer cells to be recognized by T cells, and as a result, can promote the removal of liver cancer cells. Accordingly, the liver cancer cell removal ability may also be referred to as the liver cancer cell removal induction ability.

[0506] That is, the pharmaceutical composition of the present application may be characterized by being capable of eliminating liver cancer cells when treated with liver cancer cells. The elimination of liver cancer cells means inducing the elimination of liver cancer cells by activating the immune system through the restoration of recognition by T cells, as described above.

[0507] The method for confirming the above-mentioned ability to eliminate liver cancer cells can be performed according to known techniques. As an example, the ability to eliminate liver cancer cells can be confirmed by co-culturing liver cancer cells simultaneously expressing ASGPR and PD-L1 with T cells, treating with a test substance, and then checking whether the number of liver cancer cells has decreased compared to the untreated group. As a preferred example, the ability to eliminate liver cancer cells can be evaluated by co-culturing Hep3B or HepG2 cells treated with IFN-γ with T cells, treating with a test substance, and then checking whether the number of Hep3B or HepG2 cells has decreased compared to the untreated group.

[0508] Uses of pharmaceutical compositions

[0509] The engineered anti-PD-L1 scFv conjugate of the present invention included in the pharmaceutical composition of the present invention is characterized by being able to interact with ASGPR while targeting PD-L1. Accordingly, the pharmaceutical composition of the present invention can be used to treat diseases that can be treated by removing PD-L1 from the surface of cells expressing both ASGPR and PD-L1.

[0510] For example, since it is known that most cells expressing ASGPR are liver cells, the pharmaceutical composition of the present application may be characterized as a composition for treating liver cancer. The liver cancer may be hepatocellular carcinoma, but is not limited thereto.

[0511] In other words, this application discloses the use of the engineered anti-PD-L1 scFv conjugate for the treatment of liver cancer. Furthermore, this application discloses the use of the engineered anti-PD-L1 scFv conjugate for the production of a liver cancer treatment.

[0512] Formulation of a pharmaceutical composition

[0513] The pharmaceutical composition of the present application may include suitable excipients in addition to the anti-PD-L1 scFv conjugate engineered in the present application for appropriate formulation.

[0514] For example, the pharmaceutical composition of the present application may comprise a buffer, tonicity agents, surfactants, and / or stabilizers. In one embodiment, the pharmaceutical composition of the present application may comprise histidine, phosphoric acid, citric acid, and / or acetic acid as a buffer. In another embodiment, the pharmaceutical composition of the present application may comprise sucrose, trehalose, mannitol, sorbitol, and / or sodium chloride as an isotonic agent. In another embodiment, the pharmaceutical composition of the present application may comprise polysorbate 20 (PS 20) and / or polysorbate 80 (PS 80) as a surfactant. In another embodiment, the pharmaceutical composition of the present application may comprise glycine and / or arginine as a stabilizer. The materials described above may be used in a salt state or a hydrate state. For example, the pharmaceutical composition of the present application may include sodium citrate or sodium acetate. Additionally, although the substances described above are classified as buffers or stabilizers for convenience of description, each substance is not included for only one role / purpose, but may be included in the pharmaceutical composition of the present application for two or more purposes or for other purposes.

[0515] In one embodiment, the pharmaceutical composition of the present application may comprise sodium citrate, sucrose, and PS 80. In another embodiment, the pharmaceutical composition of the present application may comprise histidine, sucrose, sodium chloride, and PS 20. In another embodiment, the pharmaceutical composition of the present application may comprise histidine, sucrose, arginine, sodium chloride, and PS 80. In another embodiment, the pharmaceutical composition of the present application may comprise sodium acetate, trehalose, sodium chloride, and PS 80.

[0516] In addition, the concentration of each excipient included in the pharmaceutical composition of the present application is not limited. For example, the buffer may be included in the pharmaceutical composition of the present application at a concentration of 1 mM to 50 mM. For another example, the isotonic agent may be included in the pharmaceutical composition of the present application at a concentration of 0.1% to 10.0%. For another example, the isotonic agent may be included in the pharmaceutical composition of the present application at a concentration of 1 mM to 500 mM. For another example, the surfactant may be included in the pharmaceutical composition of the present application at a concentration of 0.01% to 0.05%. For another example, the surfactant may be included in the pharmaceutical composition of the present application at a concentration of 0.01% to 0.05%. For another example, the stabilizer may be included in the pharmaceutical composition of the present application at a concentration of 1 mM to 100 mM.

[0517] The pharmaceutical composition of the present application may be adjusted to a specific pH for proper storage or proper formulation. For example, the pharmaceutical composition of the present application may have a pH suitable for use as an injectable. For example, the pH of the pharmaceutical composition of the present application may be pH 4.0 to pH 8.0.

[0518] In one embodiment, the pharmaceutical composition of the present application may comprise 10 mM sodium citrate, 5.8% sucrose, and 0.02% PS 80. In another embodiment, the pharmaceutical composition of the present application may comprise 10 mM sodium citrate, 5.8% sucrose, and 0.02% PS 80. In another embodiment, the pharmaceutical composition of the present application may comprise 10 mM histidine, 5% sucrose, 80 mM sodium chloride, and 0.01% PS 20. In another embodiment, the pharmaceutical composition of the present application may comprise 10 mM histidine, 7.5% sucrose, 50 mM arginine, 20 mM sodium chloride, and 0.02% PS 80. In another embodiment, the pharmaceutical composition of the present application may comprise 10 mM sodium acetate, 7.5% trehalose, 40 mM sodium chloride, and 0.02% PS 80.

[0519] In one specific embodiment, the pharmaceutical composition of the present application comprises 10 mM sodium citrate, 5.8% sucrose, and 0.02% PS 80, and the pH of the pharmaceutical composition may be 7.2. In another specific embodiment, the pharmaceutical composition of the present application comprises 10 mM sodium citrate, 5.8% sucrose, and 0.02% PS 80, and the pH of the pharmaceutical composition may be 6.0. In another specific embodiment, the pharmaceutical composition of the present application comprises 10 mM histidine, 5% sucrose, 80 mM sodium chloride, and 0.01% PS 20, and the pH of the pharmaceutical composition may be 6.0. In another specific embodiment, the pharmaceutical composition of the present application comprises 10 mM histidine, 7.5% sucrose, 50 mM arginine, 20 mM sodium chloride, and 0.02% PS 80, and the pH of the pharmaceutical composition may be 6.0. In another specific embodiment, the pharmaceutical composition of the present application comprises 10 mM sodium acetate, 7.5% trehalose, 40 mM sodium chloride, and 0.02% PS 80, and the pH of the pharmaceutical composition may be 5.5.

[0520] The pharmaceutical composition of the present application may be formulated for oral or parenteral use. In one embodiment, the pharmaceutical composition of the present application may be formulated as an injectable or the like.

[0521] Method of administration / Dosage of pharmaceutical composition

[0522] The method of administration of the pharmaceutical composition of the present application is not limited to any method thereof, provided that it is intended to deliver the anti-PD-L1 scFv engineered in the present application to the liver / liver tissue. For example, the pharmaceutical composition of the present application may be administered via intravenous injection or subcutaneous injection. The dosage of the pharmaceutical composition of the present application is not limited. For example, the pharmaceutical composition of the present application comprises 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, based on the amount of engineered anti-PD-L1 scFv of the present application. It may be intended to be administered at a dose selected from 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, and 100 mg / kg or between two selected values. In one embodiment, the pharmaceutical composition of the present application may be intended to be administered at a dose of 50 to 60 mg / kg based on the amount of the engineered anti-PD-L1 scFv of the present application.

[0523]

[0524] Chapter 4 Liver Cancer Treatment Methods

[0525] The present application specification discloses a method for treating liver cancer. Meanwhile, the method for treating liver cancer of the present application includes administering an effective amount or more of the pharmaceutical composition of the present application to a patient. The composition, formulation, method of administration, etc. of the pharmaceutical composition are incorporated into the contents of Chapter 3 of the present application specification.

[0526]

[0527] Chapter 5 Method for Producing Engineered Anti-PD-L1 scFv

[0528] generalization

[0529] The aforementioned engineered anti-PD-L1 scFv can be produced through known methods for producing proteins with inserted non-natural amino acids, but is not limited to such production methods. This specification discloses a method for producing engineered anti-PD-L1 scFv using a recombinant expression method as an example of one method by which engineered anti-PD-L1 scFv can be produced.

[0530] The method for producing engineered anti-PD-L1 scFv according to the present application is characterized by obtaining a protein with a non-natural amino acid inserted by expressing it in a specific cell line. That is, the method for producing engineered anti-PD-L1 scFv according to the present application includes the step of expressing a vector for engineered anti-PD-L1 scFv in a cell line capable of producing a protein with a non-natural amino acid inserted.

[0531] In this specification, a cell line capable of producing a protein into which the above-mentioned non-natural amino acid is inserted is referred to as a "producing cell line."

[0532] Below, the detailed configuration of the above-mentioned production cell line and the above-mentioned engineered anti-PD-L1 scFv production method is described.

[0533] Cell line capable of producing proteins with inserted non-natural amino acids (production cell line)

[0534] The production cell line is not limited to any specific type as long as it is capable of producing proteins with inserted non-natural amino acids.

[0535] For example, a cell line capable of producing a protein with the above-mentioned non-natural amino acid inserted may be selected from the genera Escherichia, Erwinia, Serratia, Providencia, Corynebacterium, Pseudomonas, Leptospira, Salmonella, Brevibacterium, Hyphomonas, Chromobacterium, Nocardia, fungi, and yeasts.

[0536] The above production cell line is characterized by including a system that enables the production of a protein with an inserted non-natural amino acid. For example, the above production cell line may be a cell line expressing a foreign-derived suppressor tRNA that recognizes a specific stop codon, and a foreign-derived tRNA synthase that links the foreign-derived suppressor tRNA with a non-natural amino acid. In one embodiment, the above production cell line may be a cell line into which a vector encoding the foreign-derived suppressor tRNA and the foreign-derived tRNA synthase has been introduced. In one specific embodiment, the above production cell line may be an E. coli into which [pEVOL-pAzF](addgene, #31186) has been introduced.

[0537] The above-mentioned foreign-derived suppressor tRNA may have several characteristics. First, the above-mentioned foreign-derived suppressor tRNA does not react with the endogenous tRNA synthase of the production cell line. Second, the above-mentioned foreign-derived suppressor tRNA can specifically react with the foreign-derived tRNA synthase and bind to non-natural amino acids. Third, the above-mentioned foreign-derived suppressor tRNA can recognize specific codons in the nucleotide sequence, for example, ember codon (UAG), ocher codon (UAA), and opal codon (UGA), and insert non-natural amino acids at the corresponding positions.

[0538] For example, the foreign-derived suppressor tRNA may be a tyrosine tRNA derived from Methanococcus jannaschii. In one specific example, the foreign-derived tRNA synthetase may be the tRNA represented by SEQ ID NO. 194. The tRNA is characterized by being able to recognize an ambercodon together with the tyrosine tRNA synthetase derived from Methanococcus jannaschii described below.

[0539] The above-mentioned foreign-derived tRNA synthase may have several characteristics. For example, the above-mentioned foreign-derived tRNA synthase does not interact with the endogenous tRNA of the production cell line. In addition, the above-mentioned foreign-derived tRNA synthase can specifically react with foreign-derived suppressor tRNA to link non-natural amino acids to the foreign-derived suppressor tRNA.

[0540] For example, the foreign-derived tRNA synthase may be a variant of tyrosine tRNA synthase derived from methanococcus jannaschii. For example, the foreign-derived tRNA synthase may be a Y32T, E107N, D158P, I159L, L162Q, or D286R variant of tyrosine tRNA synthase derived from methanococcus jannaschii. In one specific example, the foreign-derived tRNA synthase may be a tRNA synthase represented by SEQ ID NO. 193 (i.e., the production cell line may include a nucleic acid comprising SEQ ID NO. 195 encoding the tRNA synthase represented by SEQ ID NO. 193).

[0541] In one specific example, the production cell line may be a cell line comprising a plasmid (Sequence No. 196) encoding tyrosine tRNA derived from methanococcus jannaschii and tyrosine tRNA synthesizer derived from methanococcus jannaschii.

[0542] The method by which the above-mentioned production cell line expresses foreign-derived suppressor tRNA and foreign-derived tRNA synthase is not particularly limited. For example, the above-mentioned production cell line may express foreign-derived suppressor tRNA and foreign-derived suppressor tRNA by introducing foreign-derived suppressor tRNA and a vector encoding foreign-derived suppressor tRNA. In this case, foreign-derived suppressor tRNA and foreign-derived suppressor tRNA may be encoded in different vectors or in a single identical vector. Additionally, foreign-derived suppressor tRNA and the vector encoding foreign-derived suppressor tRNA may be introduced simultaneously or sequentially with a vector encoding engineered anti-PD-L1 scFv.

[0543] In this specification, foreign-derived suppressor tRNA and combinations of foreign-derived suppressor tRNA may be referred to as orthogonal tRNA / synthetase pairs. For the production of proteins with inserted non-natural amino acids, it is preferable for a production cell line to express said orthogonal tRNA / synthetase pair.

[0544] In addition to the aforementioned characteristics, the production cell line may possess additional characteristics to improve the production efficiency of proteins with inserted non-natural amino acids. For example, the production cell line may be a cell line in which the function of a release factor that recognizes a specific stop codon is deleted or reduced.

[0545] Generally, if the release factor recognizing a specific stop codon in a production cell line functions normally, it can compete with foreign-derived suppressor tRNA when expressing a vector encoding engineered anti-PD-L1 scFv. Therefore, using a production cell line in which the release factor recognizing a specific stop codon (amber codon) is non-functional or has reduced function can increase the production yield of engineered anti-PD-L1 scFv. In this case, the type of cell line in which the release factor is non-functional or has reduced function is not particularly limited as long as the release factor can be non-functional or have reduced function. For example, the cell line in which the release factor is non-functional or has reduced function may be a cell line in which the release factor-related gene has been engineered.

[0546] For example, the production cell line may be a cell line in which one or more of the selected release factors that recognize an amber codon (UAG), an ocher codon (UAA), and an opal codon (UGA) are non-functional or have reduced function. In one specific example, the production cell line may be a cell line in which the release factor that recognizes an amber codon (UAG) is non-functional or has reduced function.

[0547] Additionally, the production cell line may be a cell line in which an endogenous gene having a specific stop codon has been modified to have a different stop codon. That is, the production cell line may be a cell line in which an endogenous gene having a specific stop codon as a stop codon has been deleted or its number reduced. If the production cell line contains an endogenous gene having a specific stop codon, foreign-derived suppressor tRNA may affect the expression of the endogenous gene. Therefore, it may be desirable to use a cell line in which an endogenous gene having a specific stop codon has been modified to have a different stop codon. In this case, the effect of foreign-derived suppressor tRNA on the translation of the endogenous gene can be minimized.

[0548] For example, the above-mentioned production cell line may be a cell line in which an endogenous gene having one or more codons selected from Amber Codon (UAG), Ocker Codon (UAA), and Opal Codon (UGA) as stop codons is modified to have a different stop codon. In one specific example, the above-mentioned production cell line may be a cell line in which an endogenous gene having Amber Codon (UAG) as a stop codon is modified to have a different stop codon.

[0549] The above production cell line can express a foreign-derived suppressor tRNA that recognizes a specific stop codon and a foreign-derived tRNA synthase that links the foreign-derived suppressor tRNA with a non-natural amino acid.

[0550] In one embodiment, the production cell line may be a cell line in which a vector encoding an exogenous suppressor tRNA and an exogenous tRNA synthase is introduced into a cell line in which the function of a release factor recognizing a specific stop codon is absent or reduced, and an endogenous gene having a specific stop codon is modified to have a different stop codon. In one embodiment, the cell line may be an E. coli C321.ΔA.exp strain (addgene, #49018) into which [pEVOL-pAzF](addgene, #31186) is introduced.

[0551] Hereinafter, the method for producing the engineered anti-PD-L1 scFv of the present application using the above-described production cell line will be described.

[0552] The present application engineered method for producing anti-PD-L1 scFv

[0553] The method for producing engineered anti-PD-L1 scFv according to the present application is characterized by expressing engineered anti-PD-L1 scFv in the production cell line using a nucleic acid encoding engineered anti-PD-L1 scFv. The method for producing engineered anti-PD-L1 scFv according to the present application is not limited to the method provided that it utilizes the production cell line and the nucleic acid encoding engineered anti-PD-L1 scFv.

[0554] For example, the method for producing engineered anti-PD-L1 scFv in the present application may be a method for producing engineered anti-PD-L1 scFv using a production cell line having an exogenous suppressor tRNA and an exogenous tRNA synthase as endogenous genes.

[0555] In one specific example, the method may include: (a) preparing a cell line expressing an exogenous suppressor tRNA and an exogenous tRNA synthetase; (b) introducing a nucleic acid encoding an engineered anti-PD-L1 scFv into the cell line; and (c) culturing the cell line into which the engineered anti-PD-L1 scFv-encoding nucleic acid has been introduced in an environment where non-natural amino acids are present. The nucleic acid encoding the engineered anti-PD-L1 scFv includes a specific codon, the exogenous tRNA synthetase is an enzyme capable of linking non-natural amino acids to the exogenous suppressor tRNA, the exogenous suppressor tRNA is a tRNA that recognizes the specific codon, and the specific codon is an ember codon (UAG), an ocher codon (UAA), or an opal codon (UGA).

[0556] As another example, the method for producing engineered anti-PD-L1 scFv in the present application may be a method for producing engineered anti-PD-L1 scFv using a production cell line created by introducing a foreign-derived suppressor tRNA and a vector encoding a foreign-derived tRNA synthase.

[0557] In one embodiment, the method may include: (a) preparing a cell line comprising a nucleic acid encoding an engineered anti-PD-L1 scFv, an exogenously derived suppressor tRNA, and an exogenously derived tRNA synthase; and (b) culturing the cell line in an environment where non-natural amino acids are present. In another embodiment, the method may include: (a) preparing a cell line comprising a nucleic acid encoding an engineered anti-PD-L1 scFv; (b) introducing a nucleic acid encoding an exogenously derived suppressor tRNA and an exogenously derived tRNA synthase into the cell line; and (c) culturing the cell line into which the nucleic acid encoding the exogenously derived suppressor tRNA and exogenously derived tRNA synthase has been introduced in an environment where non-natural amino acids are present. The nucleic acid encoding the engineered anti-PD-L1 scFv contains a specific codon, the foreign-derived tRNA synthetase is an enzyme capable of linking a non-natural amino acid to the foreign-derived suppressor tRNA, the foreign-derived suppressor tRNA is a tRNA that recognizes the specific codon, and the specific codon is an amber codon (UAG), an ocher codon (UAA), or an opal codon (UGA).

[0558] As another example, the method for producing engineered anti-PD-L1 scFv in the present application may be a method for producing engineered anti-PD-L1 scFv using a production cell line in which a release factor recognizing a specific codon is non-functional or has reduced function.

[0559] In one specific embodiment, the method may include: (a) preparing a cell line comprising a nucleic acid encoding an engineered anti-PD-L1 scFv, a foreign-derived suppressor tRNA, and a foreign-derived tRNA synthesizer, wherein a release factor recognizing a specific codon is non-functional or has reduced function; and (b) culturing the cell line in an environment where non-natural amino acids are present. In this case, the nucleic acid encoding the engineered anti-PD-L1 scFv includes the specific codon, the foreign-derived tRNA synthesizer is an enzyme capable of linking non-natural amino acids to the foreign-derived suppressor tRNA, the foreign-derived suppressor tRNA is a tRNA that recognizes the specific codon, and the specific codon is an ember codon (UAG), an ocher codon (UAA), or an opal codon (UGA).

[0560] As another example, the method for producing engineered anti-PD-L1scFv in the present application may be a method for producing engineered anti-PD-L1 scFv using a production cell line having no or reduced endogenous gene having a specific codon as a stop codon.

[0561] In one specific embodiment, the method may include: (a) preparing a cell line having no or reduced endogenous gene having a specific codon as a stop codon, comprising a nucleic acid encoding an engineered anti-PD-L1 scFv, an exogenously derived suppressor tRNA, and an exogenously derived tRNA synthetase; and (b) culturing the cell line in an environment where non-natural amino acids are present. In this case, the nucleic acid encoding the engineered anti-PD-L1 scFv includes the specific codon, the exogenously derived tRNA synthetase is an enzyme capable of linking non-natural amino acids to the exogenously derived suppressor tRNA, the exogenously derived suppressor tRNA is a tRNA that recognizes the specific codon, and the specific codon is an ember codon (UAG), an ocher codon (UAA), or an opal codon (UGA).

[0562] Additionally, the method for producing engineered anti-PD-L1 scFv of the present application may further include the step of determining the non-natural amino acid position of the engineered anti-PD-L1 scFv.

[0563] In one specific example, the method may include: (a) determining the non-natural amino acid location of the engineered anti-PD-L1 scFv; (b) preparing a cell line comprising a nucleic acid encoding the engineered anti-PD-L1 scFv, a foreign-derived suppressor tRNA, and a foreign-derived tRNA synthetase; and (c) culturing the cell line in an environment where the non-natural amino acid is present. At this time, the step of determining the non-natural amino acid position of the engineered anti-PD-L1 scFv is characterized by selecting the non-natural amino acid position by referring to [Position of non-natural amino acid] and [Criteria for selecting the position of non-natural amino acid] in Chapter 1 of this specification, wherein the nucleic acid encoding the engineered anti-PD-L1 scFv includes a specific codon, the foreign-derived tRNA synthetase is an enzyme capable of linking the non-natural amino acid to the foreign-derived suppressor tRNA, the foreign-derived suppressor tRNA is a tRNA that recognizes the specific codon, and the specific codon is an ember codon (UAG), an ocher codon (UAA), or an opal codon (UGA).

[0564] Additionally, the method for producing engineered anti-PD-L1 scFv of the present application may further include the step of extracting / purifying the expressed engineered anti-PD-L1 scFv from a cell line.

[0565] In one embodiment, the extraction / purification step may include a step of extracting a cell slurry of a production cell line by one or more methods selected from enzymatic treatment, freeze / thaw, sonication, and osmotic shock, and a step of purifying engineered anti-PD-L1 scFv from the cell slurry by one or more methods selected from centrifugation, precipitation separation, chromatography, ultrafiltration, and dialysis. In one embodiment, the purification may be performed by purifying the engineered anti-PD-L1 scFv through chromatography using a his tag.

[0566] Yield of the engineered anti-PD-L1 scFv production method of the present application

[0567] The method for producing engineered anti-PD-L1 scFv in the present application is characterized by expressing a nucleic acid encoding engineered anti-PD-L1 scFv in a production cell line. Meanwhile, as described above in [Chapter 1: Engineered Anti-PD-L1 scFv], the method for producing engineered anti-PD-L1 scFv in the present application may vary in production yield depending on where the engineered anti-PD-L1 scFv to be produced includes non-natural amino acids.

[0568] In particular, even if engineered anti-PD-L1 scFv is produced based on the same albubody, the degree of expression of the engineered anti-PD-L1 scFv varies depending on where the position is changed to a non-natural amino acid. In particular, the degree of expression in the receptor state varies. The higher the degree of expression in the receptor state, the higher the proportion of engineered anti-PD-L1 scFv that can be used without additional processing. That is, when using the method for producing engineered anti-PD-L1 scFv of the present application, engineered anti-PD-L1 scFv containing a non-natural amino acid at a specific position can be produced with a higher yield than engineered anti-PD-L1 scFv containing a non-natural amino acid at a different position.

[0569] For example, even when expressing the same atezolizumab-derived engineered anti-PD-L1 scFv, the production yield may differ among methods of producing engineered anti-PD-L1 scFv using a vector containing a nucleotide sequence selected from SEQ ID NOs 198 to 207. For another example, even when expressing the same durvalumab-derived engineered anti-PD-L1 scFv, the production yield may differ among methods of producing engineered anti-PD-L1 scFv using a vector containing a nucleotide sequence selected from SEQ ID NOs 209 to 218. For another example, even when expressing the same avelumab-derived engineered anti-PD-L1 scFv, the production yield may differ among methods of producing engineered anti-PD-L1 scFv using a vector containing a nucleotide sequence selected from SEQ ID NOs 220 to 231. Each production yield will be explained in more detail in the experimental examples. In addition, the engineered anti-PD-L1 scFv sequences encoding each of the aforementioned nucleotide sequences are as follows. The sequences shown in Table 8 below are sequences containing a stop codon, and sequence numbers 198 to 207, sequence numbers 209 to 218, and sequence numbers 220 to 231 that do not contain a stop codon correspond to sequence numbers 303 to 312, sequence numbers 314 to 323, and sequence numbers 325 to 336, respectively. Additionally, when a histag is added to an engineered claim PD-L1 scFv, sequence numbers 198 to 207, sequence numbers 209 to 218, and sequence numbers 220 to 231 correspond to sequence numbers 233 to 242, sequence numbers 244 to 253, and sequence numbers 255 to 266, respectively.

[0570] Derivative-identified coding base sequence (5-3) Engineered term PD-L1 scFv sequence Atezolizumab 1 Sequence No. 198 Sequence No. 4 Atezolizumab 2 Sequence No. 199 Sequence No. 5 Atezolizumab 3 Sequence No. 200 Sequence No. 6 Atezolizumab 4 Sequence No. 201 Sequence No. 7 Atezolizumab 5 Sequence No. 202 Sequence No. 8 Atezolizumab 6 Sequence No. 203 Sequence No. 9 Atezolizumab 7 Sequence No. 204 Sequence No. 10 Atezolizumab 8 Sequence No. 205 Sequence No. 11 Atezolizumab 9 Sequence No. 206 Sequence No. 12 Atezolizumab 10 Sequence No. 207 Sequence No. 13 Durvalumab 1 Sequence No. 209 14 durvalumab 2 Sequence No. 210 Sequence No. 15 durvalumab 3 Sequence No. 211 Sequence No. 16 durvalumab 4 Sequence No. 212 Sequence No. 17 durvalumab 5 Sequence No. 213 Sequence No. 18 durvalumab 6 Sequence No. 214 Sequence No. 19 durvalumab 7 Sequence No. 215 Sequence No. 20 durvalumab 8 Sequence No. 216 Sequence No. 21 durvalumab 9 Sequence No. 217 Sequence No. 22 durvalumab 10 Sequence No. 218 Sequence No. 23 avelumab 1 Sequence No. 220 Sequence No. 24 avelumab 2 Sequence No. 221 Sequence No. 25 avelumab 3 Sequence No. 222 Sequence No. 26 avelumab 4 Sequence No. 223 Sequence No. 27 avelumab 5 Sequence No. Sequence No. 224 28 Avelumab Sequence No. 225 Sequence No. 29 Avelumab Sequence No. 226 Sequence No. 30 Avelumab Sequence No. 227 Sequence No. 31 Avelumab Sequence No. 228 Sequence No. 32 Avelumab Sequence No. 229 Sequence No. 33 Avelumab Sequence No. 230 Sequence No. 34 Avelumab Sequence No. 231 Sequence No. 35

[0571] Specific example of the engineered anti-PD-L1 scFv production method of the present application

[0572] Hereinafter, specific examples of the engineered anti-PD-L1 scFv production method of the present application will be described. The following specific examples are merely illustrative and are not limited thereto.

[0573] For example, the above method for producing engineered anti-PD-L1 scFv may include: (a) preparing a cell line comprising a nucleic acid encoding engineered anti-PD-L1 scFv, a foreign-derived suppressor tRNA, and a foreign-derived tRNA synthetase; and (b) culturing the cell line in an environment where non-natural amino acids are present. In this case, the nucleic acid encoding engineered anti-PD-L1 scFv may include an amber codon (UAG), and the nucleic acid encoding engineered anti-PD-L1 scFv may include one of the nucleic acid sequences selected from SEQ ID NOs 198 to 207, 209 to 218, and 220 to 231, and the foreign-derived tRNA synthetase is an enzyme capable of linking a non-natural amino acid to the foreign-derived suppressor tRNA, and the foreign-derived suppressor tRNA is a tRNA that recognizes the amber codon (UAG), and the non-natural amino acid may be pAzF or frTet.

[0574] As another example, the method may include: (a) preparing a cell line having a nucleic acid encoding an engineered anti-PD-L1 scFv, an exogenously derived suppressor tRNA, and an exogenously derived tRNA synthetase, wherein the release factor recognizing an amber codon (UAG) is non-functional or has reduced function, and the endogenously derived gene having an amber codon (UAG) as a stop codon is non-functional or reduced; and (b) culturing the cell line in an environment where non-natural amino acids are present. At this time, the nucleic acid encoding the engineered anti-PD-L1 scFv includes an amber codon (UAG), and the nucleic acid encoding the engineered anti-PD-L1 scFv includes one of the nucleic acid sequences selected from SEQ ID NOs 198 to 207, 209 to 218 and 220 to 231, the foreign-derived tRNA synthetase is an enzyme capable of linking a non-natural amino acid to the foreign-derived suppressor tRNA, the foreign-derived suppressor tRNA is a tRNA that recognizes the amber codon (UAG), and the non-natural amino acid may be pAzF or frTet.

[0575] As another example, the method may include: (a) preparing a cell line in which the function of a release factor recognizing an amber codon (UAG) is absent or reduced, and an endogenous gene having an amber codon (UAG) as a stop codon is absent or reduced; (b) introducing a nucleic acid encoding an engineered anti-PD-L1 scFv and a nucleic acid encoding a foreign-derived suppressor tRNA and a foreign-derived tRNA synthetase into the cell line; and (c) culturing the cell line into which the nucleic acids have been introduced in an environment in which non-natural amino acids are present. At this time, the nucleic acid encoding the engineered anti-PD-L1 scFv includes an amber codon (UAG), and the nucleic acid encoding the engineered anti-PD-L1 scFv includes one of the nucleic acid sequences selected from SEQ ID NOs 198 to 207, 209 to 218 and 220 to 231, the foreign-derived tRNA synthetase is an enzyme capable of linking a non-natural amino acid to the foreign-derived suppressor tRNA, the foreign-derived suppressor tRNA is a tRNA that recognizes the amber codon (UAG), and the non-natural amino acid may be pAzF or frTet.

[0576]

[0577] Chapter 6 Method for Producing Engineered Anti-PD-L1 scFv Conjugates

[0578] generalization

[0579] The aforementioned engineered anti-PD-L1 scFv conjugate can be produced through known methods, and there are no particular limitations on the production method. Hereinafter, the present specification discloses a method for producing the engineered anti-PD-L1 scFv conjugate of the present application as an example of one method for producing the engineered anti-PD-L1 scFv conjugate.

[0580] The method for producing an engineered anti-PD-L1 scFv conjugate of the present application may include first connecting an ASGPR-targeting glycan to a conjugating linker, and then reacting the form (structure) of the ASGPR-targeting glycan connected to the conjugating linker with the engineered anti-PD-L1 scFv. In this case, the structure formed as described above is referred to as a "conjugating linker-ASGPR-targeting glycan compound" or "ASGPR-targeting glycan connected to the conjugating linker."

[0581] Hereinafter, a conjugating linker-ASGPR targeting glycan compound is described, and the method for producing an engineered anti-PD-L1 scFv in this application is described in detail.

[0582] conjugating linker-ASGPR targeting glycan compound

[0583] The method for producing an engineered anti-PD-L1 scFv conjugate of the present application may include preparing a conjugating linker-ASGPR targeting glycan compound.

[0584] The conjugating linker-ASGPR targeting glycan compound of the present application can be prepared by linking an ASGPR targeting glycan to a conjugating linker, wherein the conjugating linker has a second click chemical functional group and a functional group capable of binding to the ASGPR targeting glycan at a different position. The preparation process of the compound can be carried out according to the ordinary techniques known to a person skilled in the art.

[0585] The structure of the above conjugating linker-ASGPR targeting glycan compound is not limited.

[0586] For example, the above conjugating linker-ASGPR targeting glycan compound can be represented by the following structural formula:

[0587] [2nd click chemistry functional group (2th CC)-[linking group (L)]-[Glycan (G)]g. The above g is a natural number selected from 1 to 10.

[0588] The click chemical functional group (second click chemical functional group) included in the above conjugating linker-ASGPR targeting glycan compound may vary. For example, the click chemical functional group may be a click chemical functional group containing an alkyne group. For another example, the click chemical functional group may be a click chemical functional group containing a cyclooctyne. For another example, the click chemical functional group may be a click chemical functional group such as DIFO (Difluorinated cyclooctyne), DBCO (Dibenzocyclooctyne), or BNC (Bicyclononyne). For another example, the click chemical functional group may be a click chemical functional group such as TCO (trans-cyclooctene).

[0589] The second click chemical functional group can selectively react with the click chemical functional group (first click chemical functional group) of the engineered anti-PD-L1 scFv of the present application. Additionally, the click chemical functional group of the conjugating linker can form a junction by binding to the side chain of a non-natural amino acid of the engineered anti-PD-L1 scFv of the present application. Accordingly, the click chemical functional group included in the conjugating linker-ASGPR targeting glycan compound of the present application can be appropriately selected depending on the type of click chemical functional group introduced into the engineered anti-PD-L1 scFv.

[0590] The conjugated linker-ASGPR targeting glycan compound of the present application may be represented by one of the following chemical formulas. Alternatively, the following chemical formula may also be used to represent the type of second click chemical functional group included in the conjugated linker-ASGPR targeting glycan compound of the present application.

[0591] [Chemical Formula 12-1]

[0592] ;

[0593] [Chemical Formula 12-2]

[0594] ; or

[0595] [Chemical Formula 12-3]

[0596] .

[0597] The above linker is used with the same meaning as the linker described in [Configuration (3) L (Linker)] of [Chapter 2 Engineered Anti-PD-L1 scFv Conjugates]. That is, the linker is not limited to any structure as long as it is a structure that links a second click chemical functional group and an ASGPR-targeting glycan. In particular, the linker may be a linker structure recognizable to a person skilled in the art for linking specific two moieties used in the field of antibody-drug conjugates. Additionally, the linker may include a configuration for improving solubility or a configuration for improving conjugation reactivity, etc. As an example, the linker may include a succinic acid-derived structure or / and a PEG structure, etc. As another example, the linker may include an amide, ester, thioester, carbamate, carbonate or / and disulfide bond.

[0598] In one specific example, the connector is -C 1-150 Alkylene-, -C 1-150 It may include heteroalkylene- or / and combinations thereof. The above C1-150 Alkylene is unsubstituted C 1-150 Alkylene or substituted C 1-150 It may be an alkylene. In addition, the above C 1-150 Heteroalkylene is unsubstituted C 1-150 Heteroalkylene or substituted C 1-150 It may be a heteroalkylene. The above substitution C 1-150 Alkylene is C 1-150 It refers to an alkylene in which at least one of the chain-forming atoms of the alkylene is substituted with another element or group. As an example, the above substitution C 1-150 Alkylene is C 1-150 C in which at least one of the chain-forming atoms of the alkylene is substituted with one group independently selected from oxo, hydroxy, amino, carboxyl, thiol, sulfonic acid, phosphate, and halogen. 1-150 It may be an alkylene. As another example, the above substitution C 1-150 Heteroalkylene is C 1-150 C in which at least one of the chain-forming atoms of the heteroalkylene is substituted with one group independently selected from oxo, hydroxy, amino, carboxyl, thiol, sulfonic acid, phosphate, and halogen. 1-150 It can be a heteroalkylene.

[0599] In one specific example, the connector is non-existent (i.e., connected) -B1-B2-B3-, and

[0600] B1 may include a structure derived from the process in which a second click chemical functional group is connected to a conjugating linker, and such structure is not limited. As another example, B1 is absent or -C 1-20 Alkylene-, -C 1-20It may include heteroalkylene- or / and combinations thereof, each described as above. As another example, B1 is absent or (-CH2) n1 -, (-CH2) n1 -SS-,(-CH2) n1 -O-, (-CH2) n1 -(C=O)-O-, (-CH2) n1 -(C=O)-, (-CH2) n1 -(C=0)-NH-, -(C=0)-NH(-CH2) n1 -, -(C=0)(-CH2) n1 -(C=0)-, -(C=0)(-CH2) n1 -NH-(C=0)-, -(C=0)-NH(-CH2) n1 -(C=0)-, -(C=0)-NH(-CH2) n1 -NH-(C=0)-, -(C=0)(-CH2) n1 -(C=0)-NH-,-O-(C=O)-NH-, -O-(C=O)-NH(-CH2) n1 -, -O-(C=O)-NH(-CH2) n1 -(C=O)-NH-, -O-(C=O)-NH(-CH2) n1 -(C=O)-O-, or a combination thereof, may be included but not limited thereto. In this case, n1 independently represents a natural number between 1 and 10. Meanwhile, the above structural formula may have the front part connected to the second click chemical functional group and the rear part connected to B2. As an example, the above (-CH2) n1 -O- is [2th click chemistry group](-CH2) n1 It may represent a connection relationship such as -O-[B2], and this may also be applied to the other structural formulas mentioned above. Furthermore, unless otherwise stated, if B1 is expressed as a specific structural formula in this specification, it shall be interpreted in the same sense as described above.

[0601] B2 may be a portion containing a structure to enhance solubility, such as PEG, and the structure is not limited. For example, B2 may be absent or -C 1-80 Alkylene-, -C 1-80 It may include heteroalkylene- or / and combinations thereof, each described as above. As another example, B2 is absent or [-CH2-CH2-O] n2 (PEG n2 )-, [-CH2-CH2-O] n2 (PEG n2 )-(C=O)-, [-CH2-CH2-O] n2 (PEG n2 )-CH2-CH2-(C=O)-, -NH-[-CH2-CH2-O] n2 (PEG n2 )-(C=O)-,-NH-[-CH2-CH2-O] n2 (PEG n2 )-CH2-CH2-(C=O)-, [-CH2-CH2-O] n2 (PEG n2 )-NH-(C=O)-, [-CH2-CH2-O] n2 (PEG n2 )-CH2-CH2-NH-(C=O)-, [-CH2-CH2-O] n2 (PEG n2 )-(C=O)-NH-, [-CH2-CH2-O] n2 (PEG n2 )-CH2-CH2-(C=O)-NH-, [-CH2-CH2-O] n2 (PEG n2 )-(C=O)-O-, [-CH2-CH2-O] n2 (PEG n2 )-CH-CH-(C=O)-O-, [-CH2-CH2-O] n2 (PEG n2It may include )-(C=O)-CH2-CH2-, or a combination thereof, but is not limited thereto. The above n2 independently represents a natural number between 1 and 20 inclusive. Meanwhile, the above structural formula may have the front part connected to B1 and the back part connected to B3. As an example, the above [-CH2-CH2-O] n2 (PEG n2 )- is [B1][-CH2-CH2-O] n2 (PEG n2 It may represent a connection relationship such as )-(C=O)-[B3], and this may also be applied to other structural formulas mentioned above. Furthermore, unless otherwise stated, if B2 is expressed as a specific structural formula in this specification, it shall be interpreted in the same sense as above.

[0602] B3 contains a suitable structure for an ASGPR-targeting glycan to be connected to a linker, but is not limited to such structure. B3 is absent or -C 1-50 Alkylene-, -C 1-50 It may include heteroalkylenes—or / and combinations thereof, and the description for each is as described above. As another example, B3 may be absent, or a linker structure or branched linker structure using an amino acid (or amino acid derivative).

[0603] The structure of the linker using the above amino acid (or amino acid derivative) is not limited. As an example, the linker using the above amino acid (or amino acid derivative) may include a structure represented by the following chemical formula. In this case, the following chemical formula represents the chemical formula of a linker using asparagine.

[0604] [Chemical Formula 8]

[0605]

[0606] The structure of the branched linker is not limited as long as it has a structure for connecting two or more glycans. For example, the branched linker can be represented by the following chemical formula:

[0607] [Chemical Formula 9-1]

[0608] , or

[0609] [Chemical Formula 9-2]

[0610] .

[0611] Each of the above B4s is independently non-existent (i.e., combined), or -C 1-20 Alkylene-, -C 1-20 It may include heteroalkylenes—or and / or combinations thereof, each described as above. In one embodiment, B4 may be -CH2-O-CH2-CH2-(C=O)-NH-CH2-CH2-CH2-NH-(C=O)-CH2-CH2-CH2-CH2-O-[G]. Additionally, where two or more glycans are connected to one -[linker]- structure in this specification, the engineered claim PD-L1 scFv in this application should be interpreted as comprising said branched linker.

[0612] In one specific example, the linker can be represented by one of the following chemical formulas.

[0613] [Chemical Formula 13-1]

[0614] , or

[0615] [Chemical Formula 13-2]

[0616] .

[0617] The above 2th CC means [2nd click chemical functional group], and G means [glycan]. Also, the above n is 12.

[0618] In one specific example, the linker is represented by the following chemical formula, and

[0619] [Chemical Formula 13-3]

[0620]

[0621] Each of the above B4s can be expressed as -CH2-O-CH2-CH2-(C=O)-NH-CH2-CH2-CH2-NH-(C=O)-CH2-CH2-CH2-CH2-O-[G]. The above [G] should be interpreted in the sense of indicating a bonding relationship (bonding direction). The above 2th CC means [second click chemical functional group], and G means [glycan].

[0622] For the above ASGPR targeting glycan, the contents of [Construction (4) G (glycan)] of [Chapter 2 Engineered Anti-PD-L1 scFv] are included by reference.

[0623] Method for producing an engineered anti-PD-L1 scFv conjugate of the present application

[0624] The method for producing an engineered anti-PD-L1 scFv conjugate of the present application is not particularly limited in form, provided that it is produced by reacting an 'engineered anti-PD-L1 scFv' with a 'conjugating linker-ASGPR targeting glycan compound'.

[0625] For example, the above method for producing an engineered anti-PD-L1 scFv conjugate may include the following:

[0626] a) reacting an ASGPR-targeting glycan with a conjugating linker to form a conjugating linker-ASGPR-targeting glycan compound; and

[0627] b) The above conjugating linker-ASGPR targeting glycan compound is reacted with an engineered anti-PD-L1 scFv, wherein the first click chemical functional group of a non-natural amino acid contained in the engineered anti-PD-L1 scFv and the second click chemical functional group of the conjugating linker-ASGPR targeting glycan compound are combined through a click reaction.

[0628] The method of reacting the above ASGPR targeting glycan and conjugating linker can be appropriately carried out according to methods known to a person skilled in the art.

[0629] As another example, the above-mentioned method for producing an engineered anti-PD-L1 scFv conjugate may include the following.

[0630] a) Prepare a conjugating linker-ASGPR targeting glycan compound; and

[0631] b) A conjugating linker-ASGPR targeting glycan compound is reacted with an engineered anti-PD-L1 scFv, wherein the first click functional group of a non-natural amino acid contained in the engineered anti-PD-L1 scFv is combined with the second click functional group of the conjugating linker-ASGPR targeting glycan compound through a click reaction.

[0632] As another example, the above-mentioned method for producing an engineered anti-PD-L1 scFv conjugate may include the following.

[0633] a) Prepare a conjugating linker-ASGPR targeting glycan compound and an engineered anti-PD-L1 scFv; and

[0634] b) A conjugating linker-ASGPR targeting glycan compound is reacted with an engineered anti-PD-L1 scFv, wherein the first click functional group of a non-natural amino acid contained in the engineered anti-PD-L1 scFv is combined with the second click functional group of the conjugating linker-ASGPR targeting glycan compound through a click reaction.

[0635] The above-mentioned engineered anti-PD-L1 scFv can be prepared by the “method for producing engineered anti-PD-L1 scFv” of this specification.

[0636] The reaction ratio of the above conjugating linker-ASGPR targeting glycan compound and the engineered anti-PD-L1 scFv can be selected in various ways. For example, the above reaction comprises the conjugating linker-ASGPR targeting glycan compound and engineered anti-PD-L1 scFv in a ratio of 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 21:1, 22:1, 23:1, 24:1, 25:1, 26:1, 27:1, 28:1, 29:1, 30:1, 31:1, 32:1, 33:1, 34:1, 35:1, 36:1, The reaction may be carried out at molar ratios of 37:1, 38:1, 39:1, and 40:1. Preferably, the molar ratio may be 20:1.

[0637] Specific example of the method for producing an engineered anti-PD-L1 scFv conjugate of the present application

[0638] Hereinafter, specific examples of the method for producing an engineered anti-PD-L1 scFv conjugate according to the present application will be described. The following specific examples are merely illustrative and are not limited thereto.

[0639] For example, the above method for producing an engineered anti-PD-L1 scFv conjugate may include the following:

[0640] a) Prepare engineered anti-PD-L1 scFv and conjugating linker-ASGPR targeting glycan compounds; and

[0641] b) Reacting a conjugating linker-ASGPR targeting glycan compound with an engineered anti-PD-L1 scFv,

[0642] The first click functional group of pAzF contained in the engineered anti-PD-L1 scFv and the second click functional group of the conjugating linker-ASGPR targeting glycan compound are combined via a click reaction.

[0643] In addition, the engineered anti-PD-L1 scFv comprises one of the amino acid sequences represented by SEQ ID NOs 4 to 35, wherein X is pAzF in the amino acid sequences represented by SEQ ID NOs 4 to 35.

[0644] The above-described reacted conjugating linker-ASGPR targeting glycan compound is represented by the following structural formula:

[0645] [2nd click chemistry functional group (2th CC)]-[linking group (L)]-[Glycan (G)],

[0646] The above [2nd click chemistry functional group (2th CC)] is represented by one selected from the following chemical formulas:

[0647] [Chemical Formula 12-1]

[0648] ; or

[0649] [Chemical Formula 12-2]

[0650] ,

[0651] In one specific embodiment, the [linking group (L)] is represented by one of the following chemical formulas, and

[0652] [Chemical Formula 13-1]

[0653] , or

[0654] [Chemical Formula 13-2]

[0655] ,

[0656] The above n is 12, and

[0657] The above [glycan (glaycan, G)] is represented by one of the following chemical formulas:

[0658] [Chemical Formula 10-1]

[0659] ;

[0660] [Chemical Formula 10-2]

[0661] ;

[0662] [Chemical Formula 10-3]

[0663] ; or

[0664] [Chemical Formula 10-4]

[0665] .

[0666] In another specific embodiment, the [linking group (L)] is represented by the following chemical formula, and

[0667] [Chemical Formula 13-3]

[0668] ,

[0669] Each of the above B4 is represented as -CH2-O-CH2-CH2-(C=O)-NH-CH2-CH2-CH2-NH-(C=O)-CH2-CH2-CH2-CH2-O-[G], and the above [glycan (glaycan, G)] is represented by the following chemical formula:

[0670] [Chemical Formula 10-5]

[0671] (GalNAc).

[0672] As another example, the above-mentioned method for producing an engineered anti-PD-L1 scFv conjugate may include the following:

[0673] a) Prepare engineered anti-PD-L1 scFv and conjugating linker-ASGPR targeting glycan compounds; and

[0674] b) Reacting a conjugating linker-ASGPR targeting glycan compound with an engineered anti-PD-L1 scFv.

[0675] The first click functional group of frTet contained in the above-mentioned engineered anti-PD-L1 scFv and the second click functional group of the conjugating linker-ASGPR targeting glycan compound are combined through a click reaction.

[0676] The above-mentioned engineered anti-PD-L1 scFv comprises one of the amino acid sequences represented by SEQ ID NOs 4 to 35, wherein in the amino acid sequences represented by SEQ ID NOs 4 to 35, X is frTet, and

[0677] The above conjugating linker-ASGPR targeting glycan compound is represented by the following structural formula:

[0678] [2nd click chemistry functional group (2th CC)]-[linking group (L)]-[Glycan (G)],

[0679] The above [2nd click chemical functional group (2th CC)] is represented by the following chemical formula:

[0680] [Chemical Formula 12-3]

[0681] ,

[0682] In one specific embodiment, the [linking group (L)] is represented by one of the following chemical formulas, and

[0683] [Chemical Formula 13-1]

[0684] , or

[0685] [Chemical Formula 13-2]

[0686] ,

[0687] The above n is 12, and

[0688] The above [glycan (glaycan, G)] is represented by one of the following chemical formulas:

[0689] [Chemical Formula 10-1]

[0690] ;

[0691] [Chemical Formula 10-2]

[0692] ;

[0693] [Chemical Formula 10-3]

[0694] ; or

[0695] [Chemical Formula 10-4]

[0696] .

[0697] In another specific embodiment, the [linking group (L)] is represented by the following chemical formula, and

[0698] [Chemical Formula 13-3]

[0699] ,

[0700] Each of the above B4 is represented as -CH2-O-CH2-CH2-(C=O)-NH-CH2-CH2-CH2-NH-(C=O)-CH2-CH2-CH2-CH2-O-[G], and the above [glycan (glaycan, G)] is represented by the following chemical formula:

[0701] [Chemical Formula 10-5]

[0702] (GalNAc).

[0703]

[0704] Possible embodiments of the invention

[0705] Hereinafter, embodiments of the present invention will be described. The following embodiments are intended to explain the present invention more specifically, and it will be obvious to those skilled in the art that the scope of the present invention is not limited by these embodiments.

[0706]

[0707] Engineered anti-PD-L1 scFv conjugate

[0708] [Example 1]

[0709] Engineered PD-L1 scFv conjugate represented by the following structural formula:

[0710] [engineered anti PD-L1 scFv (S)]-[junction (J)]-[linking group (L)]-[Glycan (G)] k ,

[0711] k is 1 to 3, and

[0712] The above-mentioned engineered anti-PD-L1 scFv is represented by one amino acid selected from SEQ ID NOs 4 to 35 or 158 to 189, and

[0713] X of the above sequence numbers 4 to 35 or 158 to 189 is an amino acid represented by the following chemical formula, and

[0714] [Chemical Formula 5]

[0715]

[0716] AA1 is an adjacent amino acid(s) or H, AA2 is an adjacent amino acid(s) or OH, g is 1, 2, or 3, and

[0717] The above-mentioned junction includes a structure formed by a click chemical reaction, and

[0718] The above connector is a structure for connecting a joint and a glycan, and

[0719] The above glycan is an ASGPR-targeting glycan.

[0720] [Example 2]

[0721] In Example 1, the junction is an engineered anti-PD-L1 scFv conjugate represented by one of the following chemical formulas:

[0722] [Chemical Formula 6-1]

[0723] ;

[0724] [Chemical Formula 7-1]

[0725] ;

[0726] [Chemical Formula 7-2]

[0727] ;

[0728] [Chemical Formula 7-3]

[0729] ; or

[0730] [Chemical Formula 7-4]

[0731] ,

[0732] A1 is non-existent (i.e., combined) or -A 11 -A 12 - and,

[0733] A 11 is absent, or -C1-5alkylene-, and

[0734] A 12 is non-existent, or -[Arilene] p -, -[Arilen] p -C 1-5 Alkylene-, -[arylene] p -C 1-5 Heteroalkylene-, -arylene-C 1-5 Alkylene-arylene-, -arylene-C 1-5 Heteroalkylene-arylene-, -arylene-heteroarylene-, -[heteroarylene] p -, -[Heteroarylene] p -C 1-5 Alkylene-, -[heteroarylene] p -C 1-5 Heteroalkylene-, -heteroarylene-C 1-5 Alkylene-arylene-, -heteroarylene-C 1-5 Alkylene-heteroarylene-, -heteroarylene-C 1-5 Heteroalkylene-arylene-, and -heteroarylene-C 1-5 It is any one selected from heteroalkylene-heteroarylene-, where p is an integer between 1 and 3 inclusive, and

[0735] R1 is H, halogen, -C 1-3 Alkyl, -C 3-6 Cycloalkyl, -C 3-6 It is any one selected from heterocycloalkyl, aryl, and heteroaryl, and

[0736] The above heterocycloalkyl, or heteroaryl, comprises one or more heteroatom groups selected from the group consisting of -NH-, -O-, -S-, -ON=, -S(=O)-, and -S(=O)2-, or one or more heteroatoms selected from the group consisting of O, N, and S.

[0737] [Example 3]

[0738] In Example 2, A1 is -C1-5alkylene-[arylene] p - and R1 is an engineered anti-PD-L1 scFv conjugate in which H.

[0739] [Example 4]

[0740] In Example 3, the junction is an engineered anti-PD-L1 scFv conjugate represented by the following chemical formula:

[0741] .

[0742] [Example 5]

[0743] An engineered anti-PD-L1 scFv conjugate in Example 4, characterized in that the junction is a structure formed by the reaction of a side chain of frTet and a TCO.

[0744] [Example 6]

[0745] In Example 3, the junction is an engineered anti-PD-L1 scFv conjugate represented by the following chemical formula:

[0746] [Chemical Formula 7-5]

[0747] ; or

[0748] [Chemical Formula 7-6]

[0749] .

[0750] [Example 7]

[0751] An engineered anti-PD-L1 scFv conjugate in Example 6, characterized in that the junction is a structure formed by the reaction of a side chain of frTet with DBCO or BCN.

[0752] [Example 8]

[0753] For one of Examples 1 to 7, the connector is -C 1-150 Alkylene-, -C 1-150 Heteroalkylene- or / and combinations thereof, comprising

[0754] The above C 1-150 Alkylene is unsubstituted C 1-150 Alkylene or substituted C 1-150 It is an alkylene, and

[0755] The above C 1-150 Heteroalkylene is unsubstituted C 1-150 Heteroalkylene or substituted C 1-150 It can be a heteroalkylene, and

[0756] The above substitution C 1-150 Alkylene is C 1-150 It means an alkylene in which at least one of the chain-forming atoms of the alkylene is substituted with a group independently selected from oxo, hydroxy, amino, carboxyl, thiol, sulfonic acid, phosphate, and halogen, and

[0757] The above substitution C 1-150 Heteroalkylene is C 1-150 C in which at least one of the chain-forming atoms of the heteroalkylene is substituted with a group independently selected from oxo, hydroxy, amino, carboxyl, thiol, sulfonic acid, phosphate, and halogen. 1-150Engineered anti-PD-L1 scFv conjugate, meaning heteroalkylene.

[0758] [Example 9]

[0759] For one of Examples 1 to 7, the connector is absent (i.e., coupled) or -B1-B2-B3-, and

[0760] B1 does not exist, or -C 1-20 Alkylene-, -C 1-20 Comprising heteroalkylene- or / and combinations thereof, the above C 1-20 Alkylene is unsubstituted C 1-20 Alkylene or substituted C 1-20 It is an alkylene, and the above C 1-20 Heteroalkylene is unsubstituted C 1-20 Heteroalkylene or substituted C 1-20 It is a heteroalkylene, and

[0761] B2 does not exist, or -C 1-80 Alkylene-, -C 1-80 Comprising heteroalkylene- or / and combinations thereof, the above C 1-80 Alkylene is unsubstituted C 1-80 Alkylene or substituted C 1-80 It is an alkylene, and the above C 1-80 Heteroalkylene is unsubstituted C 1-80 Heteroalkylene or substituted C 1-80 It is a heteroalkylene, and

[0762] B3 does not exist, or -C 1-50 Alkylene-, -C 1-50 Comprising heteroalkylene- or / and combinations thereof, the above C 1-50 Alkylene is unsubstituted C 1-50 Alkylene or substituted C 1-50 It is an alkylene, and the above C 1-50 Heteroalkylene is unsubstituted C 1-50 Heteroalkylene or substituted C 1-50 Heteroalkylene, engineered anti-PD-L1 scFv conjugate.

[0763] [Example 10]

[0764] In Example 9, B1 is (-CH2) n1 -, (-CH2) n1 -SS-,(-CH2) n1 -O-, (-CH2) n1 -(C=O)-O-, (-CH2) n1 -(C=O)-, (-CH2) n1 -(C=0)-NH-, -(C=0)-NH(-CH2) n1 -, -(C=0)(-CH2) n1 -(C=0)-, -(C=0)(-CH2) n1 -NH-(C=0)-, -(C=0)-NH(-CH2) n1 -(C=0)-, -(C=0)-NH(-CH2) n1 -NH-(C=0)-, -(C=0)(-CH2) n1 -(C=0)-NH-,-O-(C=O)-NH-, -O-(C=O)-NH(-CH2) n1 -, -O-(C=O)-NH(-CH2) n1 -(C=O)-NH-, -O-(C=O)-NH(-CH2) n1 -(C=O)-O-, or a combination thereof, comprising an engineered term PD-L1 scFv conjugate in which n1 independently means a natural number between 1 and 10.

[0765] [Example 11]

[0766] In Example 9 or 10, B2 is [-CH2-CH2-O] n2 (PEG n2 )-, [-CH2-CH2-O] n2 (PEG n2 )-(C=O)-, [-CH2-CH2-O] n2 (PEG n2 )-CH2-CH2-(C=O)-, -NH-[-CH2-CH2-O] n2 (PEG n2 )-(C=O)-,-NH-[-CH2-CH2-O] n2 (PEG n2 )-CH2-CH2-(C=O)-, [-CH2-CH2-O] n2 (PEG n2)-NH-(C=O)-, [-CH2-CH2-O] n2 (PEG n2 )-CH2-CH2-NH-(C=O)-, [-CH2-CH2-O] n2 (PEG n2 )-(C=O)-NH-, [-CH2-CH2-O] n2 (PEG n2 )-CH2-CH2-(C=O)-NH-, [-CH2-CH2-O] n2 (PEG n2 )-(C=O)-O-, [-CH2-CH2-O] n2 (PEG n2 )-CH-CH-(C=O)-O-, [-CH2-CH2-O] n2 (PEG n2 An engineered PD-L1 scFv conjugate comprising )-(C=O)-CH2-CH2-, or a combination thereof, wherein n2 independently means a natural number between 1 and 20.

[0767] [Example 12]

[0768] In any one of Examples 9 to 11, B3 is an engineered anti-PD-L1 scFv conjugate represented by the following structural formula:

[0769] .

[0770] [Example 13]

[0771] In any one of Examples 9 to 12, B3 is an engineered anti-PD-L1 scFv conjugate represented by the following structural formula:

[0772] [Chemical Formula 9-1]

[0773] , or

[0774] [Chemical Formula 9-2]

[0775]

[0776] Each of the above B4s is independently non-existent (i.e., combined), or -C 1-20 Alkylene-, -C 1-20Comprising heteroalkylene- or / and combinations thereof, the above C 1-20 Alkylene is unsubstituted C 1-20 Alkylene or substituted C 1-20 It is an alkylene, and the above C 1-20 Heteroalkylene is unsubstituted C 1-20 Heteroalkylene or substituted C 1-20 It is a heteroalkylene.

[0777] [Example 14]

[0778] In Example 13, the B4 is an engineered anti-PD-L1 scFv conjugate, wherein B4 is -CH2-O-CH2-CH2-(C=O)-NH-CH2-CH2-CH2-NH-(C=O)-CH2-CH2-CH2-CH2-O-.

[0779] [Example 15]

[0780] In any one of Examples 1 to 14, the ASGPR targeting glycan is an engineered anti-PD-L1 scFv conjugate comprising galactose or GalNAc (N-acetylgalactosamine) at the end of the sugar chain.

[0781] [Example 16]

[0782] In any one of Examples 1 to 14, the ASGPR targeting glycan is an engineered anti-PD-L1 scFv conjugate represented by one of the following chemical formulas:

[0783] [Chemical Formula 10-1]

[0784] ;

[0785] [Chemical Formula 10-2]

[0786] ;

[0787] [Chemical Formula 10-3]

[0788] ;

[0789] [Chemical Formula 10-4]

[0790] ; or

[0791] [Chemical Formula 10-5]

[0792] (GalNAc).

[0793] [Example 17]

[0794] Regarding Example 16,

[0795] The above joint is represented as follows:

[0796] ,

[0797] The above connector is represented as one of the following;

[0798] , or

[0799] ,

[0800] The above ASGPR-targeting glycan is represented as follows,

[0801]

[0802] Engineered anti-PD-L1 scFv conjugate.

[0803] [Example 18]

[0804] Regarding Example 16,

[0805] The above joint is represented as follows:

[0806] ,

[0807] The above connector is represented as follows;

[0808] ,

[0809] Each of the above B4 is -CH2-O-CH2-CH2-(C=O)-NH-CH2-CH2-CH2-NH-(C=O)-CH2-CH2-CH2-CH2-O-, and

[0810] The above ASGPR-targeting glycan is represented as follows,

[0811] , engineered anti-PD-L1 scFv conjugate.

[0812] [Example 19]

[0813] In any one of Examples 1 to 18, the engineered anti-PD-L1 scFv is an engineered anti-PD-L1 scFv conjugate represented by any one of the amino acid sequences of SEQ ID NOs 4 to 13 and 158 to 167.

[0814] [Example 20]

[0815] In any one of Examples 1 to 18, the engineered anti-PD-L1 scFv is an engineered anti-PD-L1 scFv conjugate represented by the amino acid sequence of SEQ ID NO. 6 or 160.

[0816] [Example 21]

[0817] In any one of Examples 1 to 18, the engineered anti-PD-L1 scFv is an engineered anti-PD-L1 scFv conjugate represented by any one of the amino acid sequences of SEQ ID NOs 14 to 23 and 168 to 177.

[0818] [Example 22]

[0819] In any one of Examples 1 to 18, the engineered anti-PD-L1 scFv is an engineered anti-PD-L1 scFv conjugate represented by any one of the amino acid sequences of SEQ ID NOs 24 to 35 and 178 to 189.

[0820] Pharmaceutical composition

[0821] [Example 23]

[0822] A pharmaceutical composition comprising one of the engineered anti-PD-L1 scFv conjugates of Examples 1 to 22.

[0823] [Example 24]

[0824] In Example 23, the pharmaceutical composition is a pharmaceutical composition for treating liver cancer.

[0825] [Example 25]

[0826] In Example 22 or 24, the pharmaceutical composition further comprises an excipient.

[0827] [Example 26]

[0828] A pharmaceutical composition in Example 25, wherein the excipient is selected from one or more of the following:

[0829] (a) buffer

[0830] (b) Topic

[0831] (c) Surfactants, or / and

[0832] (d) Stabilizer.

[0833] [Example 27]

[0834] In Example 26, the buffer is histidine, phosphoric acid, citric acid or / and acetic acid, and

[0835] Optionally, the concentration of the buffer is 1mM, 2mM, 3mM, 4mM, 5mM, 6mM, 7mM, 8mM, 9mM, 10mM, 11mM, 12mM, 13mM, 14mM, 15mM, 16mM, 17mM, 18mM, 19mM, 20mM, 21mM, 22mM, 23mM, 24mM, 25mM, 26mM, 27mM, 28mM, 29mM, 30mM, 31mM, 32mM, 33mM, 34mM, 35mM, 36mM, 37mM, 38mM, 39mM, 40mM, 41mM, 42mM, 43mM, 44mM, 45mM, 46mM, 47 48mM, 48mM, 49mM and A pharmaceutical composition having a concentration of one value selected from 50 mM or between two selected values.

[0836] [Example 28]

[0837] In Example 26, the isotonic agent is sucrose, trehalose, mannitol, sorbitol, or / and sodium chloride, and

[0838] Optionally, the concentration of the isotonic agent is 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4.0%, 4.1%, 4.2%, 4.3%, 4.4%, 4.5%, 4.6%, 4.7%, 4.8%, 4.9%, 5.0%, 5.1%, 5.2%, 5.3%, 5.4%, 5.5%, 5.6%, 5.7%, 5.8%, 5.9%, 6.0%, 6.1%, 6.2%, 6.3%, 6.4%, 6.5%, 6.6%, 6.7%, 6.8%, 6.9%, 7.0%, 7.1%, 7.2%, 7.3%, 7.4%, 7.5%, 7.6%, 7.7%, 7.8%, 7.9%, 8.0%, 8.1%, 8.2%, 8.3%, 8.4%, 8.5%, 8.6%, 8.7%, 8.8%, 8.9%, 9.0%, 9.1%, 9.2%, 9.3%, 9.4%, 9.5%, 9.6%, 9.7%, 9.8%, 9.9% and 10.A concentration between one selected value from 0% or two selected values, or 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, 10 mM, 11 mM, 12 mM, 13 mM, 14 mM, 15 mM, 16 mM, 17 mM, 18 mM, 19 mM, 20 mM, 21 mM, 22 mM, 23 mM, 24 mM, 25 mM, 26 mM, 27 mM, 28 mM, 29 mM, 30 mM, 31 mM, 32 mM, 33 mM, 34 mM, 35 mM, 36 mM, 37 mM, 38 mM, 39 mM, 40 mM, 41 mM, 42 mM, 43 mM, 44 mM, 45 mM, 46 mM, 47 mM, 48mM, 49mM, 50mM, 51mM, 52mM, 53mM, 54mM, 55mM, 56mM, 57mM, 58mM, 59mM, 60mM, 61mM, 62mM, 63mM, 64mM, 65mM, 66mM, 67mM, 68mM, 69mM, 70mM, 71mM, 72mM, 73mM, 74mM, 75mM, 76mM, 77mM, 78mM, 79mM, 80mM, 81mM, 82mM, 83mM, 84mM, 85mM, 86mM, 87mM, 88mM, 89mM, 90mM, 91mM, 92mM, 93mM, 94 95mM, 96mM, A pharmaceutical composition having a concentration of one value selected from 97 mM, 98 mM, 99 mM, 100 mM, 200 mM, 300 mM, 400 mM, and 500 mM, or between two selected values.

[0839] [Example 29]

[0840] In Example 26, the interface activator is polysorbate 20 or / and polysorbate 80, and

[0841] Optionally, a pharmaceutical composition in which the concentration of the surfactant is one value selected from 0.01%, 0.02%, 0.03%, 0.04%, and 0.05% or a concentration between two selected values.

[0842] [Example 30]

[0843] In Example 26, the stabilizer is glycine or / and arginine, and

[0844] Optionally, the concentration of the stabilizer is 1mM, 2mM, 3mM, 4mM, 5mM, 6mM, 7mM, 8mM, 9mM, 10mM, 11mM, 12mM, 13mM, 14mM, 15mM, 16mM, 17mM, 18mM, 19mM, 20mM, 21mM, 22mM, 23mM, 24mM, 25mM, 26mM, 27mM, 28mM, 29mM, 30mM, 31mM, 32mM, 33mM, 34mM, 35mM, 36mM, 37mM, 38mM, 39mM, 40mM, 41mM, 42mM, 43mM, 44mM, 45mM, 46mM, 47 48mM, 48mM, 49mM, 50mM, 51mM, 52mM, 53mM, 54mM, 55mM, 56mM, 57mM, 58mM, 59mM, 60mM, 61mM, 62mM, 63mM, 64mM, 65mM, 66mM, 67mM, 68mM, 69mM, 70mM, 71mM, 72mM, 73mM, 74mM, 75mM, 76mM, 77mM, 78mM, 79mM, 80mM, 81mM, 82mM, 83mM, 84mM, 85mM, 86mM, 87mM, 88mM, 89mM, 90mM, 91mM, 92mM, 93mM, 94mM, 95mM, 96 97mM, 98mM, A pharmaceutical composition having a concentration of one value selected from 99 mM and 100 mM or between two selected values.

[0845] [Example 31]

[0846] In one of Examples 23 to 30, the pH of the pharmaceutical composition is pH 4.0, pH 4.1, pH 4.2, pH 4.3, pH 4.4, pH 4.5, pH 4.6, pH 4.7, pH 4.8, pH 4.9, pH 5.0, pH 5.1, pH 5.2, pH 5.3, pH 5.4, pH 5.5, pH 5.6, pH 5.7, pH 5.8, pH 5.9, pH 6.0, pH 6.1, pH 6.2, pH 6.3, pH 6.4, pH 6.5, pH 6.6, pH 6.7, pH 6.8, pH 6.9, pH 7.0, pH 7.1, pH 7.2, pH 7.3, pH 7.4, pH 7.5, pH 7.6, pH It may be one value selected from 7.7, pH 7.8, pH 7.9, and pH 8.0, or between two selected values.

[0847] [Example 32]

[0848] In one of Examples 23 to 31, the pharmaceutical composition is

[0849] (a) containing 10 mM sodium citrate, 5.8% sucrose and 0.02% PS 80, with a pH of 7.2, or

[0850] (b) containing 10 mM sodium citrate, 5.8% sucrose and 0.02% PS 80, with a pH of 6.0, or

[0851] (c) Containing 10 mM histidine, 5% sucrose, 80 mM sodium chloride and 0.01% PS 20, with a pH of 6.0, or

[0852] (d) containing 10 mM histidine, 7.5% sucrose, 50 mM arginine, 20 mM sodium chloride, and 0.02% PS 80, with a pH of 6.0, or

[0853] (e) A pharmaceutical composition comprising 10 mM sodium acetate, 7.5% trehalose, 40 mM sodium chloride, and 0.02% PS 80, with a pH of 5.5.

[0854] [Example 33]

[0855] A pharmaceutical composition for treating liver cancer comprising an engineered anti-PD-L1 scFv conjugate represented by the following [structural formula]:

[0856] [constitutional formula]

[0857] [engineered anti PD-L1 scFv (engineered anti PD-L1 scFv, S)]-[junction (J)]-[linking group (L)]-[Glycan (G)],

[0858] The above S is indicated by sequence number 6 or 160, and

[0859] X of the above sequence number 6 or 160 is an amino acid residue represented by the following [Chemical Formula 5], and

[0860] [Chemical Formula 5]

[0861]

[0862] AA1 is an adjacent amino acid(s) or H, AA2 is an adjacent amino acid(s) or OH, g is 1, and

[0863] The above J is expressed by the following [Chemical Formula 7-5]:

[0864] [Chemical Formula 7-5]

[0865] ,

[0866] The above L is expressed by the following [Chemical Formula 11-1] or [Chemical Formula 11-1] and

[0867] [Chemical Formula 11-1]

[0868] ; or

[0869] [Chemical Formula 11-2]

[0870] ,

[0871] The above G is represented by the following [Chemical Formula 10-3]

[0872] [Chemical Formula 10-3]

[0873] , pharmaceutical composition.

[0874] [Example 34]

[0875] A pharmaceutical composition for treating liver cancer comprising an engineered anti-PD-L1 scFv conjugate represented by the following [structural formula]:

[0876] [constitutional formula]

[0877] [engineered anti PD-L1 scFv (engineered anti PD-L1 scFv, S)]-[junction (J)]-[linking group (L)]-[Glycan (G)]3,

[0878] The above S is indicated by sequence number 6 or 160, and

[0879] X of the above sequence number 6 or 160 is an amino acid residue represented by the following [Chemical Formula 5], and

[0880] [Chemical Formula 5]

[0881]

[0882] AA1 is an adjacent amino acid(s) or H, AA2 is an adjacent amino acid(s) or OH, g is 3, and

[0883] The above J is expressed by the following [Chemical Formula 7-5]:

[0884] [Chemical Formula 7-5]

[0885] ,

[0886] The above L is expressed by the following [Chemical Formula 11-3] and

[0887] [Chemical Formula 11-3]

[0888]

[0889] Each of the above B4 is expressed as -CH2-O-CH2-CH2-(C=O)-NH-CH2-CH2-CH2-NH-(C=O)-CH2-CH2-CH2-CH2-O-[G], and

[0890] The above G is represented by the following [Chemical Formula 10-5]:

[0891] (GalNAc), pharmaceutical composition.

[0892] Treatment methods

[0893] [Example 35]

[0894] A method for treating liver cancer comprising administering to a patient an engineered anti-PD-L1 scFv conjugate of any one of Examples 1 to 22 or a pharmaceutical composition of any one of Examples 23 to 34.

[0895] [Example 36]

[0896] A method for treating liver cancer comprising administering an engineered anti-PD-L1 scFv conjugate represented by the following structural formula to a patient:

[0897] [constitutional formula]

[0898] [engineered anti PD-L1 scFv (engineered anti PD-L1 scFv, S)]-[junction (J)]-[linking group (L)]-[Glycan (G)],

[0899] The above S is indicated by sequence number 6 or 160, and

[0900] X of the above sequence number 6 or 160 is an amino acid residue represented by the following [Chemical Formula 5], and

[0901] [Chemical Formula 5]

[0902]

[0903] AA1 is an adjacent amino acid(s) or H, AA2 is an adjacent amino acid(s) or OH, g is 1, and

[0904] The above J is expressed by the following [Chemical Formula 7-5]:

[0905] [Chemical Formula 7-5]

[0906] ,

[0907] The above L is expressed by the following [Chemical Formula 11-1] or [Chemical Formula 11-1] and

[0908] [Chemical Formula 11-1]

[0909] ; or

[0910] [Chemical Formula 11-2]

[0911] ,

[0912] The above G is expressed by the following [Chemical Formula 10-3]:

[0913] [Chemical Formula 10-3]

[0914] .

[0915] [Example 37]

[0916] A method for treating liver cancer comprising administering an engineered anti-PD-L1 scFv conjugate represented by the following structural formula to a patient:

[0917] [constitutional formula]

[0918] [engineered anti PD-L1 scFv (engineered anti PD-L1 scFv, S)]-[junction (J)]-[linking group (L)]-[Glycan (G)]3,

[0919] The above S is indicated by sequence number 6 or 160, and

[0920] X of the above sequence number 6 or 160 is an amino acid residue represented by the following [Chemical Formula 5], and

[0921] [Chemical Formula 5]

[0922]

[0923] AA1 is an adjacent amino acid(s) or H, AA2 is an adjacent amino acid(s) or OH, g is 3, and

[0924] The above J is expressed by the following [Chemical Formula 7-5]:

[0925] [Chemical Formula 7-5]

[0926] ,

[0927] The above L is expressed by the following [Chemical Formula 11-3] and

[0928] [Chemical Formula 11-3]

[0929]

[0930] Each of the above B4 is expressed as -CH2-O-CH2-CH2-(C=O)-NH-CH2-CH2-CH2-NH-(C=O)-CH2-CH2-CH2-CH2-O-[G], and

[0931] The above G is expressed by the following [Chemical Formula 10-5]:

[0932] (GalNAc).

[0933] [Example 38]

[0934] A method for treating liver cancer, wherein in any one of Examples 35 to 37, the engineered anti-PD-L1 scFv conjugate or pharmaceutical composition is administered via subcutaneous or intravenous injection.

[0935] [Example 39]

[0936] A method for treating liver cancer in any one of Examples 35 to 38, wherein the patient is a liver cancer patient.

[0937]

[0938] [Experimental Example]

[0939] The present invention will be explained in more detail below through experimental examples.

[0940] These experimental examples are solely for the purpose of illustrating the present invention more specifically, and it will be obvious to those skilled in the art that the scope of the present invention is not limited by these examples.

[0941] Experimental Example 1. Production of Engineered Anti-PD-L1 scFv

[0942] Experimental Example 1.1. Preparation of Engineered Paragraph PD-L1 scFv Encryption Vector

[0943] As described in "Location of Non-Natural Amino Acids" and "Criteria for Selecting the Location of Non-Natural Amino Acids" in Chapter 1 of this specification, the introduction site of non-natural amino acids was selected based on protein structure analysis, taking into account the free energy change, solvent accessibility, and the influence on the CDR region. In particular, at 10 positions (K45, K78, S77, S87, A90, E91, Q195, S201, K234, and K237) in atezolizumab albubody (SEQ No. 1, SEQ No. 158 if histag is present), 10 positions (K45, A77, K78, S87, A90, V198, P203, G204, D256, and P276) in durvalumab albubody (SEQ No. 2, SEQ No. 159 if histag is present), and 12 positions (S77, S87, A90, E91, Q114, P181, S196, T199, A202, S203, S252) in avelumab albubody (SEQ No. 3, SEQ No. 160 if histag is present. and S263) were selected. Accordingly, atezolizumab-engineered scFvs (SEQ Nos. 4 to 13), durvalumab-engineered scFvs (SEQ Nos. 14 to 23), and avelumab-engineered scFvs (SEQ Nos. 24 to 35) were designed, as described in Tables 1 to 7. In addition, the names for each engineered anti-PD-L1 in the present experimental examples are summarized in Table 9 below.

[0944] Origin Sequence Number Name Atezolizumab Sequence Number 4K45X Atezolizumab Sequence Number 5K78X Atezolizumab Sequence Number 6S201X Atezolizumab Sequence Number 7K234X Atezolizumab Sequence Number 8K237X Atezolizumab Sequence Number 9S77X Atezolizumab Sequence Number 10S87X Atezolizumab Sequence Number 11A90X Atezolizumab Sequence Number 12E91X Atezolizumab Sequence Number 13Q195X Durvalumab Sequence Number 14K78X Durvalumab Sequence Number 15S87X Durvalumab Sequence Number 16A90X Durvalumab Sequence Number 17D256X Durvalumab Sequence Number 18P276X Durvalumab Sequence Number 19K45X durvalumab sequence number 20A77X durvalumab sequence number 21V198X durvalumab sequence number 22P203X durvalumab sequence number 23G204X avelumab sequence number 24S77X avelumab sequence number 25S87X avelumab sequence number 26A90X avelumab sequence number 27E91X avelumab sequence number 28Q114X avelumab sequence number 29P181X avelumab sequence number 30S196X avelumab sequence number 31T199X avelumab sequence number 32A202X avelumab sequence number 33S203X avelumab sequence number 34S252X avelumab sequence number 35S263X

[0945] In this experimental example, an engineered anti-PD-L1 scFv linked with a hig-tag was used. Accordingly, plasmids (pBAD-based; full sequences: SEQ ID NOs 268 to 277) containing SEQ ID NOs 233 to 242, respectively, as vectors encoding atezolizumab-engineered scFvs were prepared. Additionally, plasmids (pBAD-based; full sequences: SEQ ID NOs 279 to 288) containing SEQ ID NOs 244 to 253, respectively, as vectors encoding durvalumab-engineered scFvs were prepared. Furthermore, plasmids (pBAD-based; full sequences: SEQ ID NOs 290 to 301) containing SEQ ID NOs 255 to 266, respectively, as vectors encoding avelumab-engineered scFvs were prepared.

[0946] In addition, an engineered anti-PD-L1 scFv (albubody) that does not contain non-natural amino acids was prepared as a comparison group, and a vector containing SEQ ID NO. 232 (full sequence: SEQ ID NO. 267) was prepared as a vector encoding atezolizumab albubody containing a hig-tag. In addition, a vector containing SEQ ID NO. 243 (full sequence: SEQ ID NO. 278) was prepared as a vector encoding durvalumab albubody containing a hig-tag. In addition, a vector containing SEQ ID NO. 254 (full sequence: SEQ ID NO. 289) was prepared as a vector encoding avelumab albubody containing a hig-tag.

[0947] Experimental Example 1.2. Expression and Purification of Engineered Anti-PD-L1 scFv

[0948] In the experimental examples of the present application, TOP10 [F- mcrA Δ(mrr-hsdRMS-mcrBC) φ80 lacZΔM15Δ lacX74 recA1 araΔ139Δ(ara-leu)7697 galU galK rpsL (StrR) endA1 nupG], into which pEVOL-pAzF was introduced, was used as the production cell line and was transduced with plasmids encoding each of the aforementioned engineered anti-PD-L1 scFvs.

[0949] Subsequently, a culture medium was prepared by mixing 5 mL of 2 X YT medium and 5 mL of ampicillin (100 mg / mL) in a 50 mL tube, and 30 μL of the aforementioned transduced cell stock vial was taken and inoculated into the culture medium, followed by incubation under conditions of 37°C / 200 rpm / 18 h (primary cell culture). In addition, 2 mL of the primary cell culture was inoculated into a sterile 1 L Erlenmeyer flask containing 200 mL of 2 X YT medium, followed by incubation under conditions of 37°C / 200 rpm / 1.5 h (secondary cell culture). For the secondary cell culture, the OD600 of the culture medium was measured; if it was less than 0.5, it was incubated for an additional 20 minutes, and if it reached 0.5, the subsequent experiment was conducted.

[0950] For the secondary cell culture medium in which the OD600 reached 0.5, 1 mM pAzF was added to the flask containing the secondary cell culture medium, shaken well to mix, and left at room temperature for 20 minutes. Afterward, 20% arabinose (w / v) at a ratio of 1:100 (v / v) was added to the flask, and expression was induced by incubating at 23°C / 200 rpm / 18 h (tertiary cell culture medium). The tertiary cell culture medium was recovered after incubation and centrifuged at 9000 x g / 10 min, and the cell pellet was recovered and stored at -80°C for subsequent experiments.

[0951] The albubody used as a control was prepared using an expression method similar to the above.

[0952] Purification of the engineered anti-PD-L1 scFv from the above cell pellet was carried out through the following process: 1) Resuspending the cell pellet stored in a solution of 20 mM Sodium phosphate, 0.5 M NaCl, and 5 mM Imidazole (concentration) at pH 7.4. 2) Perform ultrasonic disruption under the conditions of Amplitube (%): 40 / On time (sec): 5 / Off time (sec): 5 / Cycles: 120. 3) Centrifuge the disrupted solution at 9000 x g / 20 min to recover the supernatant. 4) Filter the supernatant through a 0.2 µm filter to recover the water-soluble protein solution. 5) Purify using Ni-NTA resin. 6) Perform solvent exchange with Buffer 4. 7) Place the engineered anti-PD-L1 scFv solution, after solvent exchange, into a 10 kDa cut-off filter tube, centrifuge at 6000 x g, 4 °C, 20 min to concentrate, and use for subsequent experiments.

[0953] Experimental Example 1.3. Confirmation of Engineered Anti-PD-L1 scFv Production

[0954] To confirm whether the anti-PD-L1 scFv engineered according to Experimental Example 1.2 was produced, 0.2 µL of 1 mM DBCO-FITC (Fluorescein isothiocyanate) was added to 20 µL of each solution concentrated according to Experimental Example 1.2, and the reaction was carried out at room temperature for 1 hour under light blockage. After the reaction was completed, 4 µL of 5 X protein loading dye (Elpis bio, Daejoen) was mixed into the solution and inactivated at 100°C for 10 minutes. Subsequently, 5 µL of the solution and protein ladder (Bio-Rad, CA) were loaded onto a 12-well SDS-PAGE gel (Thermo, MA), and electrophoresis was performed at 150 V for 40 minutes. The gel after electrophoresis was visualized using a Blue / white transilluminator (Bioneer, Daejoen). Since the azide group present in pAzF will become a fluorescent label if it binds to DBCO-FITC, the production of engineered anti-PD-L1 scFv containing pAzF can be confirmed through this experiment. Consequently, fluorescent labeling was confirmed, confirming that the production of engineered anti-PD-L1 scFv containing pAzF proceeded normally (Fig. 1).

[0955] In addition, the expression level and expression pattern in insoluble / soluble states of each engineered anti-PD-L1 scFv were also confirmed in Figure 1. The expression pattern in the insoluble state was confirmed using a sample completely dissolved in 1 mL of 2 M urea.

[0956] Experimental Example 1.4. Evaluation of Engineered Anti-PD-L1 scFv

[0957] The engineered anti-PD-L1 scFv prepared in Experimental Example 1.1 was evaluated based on three selection criteria (production yield, bonding strength, and structure basis), and one of the engineered anti-PD-L1 scFvs was selected as the subject for subsequent experiments.

[0958] First, the binding ability of the albubody serving as the basis for each engineered anti-PD-L1 scFv was confirmed to PD-L1 through the method described below in Experimental Example 3.1 (Fig. 2). As a result of the experiment, the binding ability of the albubody serving as the basis for the avelumab-engineered scFv was the lowest, and the yield of the avelumab-engineered scFv was also the lowest in terms of expression; therefore, subsequent evaluations were conducted mainly on the atezolizumab-engineered scFv and the durvalumab-engineered scFv.

[0959] In addition, when comparing the expression yields of atezolizumab-engineered scFvs and durvalumab-engineered scFvs, it was confirmed that the yield of atezolizumab-engineered scFvs was higher. Furthermore, the binding affinities to PD-L1 were compared using the method described below in Experimental Example 3.1 (Fig. 3). Based on these results, an evaluation was conducted based on production yield, binding affinity, and structure, and S201X was selected as the final experimental subject among the atezolizumab-engineered scFvs. In particular, although the expression yield of S201X was moderate compared to the others, it showed the highest PD-L1 binding affinity. Additionally, when predicting the structure of S201X, the distance between the binding sites for albumin, ASGR1, and PD-L1 was long, so it was predicted to have the lowest steric hinderance and was selected.

[0960]

[0961] Experimental Example 2. Production of Engineered Anti-PD-L1 scFv Conjugate

[0962] Experimental Example 2.1. Preparation of Conjugating Linker-ASGPR Targeting Glycan Compound

[0963] The structure of the conjugating linker-ASGPR targeting glycan used in the present experimental example is as shown in FIG. 4 below. A3G3[3] and A3G3[3]·PEG12 described in FIG. 4 refer substantially the same as the glycan described in [Formula 10-3] of the present application connected to the conjugating linker. In addition, tri-GalNAc described in FIG. 4 refers substantially the same as three glycans described in [Formula 10-5] connected to the conjugating linker.

[0964] In the following, a material in which A3G3[3] is connected to S201X is referred to as LYTAC(A3G3[3]), a material in which A3G3[3]·PEG12 is connected to S201X is referred to as LYTAC(A3G3[3]·PEG12), and a material in which tri-GalNAc is connected to S201X is referred to as LYTAC(tri-GalNAc).

[0965] Experimental Example 2.2. Production Method

[0966] As described in Experimental Example 6, the engineered anti-PD-L1 scFv of the present application was produced by mixing the engineered anti-PD-L1 scFv (S201X) and the conjugating linker-ASGPR targeting glycan at a molar concentration of 1:20.

[0967] Experimental Example 2.3. Confirmation of Production of Engineered Anti-PD-L1 scFv Conjugate

[0968] Confirmation of the production of engineered anti-PD-L1 scFv conjugates was evaluated by comparing engineered anti-PD-L1 scFv and engineered anti-PD-L1 scFv conjugates via SDS-PAGE analysis. As a result, engineered anti-PD-L1 scFv and engineered anti-PD-L1 scFv conjugates showed a significant difference in mobility (Fig. 5). Notably, no observations regarding protein degradation or unexpected fragmentation were made during the analysis process. Additionally, engineered anti-PD-L1 scFv and engineered anti-PD-L1 scFv conjugates were analyzed using size exclusion chromatography (SEC) and RP-HPLC, respectively, and it was confirmed that the two substances exhibited distinct characteristics in both experiments (Fig. 6). In particular, no peaks in the high molecular weight region were observed for the engineered anti-PD-L1 scFv conjugates in the SEC experiment results. Furthermore, RP-HPLC confirmed that the molecules became more hydrophilic, as expected due to glycan attachment.

[0969] Additionally, mass spectrometry experiments were conducted to verify the production of the anti-PD-L1 scFv conjugate. Among the mass spectrometry experiments, a total ion chromatogram (TIC) (Fig. 7) and a deconvolution mass spectra (Fig. 8) were performed. The TIC results confirmed once again that the engineered anti-PD-L1 scFv and the engineered anti-PD-L1 scFv conjugate exhibited different characteristics. Furthermore, the deconvolution mass spectra results confirmed that the engineered anti-PD-L1 scFv conjugate showed a mass increase to the extent expected due to glycan attachment.

[0970] Based on the above results, it was confirmed that the desired engineered anti-PD-L1 scFv conjugate was produced.

[0971]

[0972] Experimental Example 3. Confirmation of binding ability of engineered anti-PD-L1 scFv conjugate

[0973] Experimental Example 3.1. Experimental Method

[0974] The engineered anti-PD-L1 scFv conjugate of the present application is characterized by having an increased half-life through binding to albumin, while simultaneously possessing binding ability to PD-L1 and being able to interact with ASGPR.

[0975] To confirm the above, the binding ability of the engineered anti-PD-L1 scFv conjugate prepared according to Experimental Example 2 to PD-L1, albumin, and ASGPR was confirmed. Meanwhile, the binding ability to ASGPR was confirmed by verifying the binding ability to ASGR1, one of the subunits of ASGPR.

[0976] First, the LBA (Ligand Binding Assay) to confirm the binding ability to PD-L1 was performed in the following manner: 1) Recombinant human PD-L1 was prepared at 1 µg / mL in 1 X PBS, added to a high binding 96-well plate at a rate of 100 µL / well, and coated at 4°C for 18 hours; 2) The supernatant of the coated plate was discarded, and washing was performed 4 times for each well using 300 µL of 1 X PBS solution (containing 0.05% Tween-20); 3) A 1 X PBS solution containing 4% skim milk and 0.05% Tween-20 (hereinafter referred to as 4% skim milk) was added to each well at a rate of 300 µL, and blocking was performed at room temperature for 1 hour; 4) The washing described in 2) was performed 4 times; 5) 2% skim milk and 0.Prepare a solution containing the target substance to be tested at a concentration of 100 nM in a 1 X PBS solution containing 0.5% tween-20 (hereinafter referred to as 2% skim milk); 6) Add 120 uL of the solution from 5) to 240 uL of 2% skim milk, repeating this 7 times to prepare a total of 8 solutions containing the target substance; 7) Add the solution prepared in 6) to the plate washed in 4) and induce binding at room temperature for 1 hour; 8) Repeat the washing process described in 2) 4 times; 9) Dilute anti-His antibody to 1:4000 in 2% skim milk, add 100 uL to each well of the washed plate, and induce binding at room temperature for 1 hour; 10) Repeat the washing process described in 2) 4 times; 11) Dilute anti-rabbit IgG-HRP antibody to 1:10000 in 2% skim milk, add 100 µL to each well of the plate from 10) after washing, and bind for 1 h at room temperature; 12) Repeat the washing process from 2) above 4 times; 13) Add 50 µL of TMB solution to each well of the plate from 12) after washing, and induce color development at room temperature for 20 minutes under light blockage; 14) Add 50 µL / well of 2 nm H2SO4 solution to stop color development, and measure absorbance at 450 nm; 15) Plot a binding curve based on the absorbance values ​​and calculate the binding-dissociation constant (KD).

[0977] In addition, LBA to confirm binding ability to albumin was performed in the following manner: 1) Recombinant human PD-L1 was prepared at 1 µg / mL in 1 X PBS, added to a high binding 96-well plate at 100 µL / well, and coated at 4°C for 18 h; 2) The supernatant of the coated plate was discarded, and washing was repeated 4 times for each well using 300 µL of 1 X PBS solution (containing 0.05% Tween-20); 3) 300 µL of 1 X PBS solution containing 4% skim milk and 0.05% Tween-20 (hereinafter referred to as 4% skim milk) was added to each well, and blocking was performed at room temperature for 1 h; 4) The washing described in 2) was repeated 4 times; 5) 2% skim milk and 0.Prepare a solution containing the target substance to be tested at a concentration of 100 nM in a 1 X PBS solution containing 0.5% Tween-20 (hereinafter referred to as 2% skim milk); 6) Add the solution prepared in 5) to the plate washed in 4) and induce binding at room temperature for 1 hour; 7) Repeat the washing process described in 2) above 4 times; 8) Prepare recombinant human albumin at a concentration of 1 nM in 240 uL of 2% skim milk solution; 9) Add 120 uL of the solution from 8) to 240 uL of 2% skim milk 7 times to prepare a total of 8 albumin-containing solutions; 10) Add the solution from 9) to the plate washed in 7) and induce binding at room temperature for 1 hour; 11) Repeat the washing process described in 2) above 4 times; 12) Dilute anti-Albumin antibody 1:10000 in 2% skim milk, add 100 µL to each well of the washed plate, and induce binding at room temperature for 1 hour; 13) Repeat the washing step described in 2) 4 times; 14) Dilute anti-rabbit IgG-HRP antibody 1:10000 in 2% skim milk, add 100 µL to each well of the washed plate from 13), and induce binding at room temperature for 1 hour; 15) Repeat the washing step described in 2) 4 times; 16) Add 50 µL of TMB solution to each well of the washed plate from 15), and induce color development at room temperature for 20 minutes under light blockage; 17) Add 2 nm H2SO4 solution at a rate of 50 uL / well to stop color development and measure absorbance at 450 nm; 18) Plot the binding curve based on the absorbance values ​​and calculate the binding-dissociation constant (KD).

[0978] In addition, LBA to confirm binding ability to ASGPR was performed in the following manner: 1) Human ASGR1 was prepared at 4 µg / mL in 1 X PBS, added to a high-binding 96-well plate at 100 µL / well, and coated for 18 hours at 4°C; 2) The supernatant from the plate in 1) was discarded, and washing was performed 4 times per well using a 1 X TBS solution containing 300 µl of 0.05% Tween-20 and 10 mM CaCl2; 3) 300 µL of Superblock solution was added to each well, and blocking was performed for 1 hour at room temperature; 4) During blocking, an engineered anti-PD-L1 scFv conjugate was prepared at 0.5 mg / mL and mixed with NHS-biotin at a molar ratio of 1:1 to perform biotinylation (hereinafter referred to as Biotin-LYTAC). 5) Terminate the biotinylation reaction by adding 50 mM tris-HCl to 4); 6) Repeat the wash described in 2) 4 times; 7) Prepare a total of 8 points of LYTAC solution by adding Biotin-LYTAC to 220 µL of 1 X TBS solution containing 0.05% tween-20 and 10 mM CaCl2, and repeating the process of diluting 1:1 7 times; 8) Add 100 µL of LYTAC solution to each plate after the wash in 6) and react at room temperature for 1 hour; 9) Repeat the wash described in 2) 4 times; 10) 0.Streptavidin-HRP was diluted to 20 ng / mL in a 1 X TBS solution containing 0.5% tween-20 and 10 mM CaCl2, and 100 µL was added to each well of the plate washed in step 9) and reacted at room temperature for 1 hour; 11) the washing described in step 2) was repeated 4 times; 12) 50 µL of TMB solution was added to each well of the plate washed in step 11) and color development was induced at room temperature for 20 minutes under light blockage; 13) 2 nm H2SO4 solution was added at a rate of 50 µL / well to stop color development and absorbance was measured at 450 nm; 14) a binding curve was plotted based on the absorbance values ​​and the binding-dissociation constant (KD) was calculated.

[0979] In addition, bio-layer interferometry (BLI) to confirm the binding ability to ASGPR was performed in the following manner: 1) His-tagged recombinant human ASGR1 was immobilized using an NTA (or HIS1K) biosensor (5.82 μg / mL and 1.16 μg / mL), and the appropriate loading response was verified under each condition; 2) After establishing a baseline in the buffer, the sensor was immersed in a glycan solution (100 μM or 20 μM) to measure association for 300 seconds. Subsequently, the sensor was moved to the buffer to measure dissociation for 300 seconds; 3) The obtained sensorgram was fitted using a 1:1 binding model after reference subtraction, thereby calculating the binding and dissociation constants of the glycan to ASGR1.

[0980] Experimental Example 3.2. Confirmation of PD-L1 binding ability

[0981] According to Experimental Example 3.1, an experiment was conducted to confirm the binding ability of LYTAC (A3G3[3]) and LYTAC (tri-GalNAc) to PD-L1, and it was confirmed that both LYTAC (A3G3[3]) and LYTAC (tri-GalNAc) possessed PD-L1 binding ability similar to that of S201X albubody (Fig. 9).

[0982] Experimental Example 3.3. Confirmation of Albumin Binding Ability

[0983] According to Experimental Example 3.1, an experiment was conducted to confirm the binding ability of LYTAC (A3G3[3]) and LYTAC (tri-GalNAc) to human serum albumin, and it was confirmed that both LYTAC (A3G3[3]) and LYTAC (tri-GalNAc) possess human serum albumin binding ability similar to that of S201X albumadi (Fig. 10).

[0984] Experimental Example 3.4. Confirmation of ASGPR binding ability - LYTAC(A3G3[3])

[0985] According to Experimental Example 3.1, the binding ability of LYTAC (A3G3[3]) to ASGPR was confirmed via LBA. As a result, it was confirmed that LYTAC (A3G3[3]) possessed a measurable level of binding ability to ASGPR (Fig. 11). However, since this degree of binding ability was measured using only ASGR1, a subunit of ASGPR, it is presumed that a lower binding ability would have been measured. If the experiment had been conducted using ASGPR, it is estimated that a higher binding ability would have been measured. In this context, the fact that PD-L1 clearance ability was confirmed in vivo, as described below in Experimental Example 5, suggests that the binding ability to ASGPR was sufficiently high beyond the level required to exert a therapeutic effect.

[0986] Experimental Example 3.4. Confirmation of ASGPR Binding Ability - LYTAC(tri-GalNAc)

[0987] According to Experimental Example 3.1, the binding ability of LYTAC(tri-GalNAc) to ASGPR was confirmed via BLI. As a result, it was confirmed that LYTAC(tri-GalNAc) possesses a measurable level of binding ability to ASGPR (Fig. 12).

[0988]

[0989] Experimental Example 4. Confirmation of Lysosome-Associated Localization of Engineered Anti-PD-L1 scFv Conjugates

[0990] Experimental Example 4.1. Experimental Method

[0991] The engineered anti-PD-L1 scFv conjugate of the present application is characterized by being able to bind to albumin and simultaneously interact with ASGPR to cause lysosome-mediated degradation. Accordingly, if the engineered anti-PD-L1 scFv conjugate of the present application is treated in a cell and compartmentalized within the cell by lysosomes, then 1) the lysosomes are labeled by treating with a fluorescently linked anti-lysosomal antibody and 2) the engineered anti-PD-L1 scFv conjugate is labeled by treating with a fluorescently linked albumin so that it attaches to the conjugate, then the two labels will be present nearby.

[0992] To confirm the above, the lysosome-associated localization of the engineered anti-PD-L1 scFv conjugate was verified in the following manner: 1) To prepare PD-L1 and ASGPR-expressing HepG2 cells selected according to Experimental Example 9, HepG2 cells were seeded at 1.00E+05 cells in an 8-well plate and cultured for 24 hours in a 37°C / 5% CO2 incubator. After culture was complete, the plates were removed and the supernatant was removed; then, medium supplemented with IFN-γ at a concentration of 20 ng / mL was added to the HepG2 cells, and the cells were cultured for 24 hours in a 37°C / 5% CO2 incubator. Subsequently, the plates were removed and the supernatant was removed for use in the experiment; 2) Add medium containing S201X albumabody, LYTAC (A3G3[3]), or LYTAC (tri-GalNAc) at a concentration of 200 nM and incubate for 1 hour in a 37°C / 37°C / CO25% incubator; 3) Remove the plates after incubation and remove the supernatant; 4) Perform cell fixation and permeabilization using PFA; 5) Stain lysosomes by adding FITC-conjugated LAMP-1 antibody, stain with LYTAC by adding Albumin-647, and stain the nuclei with DAPI at room temperature for 1 hour; 6) After washing, perform tomography using a confocal microscope.

[0993] Experimental Example 4.2. Verification of Results

[0994] As a result of conducting the experiment according to Experimental Example 4.1, LAMP-1 positive signals were clearly observed in the group treated with no substance and the group treated only with S201X albubody, but signals associated with Albumin-647 were hardly observed. In contrast, in the group treated with LYTAC, distinct punctate signals associated with Albumin-647 were observed, and a pattern of spatial overlap with LAMP-1 positive signals was confirmed (Fig. 13).

[0995] This suggests that the engineered anti-PD-L1 scFv conjugate of the present application can exhibit the mechanism intended for the design purpose.

[0996]

[0997] Experimental Example 5. Confirmation of liver cancer therapeutic ability of engineered anti-PD-L1 scFv conjugate

[0998] Experimental Example 5.1. Experimental Method

[0999] Experimental Example 5.1.1. PD-L1 Removal Capacity Test Method

[1000] To confirm that the engineered anti-PD-L1 scFv conjugate of the present application has therapeutic efficacy against liver cancer, it was confirmed that the engineered anti-PD-L1 scFv conjugate of the present application has PD-L1 elimination ability. First, when cells were treated with the engineered anti-PD-L1 scFv conjugate of the present application, it was confirmed using Western blot whether PD-L1 was eliminated, and the detailed method is as follows: 1) To prepare PD-L1 and ASGPR-expressing HepG2 cells selected according to Experimental Example 9, HepG2 cells were seeded at 1.00E+05 cells in an 8-well plate and cultured for 24 hours in a 37°C / CO25% incubator. After the culture was completed, the plate was removed and the supernatant was removed. Then, medium containing IFN-γ at a concentration of 20 ng / mL was added to the HepG2 cells, and the cells were cultured for 24 hours in a 37°C / CO25% incubator. Afterward, the plate was removed and the supernatant was removed for use in the experiment. Among the control groups, there was also a group not treated with IFN-γ; 2) Medium containing S201X albubody, LYTAC(A3G3[3]), LYTAC(A3G3[3]·PEG12), or LYTAC(tri-GalNAc) at a concentration of 200 nM was added and incubated for 24 h in a 37°C / CO25% incubator; 3) Plates were removed after incubation, the supernatant was removed, and the supernatant was recovered after cell lysis; 4) After measuring protein concentration, SDS-PAGE loading was performed at a volume of 20 µg / well, and PD-L1 expression levels were confirmed by Western blot.

[1001] Additionally, experiments were conducted similarly to the above process to determine whether the process of PD-L1 removal was through the intended LYTAC-related process. In particular, Western blot was used to confirm whether PD-L1 was removed depending on whether it was treated with a lysosomal inhibitor (chloroquine, CQ) or a proteosome inhibitor (MG132).

[1002] In addition, whether PD-L1 was eliminated was also confirmed through immunofluorescence analysis, and the detailed procedure is as follows: 1) To prepare PD-L1 and ASGPR-expressing HepG2 cells selected according to Experimental Example 9, HepG2 cells were seeded at 1.00E+05 cells in an 8-well plate and cultured for 24 hours in a 37°C / 25% CO₂ incubator. After culture was complete, the plates were removed and the supernatant was removed; then, medium containing IFN-γ at a concentration of 20 ng / mL was added to the HepG2 cells, and the cells were cultured for 24 hours in a 37°C / 25% CO₂ incubator. Afterward, the plates were removed and the supernatant was removed for use in the experiment. Among the control groups, there was also a group not treated with IFN-γ; 2) Add medium containing S201X albumin, LYTAC (A3G3[3]) or LYTAC (tri-GalNAc) at a concentration of 200 nM and incubate for 24 hours in a 37°C / 25% CO2 incubator; 3) Remove the plates after incubation and remove the supernatant; 4) Perform fixation and permeabilization of the cells using PFA; 5) Add FITC-linked PD-L1 antibody to stain PD-L1 and stain the nuclei using DAPI; 6) After washing, perform tomography using a confocal microscope.

[1003] Experimental Example 5.1.2. Experimental method for confirming liver cancer cell removal ability

[1004] The experiment to confirm the ability to eliminate liver cancer cells was conducted by treating liver cancer cells and Jurkat cells (T-cells) with the substance LYTAC when co-culturing them.

[1005] First, the above experiment was conducted starting with the preparation of activated Jurkat T-cells, and the detailed procedure is as follows: 1) Jurkat cells were seeded at a concentration of 1.0 × 10⁶ cells / mL, treated with 2 μg / mL of PHA, and cultured for 48 hours in an incubator at 37°C / 5% CO₂ to induce T-cell activation. 2) Upon completion of culture, the cells were harvested in the form of a pellet by centrifuging at 2,000 rpm for 2 minutes, and the supernatant was removed. 3) Subsequently, cell lysis buffer was added to lyse the cells while simultaneously stably preserving the RNA. 4) 70% ethanol was added to the cell lysate and mixed; the solution was then transferred to a spin column and centrifuged at 8,000 × g for 15 seconds to bind the RNA to the column. 5) Subsequently, impurities were removed by centrifugation using washing buffer under the same conditions (8,000 × g, 15 sec). 6) Afterward, RNase-free distilled water was added, and RNA was eluted by centrifugation at 8,000 × g for 15 seconds. The concentration and purity of the extracted RNA were measured using a spectrophotometer. 7) Finally, qPCR was performed on T cell marker genes to analyze gene expression levels.

[1006] Additionally, the detailed experimental procedure to determine whether liver cancer cells die upon co-culture with T-cells is as follows: 1) To prepare PD-L1 and ASGPR-expressing HepG2 cells selected according to Experimental Example 9, HepG2 cells were seeded at 1.00E+05 cells in an 8-well plate and cultured for 24 hours in a 37°C / CO25% incubator. After the culture was completed, the plates were removed and the supernatant was drained. Then, medium containing IFN-γ at a concentration of 20 ng / mL was added to the HepG2 cells, and they were cultured for 24 hours in a 37°C / CO25% incubator. Subsequently, remove the cultured plates, remove the supernatant, and use them for the experiment. 2) Add medium containing S201X albumin, LYTAC (A3G3[3]), or LYTAC (tri-GalNAc) at a concentration of 200 nM, and incubate for 24 hours in a 37°C / 5% CO2 incubator; 3) Remove the cultured plates and remove the supernatant; 4) Add Jurkat T cells at an ET ratio of 5:1 and incubate for 48 hours in a 37°C, 5% CO2 incubator; 5) Measure cell viability using a plate reader via WST-8 staining.

[1007] Experimental Example 5.2. Results of the experiment confirming PD-L1 removal ability

[1008] As a result of confirming the PD-L1 removal ability by Western blot according to Experimental Example 5.1.1, it was confirmed that PD-L1 was significantly reduced when treated with LYTAC compared to the control group (untreated group, albubody treated group) (Fig. 14). In addition, it was confirmed that LYTAC (A3G3[3]) and LYTAC (A3G3[3]·PEG12) had superior PD-L1 removal ability compared to LYTAC (tri-GalNAc) (Fig. 15).

[1009] Additionally, it was confirmed that PD-L1 decreases depending on whether a lysosome inhibitor (chloroquine, CQ) or a proteosome inhibitor (MG132) is treated. When CQ is treated, PD-L1 does not decrease even when LYTAC (A3G3[3]) is treated, but when MG132 is treated, PD-L1 decreases when LYTAC (A3G3[3]) is treated (Fig. 16). These results show that PD-L1 does not decrease when lysosome function is inhibited, and accordingly, suggest that the anti-PD-L1 scFv conjugate engineered in this application eliminates PD-L1 via the LYTAC mechanism as intended.

[1010] In addition, as a result of confirming the PD-L1 removal ability by immunofluorescence analysis according to Experimental Example 5.1.1, the same trend as the results of the Western blot was obtained (Fig. 17).

[1011] The above results indicate that the anti-PD-L1 scFv conjugate engineered in this application can effectively eliminate PD-L1 through the LYTAC mechanism, and suggest that the anti-PD-L1 scFv conjugate engineered in this application can suppress immune evasion of liver cancer cells and, consequently, treat liver cancer.

[1012] Experimental Example 5.3. Results of the experiment confirming liver cancer cell elimination ability

[1013] As shown in Fig. 18, the activation markers and cytokines (CD25, IFN-γ, TNF-α, IL-2, PD-1) of the Jurkat T-cells used in the present experiment were measured, and it was confirmed that the Jurkat T-cells treated with PHA used in the present experiment were activated cells (Fig. 18).

[1014] In addition, it was confirmed that liver cancer cells were killed when treated with the LYTAC substance in co-culture with T-cells according to Experimental Example 5.1.2. In particular, for both types of LYTAC substances used in this experiment (LYTAC(A3G3[3]) and LYTAC(tri-GalNAc)), it was confirmed that the viability of liver cancer cells was significantly reduced when compared to the control group (Fig. 19).

[1015] The above results suggest that when the engineered anti-PD-L1 scFv conjugate of the present application is treated with liver cancer cells, it has the ability to eliminate liver cancer cells. Furthermore, the engineered anti-PD-L1 scFv conjugate of the present application suggests that it has the ability to treat liver cancer.

[1016]

[1017] Experimental Example 6. Additional Experiment_Optimization of Production Method for Engineered Anti-PD-L1 scFv Conjugates

[1018] Experiments were conducted to determine the appropriate reaction ratio of engineered anti-PD-L1 scFv and conjugating linker-ASGPR targeting glycan compounds for producing engineered anti-PD-L1 scFv conjugates.

[1019] First, using a method similar to that described in Experimental Example 2.3, the fluorescent labeling agent was reacted with the product obtained by reacting engineered anti-PD-L1 scFv and conjugating linker-ASGPR targeting glycan compounds at various molar ratios (1:2, 1:5, 1:10, 1:15, 1:20) to determine how much fluorescent labeling occurs. If, when engineered anti-PD-L1 scFv and conjugating linker-ASGPR targeting glycan compounds at a specific molar ratio are reacted, there is an engineered anti-PD-L1 scFv that is not conjugated, it will be fluorescently labeled by the fluorescent labeling agent.

[1020] As a result of the experiment, it was confirmed that as the molar ratio of the conjugating linker-ASGPR targeting glycan compound increased, the degree of fluorescent labeling decreased, and at a ratio of 1:20, the least fluorescent labeling was observed (Fig. 20).

[1021] Additionally, when confirmed using RP-HPLC, it was confirmed that there was a distinct signal change toward hydrophilicity as the molar ratio of the conjugating linker-ASGPR targeting glycan compound increased (Fig. 21).

[1022] Accordingly, the LYTAC material used in this experimental example was prepared through a 1:20 reaction of an engineered anti-PD-L1 scFv and a conjugating linker-ASGPR targeting glycan compound.

[1023]

[1024] Experimental Example 7. Additional Experiment_Preliminary Formulation Study

[1025] Experimental Example 7.1. Experimental Group and Research Method

[1026] In the LYTAC experiment, the stability of the drug was evaluated according to formulation. The experiment was conducted under accelerated conditions (25°C). For the experimental group, phosphate-buffered saline (PBS) containing 0.5 M NaCl (pH 7.4), which had been used in previous drug experiments, was used as the control group, and additional experimental groups are summarized in Table 10 below.

[1027] Buffer Name | Composition Buffer 110 mM sodium citrate, 5.8% sucrose, and 0.02% PS 80. pH 7.2 Buffer 210 mM sodium citrate, 5.8% sucrose, and 0.02% PS 80. pH 6.0 Buffer 310 mM histidine, 5% sucrose, 80 mM sodium chloride, and 0.01% PS 20. pH 6.0 Buffer 410 mM histidine, 7.5% sucrose, 50 mM arginine, 20 mM sodium chloride, and 0.02% PS 80. pH 6.0 Buffer 510 mM sodium acetate, 7.5% trehalose, 40 mM sodium chloride, and 0.02% PS 80. pH 5.5

[1028] The stability of the drug was evaluated by collecting samples on specific dates (D0, D1, D3 or D0, D1, D3, D7) and analyzing them using the methods described above in the experimental examples, including SDS-PAGE, fluorescence detection after DBCO-FITC labeling, RP-HPLC analysis, SEC-HPLC, and LBA analysis.

[1029] Experimental Example 7.2. Research Results

[1030] Protein integrity was evaluated using SDS-PAGE, and while there were differences between the buffers, no significant differences were observed (Fig. 22). Additionally, fluorescence detection experiments were conducted after DBCO-FITC labeling, and similar results were confirmed (Fig. 22). Although there were differences between the buffers in the LBA functional evaluation, binding activity was maintained in most cases (Fig. 23).

[1031] These results show that the stability of the LYTAC material under accelerated storage conditions depends on the buffer composition, and Buffer 4 was evaluated as being able to store the LYTAC material most stably. Additionally, when using Buffer 4, it was confirmed that the binding ability to PD-L1 was maintained over time, and it was confirmed that the LYTAC material and S201X contained in Buffer 4 maintained their binding ability to PD-L1 until day 7 (Fig. 24). Accordingly, Buffer 4 was used in the following experimental examples.

[1032]

[1033] Experimental Example 8. Additional Experiment_Verification of Scale-up for Manufacturing Engineered Anti-PD-L1 scFv

[1034] When producing the engineered anti-PD-L1 scFv (S201X) of the present application, verification was conducted to determine if manufacturing scale-up was possible. First, in addition to culture on a 200 mL flask scale, the engineered anti-PD-L1 scFv was produced using a 3 L fermenter-based process, and the glucose concentration in the medium was varied (0.5% and 1%) at the start of culture. As a result, it was confirmed that the production efficiency increased by approximately four times, ranging from 12 g / L to 16 g / L, compared to the case of culture on a 200 mL flask scale. The experimental results are shown in Table 11 below.

[1035] Classification | Culture Method | Production Efficiency | Remarks Comparison Group | 200ml flask | 4.5 g / 1 L | 2 X Y | Batch | 13L fermenter | 12 g / 1 L | 2 X Y | 0.5 % glucose Batch | 23L fermenter | 16 g / 1 L | 2 X Y | 1 % glucose

[1036] Additionally, several experiments were conducted on engineered anti-PD-L1 scFv produced through scale-up manufacturing. First, SDS-PAGE was performed on the produced engineered anti-PD-L1 scFv, confirming that the engineered anti-PD-L1 scFv was successfully produced (Fig. 25). Furthermore, SDS-PAGE was performed after connecting different types of ASGPR-targeting glycans to the produced engineered anti-PD-L1 scFv in a molar ratio of 1:20 as described above, confirming that LYTAC material was successfully produced. It was also confirmed that the conjugate could be successfully produced by reacting at a molar ratio of 1:20 in an experiment with DBCO-FITC attachment (Fig. 26).

[1037] In addition, as a result of experiments conducted using RP-HPLC and SEC-HPLC, band shifts were observed due to LYTAC production, just as with the flask-scale preparation (Fig. 27), and it was confirmed that the binding ability was maintained even for LBA (Fig. 28).

[1038]

[1039] Experimental Example 9. Additional Experiment_Preparation of PD-L1 and ASGPR Expressing Cell Lines

[1040] In this experimental example, it is necessary to use cell lines that simultaneously express PD-L1 and ASGPR for the experiment. Accordingly, an experiment was conducted to construct cell lines expressing PD-L1 and ASGPR. First, the expression of PD-L1 and ASGPR was confirmed in HCC (hepatocellular carcinoma) cell lines such as Hep3B, Huh7, HepG2, PLC / PRF5, SNU449, and SNU475. Basal expression of PD-L1 was confirmed only in the SNU449 cell line, and expression of ASGPR was observed only in the HepG2 and Hep3B cell lines (Fig. 29).

[1041] Subsequently, PD-L1 and ASGPR expression were checked after treating SNU449, HepG2, and Hep3B cell lines with DMSO, IFN-γ, EGF, or Alpelisib. As a result of treating with IFN-γ for 24 hours, PD-L1 expression increased in all cases while ASGPR expression was maintained (Fig. 30).

[1042] Additionally, after treating HepG2 with 20 ng / mL IFN-γ, flow cytometry (FACS analysis) was performed. As a result, a shift to the right was observed for the PD-L1 fluorescent label, confirming an increase in PD-L1 expression (Fig. 31).

[1043] In summary, the above results suggest that HepG2 and Hep3B cell lines, which express ASGPR and exhibit strong PD-L1 expression inducibly upon IFN-γ treatment, are suitable HCC cell lines for evaluating LYTAC activity.

[1044]

[1045] The engineered anti-PD-L1 conjugate disclosed in this specification can be used for the treatment of liver cancer through LYTAC technology. Additionally, the engineered anti-PD-L1 conjugate that can be used for said treatment can be produced through the method for producing the engineered anti-PD-L1 conjugate disclosed in this specification.

Claims

1. An engineered anti-PD-L1 scFv conjugate represented by the following structural formula, [constitutional formula] [engineered anti PD-L1 scFv (S)]-[junction (J)]-[linking group (L)]-[Glycan (G)] g , In this case, g is a natural number selected from 1 to 3, and At this time, the engineered anti-PD-L1 scFv is represented by one amino acid sequence selected from SEQ ID NOs. 4 to 13 and 158 to 167, and X of SEQ ID NOs 4 to 13 and 158 to 167 is an amino acid residue represented by the following [Chemical Formula 5], and [Chemical Formula 5] , AA1 and AA2 are adjacent amino acid residue(s), and At this time, the above joint is represented by the following [Formula 7-5] or [Formula 7-6]: [Chemical Formula 7-5] ; or [Chemical Formula 7-6] , At this time, the connector is a bond or includes a structure connecting the joint and the glycan, and At this time, the above glycan is an ASGPR-targeting glycan, and The above-mentioned ASGPR-targeting glycan comprises a non-reducing terminal sugar capable of binding to ASGPR, wherein the non-reducing terminal sugar is galactose or GalNAc(N-acetylgalactosamine), and is an engineered anti-PD-L1 scFv conjugate.

2. In claim 1, the ASGPR targeting glycan is an engineered anti-PD-L1 scFv conjugate that is an N-bonded glycan.

3. In paragraph 2, the ASGPR targeting glycan is an engineered anti-PD-L1 scFv conjugate in which the ASGPR targeting glycan is a biantennary N-bond glycan or a triantennary N-bond glycan.

4. An engineered anti-PD-L1 scFv conjugate according to any one of claims 1 to 3, wherein the ASGPR targeting glycan comprises at least one galactose at a non-reducing terminal position.

5. An engineered anti-PD-L1 scFv conjugate according to any one of claims 1 to 3, wherein the ASGPR targeting glycan comprises at least one GalNAc(N-acetylgalactosamine) at a non-reducing terminal position.

6. In any one of claims 1 to 4, the ASGPR targeting glycan is an engineered anti-PD-L1 scFv conjugate that is A3G3 or a positional isomer thereof.

7. In paragraph 6, the above ASGPR targeting glycan is an engineered anti-PD-L1 scFv conjugate, which is A3G3[3].

8. In any one of paragraphs 1 to 7, the connector is -C 1-150 Alkylene-, -C 1-150 Heteroalkylene- or / and combinations thereof, comprising The above C 1-150 Alkylene is unsubstituted C 1-150 Alkylene or substituted C 1-150 It is an alkylene, and The above C 1-150 Heteroalkylene is unsubstituted C 1-150 Heteroalkylene or substituted C 1-150 It is a heteroalkylene, and The above substitution C 1-150 Alkylene is C 1-150 At least one of the chain-forming atoms of the alkylene is an alkylene substituted with a group independently selected from oxo, hydroxy, amino, carboxyl, thiol, sulfonic acid, phosphate, and halogen, and The above substitution C 1-150 Heteroalkylene is C 1-150 C in which at least one of the chain-forming atoms of the heteroalkylene is substituted with a group independently selected from oxo, hydroxy, amino, carboxyl, thiol, sulfonic acid, phosphate, and halogen. 1-150 Heteroalkylene, engineered anti-PD-L1 scFv conjugate.

9. In claim 8, the connector is an engineered PD-L1 scFv conjugate comprising PEG.

10. In claim 1, the ASGPR targeting glycan is represented by the following [Formula 10-3]: [Chemical Formula 10-3] , Engineered anti-PD-L1 scFv conjugate.

11. In paragraph 10, the above linker is represented by the following [Formula 11-1] or [Formula 11-2]: [Chemical Formula 11-1] ; or [Chemical Formula 11-2] , At this time, the above n is 12, Engineered anti-PD-L1 scFv conjugate.

12. In claim 1, the ASGPR targeting glycan is represented by the following [Chemical Formula 10-5]: [Chemical Formula 10-5] , Engineered anti-PD-L1 scFv conjugate.

13. In Clause 12, the above linker is represented by the following [Chemical Formula 11-3]: [Chemical Formula 11-3] , At this time, each of the above B4 is expressed as -CH2-O-CH2-CH2-(C=O)-NH-CH2-CH2-CH2-NH-(C=O)-CH2-CH2-CH2-CH2-O-, Engineered anti-PD-L1 scFv conjugate.

14. A composition comprising an engineered PD-L1 scFv conjugate and an excipient according to any one of claims 1 to 13.

15. A composition according to claim 14, wherein the excipient is a buffer, an isotonic agent, a surfactant, a stabilizer, or / and a combination thereof.

16. In paragraph 15, the buffer is histidine, phosphoric acid, citric acid or / and acetic acid, and The above isotonic agent is sucrose, trehalose, mannitol, sorbitol, or / and sodium chloride, and The above-mentioned surfactant is polysorbate 20 or / and polysorbate 80, and The above-mentioned stabilizer is glycine or / and arginine, in a composition.

17. In paragraph 16, the composition comprises histidine, sucrose, sodium chloride polysorbate 80, and arginine.

18. A composition according to claim 17, wherein the concentration of histidine is 1 to 50 mM, the concentration of sucrose is 0.1 to 10%, the concentration of sodium chloride is 1 to 500 mM, the concentration of polysorbate 80 is 0.01 to 0.05%, and the concentration of arginine is 1 to 100 mM.